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Abstract 
Streptococcus pneumoniae (pneumococcus) is associated with high morbidity and 
mortality, particularly in young children under the age of 5 and elderly people. Currently, 
vaccinations against S. pneumoniae are polysaccharide based. While these are effective, 
they are limited in several ways including their serotype coverage. Recently, research focus 
has moved to looking at the development of a vaccine that could be effective across all S. 
pneumoniae serotypes and as such pneumococcal proteins which are conserved across all 
serotypes are being investigated for possible inclusion in a vaccine.  
Regulatory T cells are known to have an important role in the modulation of immune 
responses to pathogens. Previous studies have shown that pneumococcal proteins may be 
involved in the activation of Foxp3+ Treg cells in tonsillar tissue.  Pneumococcal whole cell 
antigen (WCA) has been shown to promote an increased number of Foxp3+ Treg cells in 
tonsillar tissue which suggests there is a pneumococcal component which influences 
numbers of this cell type.  
Type 1 regulatory T (Tr1) cells are an inducible subset of regulatory T cells that play a role in 
promoting and maintaining tolerance. The secretion of high levels of IL-10 is the main 
mechanism by which Tr1 cells exert their effects. In 2013, Roncarolo et al showed that the 
co-expression of cell surface markers CD49b and LAG-3 could be used to identify Tr1 cells 
and for the purposes of this study it was the co-expression of these cell surface markers 
that was used to identify the numbers of Tr1 cells present1.   
The frequency of Foxp3+ Treg and Tr1 cells in tonsillar tissue and peripheral blood samples 
from both adults and children were analysed for the intracellular expression of Foxp3 and 
IL10 respectively. Tr1 cells were also characterised by the co expression of cell surface 
markers CD49b and LAG3. Tonsillar MNC and PBMC were also stimulated using 
pneumococcal concentrated culture supernatant (CCS), a toxoid of pneumolysin (W433F) 
and purified polysaccharide capsule (T3P and 6B). 
Numbers of Foxp3+ Treg and Tr1 cells were shown to be significantly higher in tonsillar 
tissue than in peripheral blood in both adult and children samples. After stimulation of 
tonsillar MNC and PBMC, , using WT pneumococcal CCS a significant increase in numbers of 
Foxp3+ Treg and Tr1 cells was shown compared to a negative control. The use of isogenic 
mutant strains deficient in pneumolysin (Ply-/-) and capsule (Cap-/-) showed a significantly 
lower activation of Foxp3+ Treg and Tr1 cells. This suggests that pneumolysin and capsule 
may be important for the activation of Foxp3+ Treg and Tr1 cells. The same experiments 
were carried out using a toxoid of pneumolysin (W433F) and purified capsular 
polysaccharide (T3P and 6B) and the results showed that both W433F and T3P and 6B were 
able to activate significantly more Foxp3+ Treg and Tr1 cells. 
TGF-β has been shown to be important for the induction of Foxp3+ Treg cells. TGF-β is 
released in an inactive form and must be activated to exert its suppressive effects. The 
integrin αvβ8 has been shown to have a role in the activation of TGF-β. Tonsillar MNC were 
stimulated by pneumococcal CCS and the supernatant was collected and analysed using 
ELISA. Cells were pre-incubated using anti-TGF-β and anti-αvβ8. Intracellular cytokine 
staining of samples was also performed which determined that TGF-β concentration did 
correlate with the presence or absence of Foxp3+ Treg cells and that avb8 did appear to 
play a role in the activation of TGF-β 
iii 
 
 Index 
Abstract         ii 
Declaration         iv 
Acknowledgments        v 
Table of contents        vi-xiv 
List of tables and figures       xv-xvii  
List of abbreviations        xviii-xix 
Chapter 1: General Introduction      1-55 
Chapter 2: Materials and Methods      56-75 
Chapter 3: Characterisation of Foxp3+ T regulatory and Type 1   76-91 
regulatory T cells in Human Nasal Associated Lymphoid Tissue and Peripheral 
Blood Mononuclear Cells  
Chapter 4: Foxp3+ Treg cell activation by Pneumococcal Antigens in  92-111 
Human Nasopharynx-Associated Lymphoid Tissues  
Chapter 5: Tr1 cell activation and induction by Pneumococcal Antigens 112-136 
in Human Nasopharynx Associated Lymphoid Tissues 
Chapter 6: Role of TGF-β in the induction of Foxp3+ Treg cells in Human  137-154 
Nasal Associated Lymphoid Tissues 
Chapter 7: General discussion and conclusion    155-172 
References         173-189 
Appendices         190-194 
 
 
 
 
 
 
iv 
 
Declaration 
The original work of the author is presented in this thesis unless stated otherwise. All 
laboratory experiments described here have been performed by the author in The 
Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and 
Global Health, University of Liverpool. 
Aimee Lorna Taylor 
December 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
Acknowledgments 
Firstly, I would like to express my sincere gratitude to my supervisor Dr. Qibo Zhang for his 
continuous support throughout the four years of my PhD study Thanks for his patience, 
motivation, and immense knowledge. I would also like to thank my other supervisors, Dr 
Aras Kadioglu and Dr Paul McNamara for their help throughout this process. It has been a 
rollercoaster journey and would have been much harder to complete without their help 
and support, especially after moving away from Liverpool. 
A huge thanks to the entire PGR team for their support, particularly in the last few years 
when I moved away from the city, had to take time out during my pregnancy and have had 
to fit full time work and being a new mum around my thesis writing. A significant number 
of emails were sent and help and advice received gladly in return.  
I would like to express my thanks to Dr. Debbie Howarth and Ms. Caroline Broughton for 
their technical support in the lab and for their support, friendship and encouragement. 
Thanks to all other academics, researchers and members of staff within the Department of 
Clinical Infection, Microbiology and Immunology for producing such a supportive 
environment in which to work.  
Thanks to all patients who have participated in this study as well as to all the surgeons who 
have worked on providing the samples, without which this project wouldn’t have been 
possible.  
Finally, I would like to thank my family. My parents, sister and Grandparents. For their 
continued support, not just over the last 4 years but also throughout my entire life. It is 
because of them that I have always pushed myself to achieve the best I can and have never 
given up. Grandpa, you were always my biggest advocate. The one who always believed in 
me. I hate that you aren’t here to see me achieve this dream, but I know you were always 
watching, always supporting and will continue to do so forever.  My Undying and eternal 
gratitude to my wonderful husband Andrew who has put up with many late nights and 
takeaway meals over the last 4 years to allow me to focus on my work, His unquestioning 
and unflinching emotional support has been essential to allow me to get to where I am 
now. And to my little girl Lily, you are why I have continued to push myself to finish this 
work. It has been a long and hard path and knowing you will be there to see the result is so 
so special.  
 
 
 
 
 
 
 
 
 
vi 
 
Table of contents 
Chapter 1  General Introduction      1 
1.1  Natural immunity to Streptococcus pneumoniae   2-4 
1.2  Microbiology of Streptococcus pneumoniae   4-5 
1.3  Pathogenesis of Streptococcus pneumoniae   5 
1.3.1  Otitis media       5-6 
1.3.2  Pneumococcal pneumonia     6 
1.3.3  Bacteraemia       6 
1.3.4  Meningitis       6-7 
1.4  Epidemiology of Streptococcus pneumoniae   7-8 
1.5  Pneumococcal virulence factors     9 
1.5.1  Polysaccharide capsule      9 
1.5.2  Pneumococcal surface proteins     9 
1.5.3  Choline binding proteins     10 
1.5.4  Lipoproteins       10 
1.5.5  LPXTG proteins       10 
1.5.6  Non-classical surface proteins     10-11 
1.5.7  Pneumolysin       11 
1.6  Host immunity to Streptococcus pneumoniae   11-12 
1.6.1  Innate immune response     12-13 
1.6.1.1  Breakdown of epithelium     13 
1.6.1.2  Complement       13-14 
1.6.1.3  Pattern Recognition Receptors (PRR)    14-15 
1.6.1.4  Toll-like receptors (TLR)      15-16 
1.6.1.5  NOD-like receptors (NLR)     16 
vii 
 
1.6.2  Adaptive immune response     16-17 
1.6.2.1  Cellular immunity      17 
1.6.2.1.1 CD4+ T cells       17-18 
1.6.2.1.2 T cell activation       18-20 
1.6.2.2  Effector T cells       20 
1.6.2.2.1 Th1/Th2 cells       20-21 
1.6.2.2.2 Th17 cells       21-22 
1.6.2.2.2.1 Th17 cells and pneumococcal infection    22-23 
1.7  Regulatory T cells      23 
1.7.1  Classification       23 
1.7.2  Foxp3+ Treg cells      24 
1.7.2.1  Identification of Foxp3+ Treg cells    24 
1.7.2.2  Mechanisms of suppression     24-25 
1.7.3  Type 1 regulatory T cells (Tr1)     25-26 
1.7.3.1  Identification of Tr1 cells     26 
1.7.3.1.1 IL-10        26-27 
1.7.3.1.2 CD49b/LAG-3       27-28 
1.8  Role of regulatory T cells in pneumococcal disease  28-31 
1.9  Role of regulatory T cells in pathogen persistence  31-32 
1.9.1  Bacteria       32-34 
1.9.2  Fungi        34 
1.9.3  Virus        35 
1.9.4  Parasite       35-36 
1.10  Antibody responses against Streptococcus pneumoniae  36 
1.10.1  B cells        36-38 
viii 
 
1.10.2  B cells and Streptococcus pneumoniae   38-39 
1.11  Mucosal immune system     39 
1.11.1  Nasopharynx-associated lymphoid tissue (NALT)   40 
1.11.2  Consequence of adenotonsillectomy    40-41 
1.13  Pneumococcal vaccines      41 
1.13.1  History        41-42 
1.13.2  Pneumococcal polysaccharide vaccine (PPSV)   42-43  
1.13.3  Pneumococcal conjugate vaccine (PCV)    43-45 
1.13.4  Immune mechanisms of PPSV and PCV    45-46 
1.13.5  Advantages and disadvantages of PPSV and PCV   46-47 
1.13.6  Development of protein-based vaccines    47-48 
1.13.6.1 Current research into pneumococcal protein-based vaccines 48-49 
1.14  TGF-β        49-50 
1.14.1  Latent TGF-β       50 
1.14.1.1 Enzyme mediated TGF-β activation    51 
1.14.1.2 Receptor mediated TGF-β activation    51-52 
1.14.2  Signalling pathways      52 
1.14.3  Smad pathway       52-53 
1.14.4  TGF-β and regulatory T cells     53 
1.15  Integrins       54 
1.15.1  TGF-β and the integrin αvβ8 in the development of Treg cells 54-55 
1.16  Aims/Objectives of this thesis     55 
Chapter 2  Materials and Methods      56 
2.1  Subjects and samples      57 
2.1.1  Subjects       57 
ix 
 
2.1.2  Patients samples      57 
2.1.2.1  Adenotonsillar tissues      57 
2.1.2.2  Peripheral blood      57 
2.1.2.3  Nasopharyngeal swabs      57-58 
2.1.2.4  Saliva        58 
2.2  Processing of samples      58 
2.2.1  Isolation of mononuclear cells from adenotonsillar tissue 58-59 
2.2.2                    Collection of blood serum and isolation of peripheral blood  59 
mononuclear cells (PBMC) 
2.3                       Pneumococcal concentrated culture supernatant (CCS)  60 
2.3.1                    Preparation of pneumococcal CCS    60 
2.3.2  Measurement of protein concentration in pneumococcal CCS 60-61 
2.4  Western blotting      62 
2.4.1  Principle of the assay      62 
2.4.2  Western blotting of pneumococcal CCS    62 
2.4.2.1  Gel electrophoresis      62 
2.4.2.2  Protein transfer by western blotting    63 
2.4.2.3  Detection of Pneumolysin (Ply) proteins in pneumococcal CCS 63-64 
2.5  Analysis of immune cells by flow cytometry   64 
2.5.1  Principle of test       64-65 
2.5.2  Intracellular cytokine staining     65 
2.5.2.1  Principle of intracellular cytokine staining   65 
2.5.2.2  Identification of regulatory T cells    66 
2.5.3  Staining procedure      66 
2.5.3.1  Foxp3+ Treg cell staining     66-67 
x 
 
2.5.3.2  Tr1 cell staining procedure     67-68 
2.5.4  Activation of regulatory T cells     69 
2.5.4.1  Foxp3+ Treg cells      69 
2.5.4.1.2 Cell stimulation       69 
2.5.4.1.3 Cell harvest and staining     69 
2.5.4.2  Tr1 cells       69 
2.5.4.2.1 Cell stimulation       69-70 
2.5.4.2.2 Cell harvest and staining     70 
2.5.4.3  Induction of Tr1 cells      70 
2.5.4.3.1 Principle of MACS separation     70-71 
2.5.4.3.2 Depletion for induction of Tr1 cells    71 
2.5.4.3.3 Magnetic labelling and depletion of CD45RO   72 
2.6                        Enzyme-linked immunosorbent assay (ELISA) for measurement  72 
of cytokine   production in cell culture supernatant  
 
2.6.1                    Principle of assay      72 
2.6.2                    Measurement of IL-10      72-73 
2.6.3                    Measurement of TGF-β      74-75 
2.7                       Statistical analysis      75 
Chapter 3           Characterisation of Foxp3+ T regulatory and Type 1  76 
regulatory T cells in Human Nasal Associated Lymphoid Tissue and  
Peripheral Blood Mononuclear Cells  
 
3.1  Introduction       77-78 
3.1.1  Foxp3+ Treg cells      78-79 
3.1.2  Tr1 cells       79-80 
3.1.3  Nasopharynx associated lymphoid tissue   80-81 
3.2  Aims of the study      81 
xi 
 
3.3  Experimental design      81 
3.3.1  Human subjects and samples     81 
3.3.2  Detection of Foxp3+ Treg cells     81-82 
3.3.3  Detection of Tr1 cells      82 
3.3.4  Statistical analysis      82-83 
3.4  Results        84 
3.4.1  The frequency of Foxp3+ Treg cells in tonsillar MNC and PBMC 84-85 
samples 
 
3.4.2  The frequency of Tr1 cells in tonsillar MMC and PBMC samples 85-86 
3.4.3                    Foxp3+ Treg cell frequency is higher in children tonsillar MNC  87 
samples than in adults tonsillar MNC and PBMC samples 
 
3.4.4                    Tr1 cell frequency is higher in children tonsillar MNC samples  87-88 
than in adult tonsillar MNC and PBMC samples 
 
3.5                       Discussion       88-90 
3.6                       Summary       91 
Chapter 4           Foxp3+ Treg cell activation by Pneumococcal Antigens in 92  
Human Nasopharynx Associated Lymphoid Tissues 
 
4.1  Introduction       93-97 
4.2  Aims of the study      97 
4.3  Experimental design      97 
4.3.1  Human subjects and samples     97 
4.3.2  Pneumococcal concentrated culture supernatant (CCS)  97-98 
4.3.3  Foxp3+ Treg cell harvesting, staining and analysis  98 
4.3.3.1  Cell stimulation       98-99 
4.3.3.2  Cell harvest and staining     99 
4.3.3.3  Foxp3+ Treg cell staining     99-100 
4.3.4  Statistical analysis      100 
xii 
 
4.4  Results        101 
4.4.1  Gating strategy for Foxp3+ Treg cells    101 
4.4.2                    Determination of optimal doses of pneumococcal CCS to be 101-103  
used for the activation and induction of Foxp3+ Treg cells in  
human tonsillar MNC 
 
4.4.3                    Determination of the optimal doses of W433F, T3P and 6B  103-104 
to be used for the activation of Foxp3+ Treg cells in human  
tonsillar MNC 
 
4.4.4                    Stimulation of tonsillar MNC with pneumococcal CCS   104-105 
deficient in pneumolysin (Ply) or capsular polysaccharide show 
lower Treg cell activation compared to stimulation with wild  
type (WT) pneumococcal CCS 
 
4.4.5                    Activation of Foxp3+ Treg cells in tonsillar MNC by pneumolysin 105-107 
toxoid W433F and purified capsular polysaccharide (T3P and 6B) 
 
4.5                       Discussion       107-110 
4.6                       Summary       111 
Chapter 5           Tr1 cell activation and induction by Pneumococcal Antigens  112 
in Human Nasopharynx Associated Lymphoid Tissues 
 
5.1  Introduction       113-118 
5.2  Aims of the study      118 
5.3  Experimental design      118-119 
5.3.1  Human subjects and samples     119 
5.3.2  Pneumococcal concentrated culture supernatant (CCS)  119-120 
5.3.3  Depletion of CD45RO+ cells from tonsillar MNC   120 
5.3.4                   Stimulation of Tr1 cells from freshly isolated tonsillar MNC  121 
and CD45RO+ depleted tonsillar MNC 
 
5.3.4.1                Intracellular staining      121-122 
5.4                       Results        123 
5.4.1                    Gating strategy for the identification of Tr1 cells   123-124 
5.4.2                    Optimal doses of pneumococcal CCS, pneumolysin toxoid  124-126 
W433F and purified capsular polysaccharide T3P and 6B to be  
xiii 
 
used for the stimulation of Tr1 cells in human tonsillar MNC 
 
5.4.3                    Stimulation of human tonsillar MNC with pneumococcal CCS 126-127 
                             deficient in Ply and capsular polysaccharide show lower  
frequencies of Tr1 cell activation compared to stimulation 
with WT pneumococcal CCS 
 
5.4.4                    Stimulation of human tonsillar MNC with pneumolysin toxoid 127-128 
                             W433F and purified capsular polysaccharide (T3p and 6B)  
supports the importance of pneumolysin and polysaccharide in  
Tr1 cell activation 
 
5.4.5                    Stimulation of CD45RO+ cell-depleted tonsillar MNC with  129 
Pneumococcal CCS deficient in Ply and capsular polysaccharide  
show lower frequencies of Tr1 cell induction compared to  
stimulation with WT pneumococcal CCS. 
 
5.4.6                    Stimulation of CD45RO+ cells-depleted human tonsillar MNC 130-131 
With pneumolysin toxoid W433F and purified capsular  
polysaccharide (T3P and 6B) supports the importance of 
pneumolysin and polysaccharide in Tr1 cell induction. 
 
5.5                         Discussion       132-136 
5.6                         Summary       136 
Chapter 6            Role of TGF beta in the induction of Foxp3+ Treg cells in  137 
Human Nasal Associated Lymphoid Tissues 
 
6.1   Introduction       138-140 
6.1.1   Transforming growth factor beta (TGF-β)   140 
6.1.2   Role of TGF-β in Foxp3+ Treg cell activation   140-141 
6.1.3   αvβ8         141 
6.1.4   Role of αvβ8 and Foxp3+ Treg cells in TGF-β activation  141-142 
6.2   Aims of the study      142 
6.3   Experimental design      142 
6.3.1   Patients and samples      142 
6.3.2   Pneumococcal CCS      142-143 
6.3.3   Cell culture and pre-incubation     143-144 
6.3.4                     Intracellular cytokine staining of Foxp3     144 
xiv 
 
6.3.5                     TGF-β ELISA       144-145 
6.4                         Results       145 
6.4.1                    TGF-β present in medium control but level increases when  145-146 
Stimulated with WT pneumococcal CCS  
 
6.4.2                    Foxp3+ Treg cell percentage increases upon stimulation of  146-147 
tonsillar MNC with WT pneumococcal CCS  
 
6.4.3                    TGF-β level decreases upon pre-incubation using anti-TGF-β  147-148 
or anti-αvβ8 
 
6.4.4                    Foxp3+ Treg cell percentage is reduced when cells are  148-149 
pre-incubated with anti-αvβ8 or anti- TGF-β 
 
6.5                         Discussion       150-154 
6.6                         Summary       154 
Chapter 7   General discussion and conclusion    155 
7.1   Discussion       156-171 
7.2   Conclusion       171-172 
Chapter 8  References       173-189 
Chapter 9   Appendices       190-194 
 
 
 
 
 
 
 
 
 
 
xv 
 
List of tables 
Table-2.3.1:  Concentration of Pneumococcal CCS measured by 61 
Bradford protein assay 
 
List of figures 
Figure-2.3.1:  Standard curve of Bradford protein assay  61 
Figure-2.4.3:  Western blot analysis of pneumococcal CCS 
Figure-2.5.3.1: A representative figure which shows the gating  64 
strategy used for the identification of Foxp3+  
Treg cells (CD4+Foxp3+) in freshly isolated tonsillar  
MNC 
 
Figure-2.5.3.2:  A representative figure which shows the gating   68 
Strategy used for the identification of Tr1 cell frequency  
in freshly isolated tonsillar MNC 
 
Figure 3.1:  Different subsets of Treg cells    77 
 
Figure-3.4.1a:     A representative figure which shows the gating   84 
strategy used for the identification of Foxp3+ Treg  
cells (CD4+Foxp3+) in freshly isolated tonsillar MNC 
and PBMC 
 
Figure-3.4.1b(a):  The frequency of Foxp3+ Treg cells in children   85 
tonsillar MNC and PBMC 
 
Figure-3.4.1b(b):  The frequency of Foxp3+ Treg cells in adult   85 
tonsillar MNC and PBMC 
 
Figure-3.4.2a:      A representative figure which shows the gating   86 
strategy used for the identification of Tr1 cell  
frequency in freshly isolated tonsillar MNC and PBMC 
 
Figure-3.4.2b (a):  The frequency of Tr1 cells in children tonsillar MNC 86  
and PBMC  
 
Figure-3.4.2b (b):  The frequency of Tr1 cells in adult tonsillar MNC  86 
and PBMC  
 
Figure-3.4.3:       Frequencies of Foxp3+ Treg cells in adult and children  87 
tonsillar MNC and PBMC samples 
 
Figure-3.4.4:       Frequencies of Tr1 cells in adult and children tonsillar  88 
MNC and PBMC samples 
 
Figure-4.4.1:       A representative figure which shows the gating   101 
xvi 
 
strategy used for the identification of Foxp3+ Treg cells 
(CD4+Foxp3+) in freshly isolated tonsillar MNC 
 
Figure-4.4.2:       Dose curve of WT pneumococcal CCS for the   103 
stimulation of Foxp3+ Treg cells 
 
Figure-4.4.3:       Dose response curves for W433F, T3P and 6B for  104 
Foxp3+ Treg cell stimulation 
 
Figure-4.4.4:       The frequency of Foxp3+ Treg cell activation after  105 
stimulation with pneumococcal CCS 
 
Figure-4.4.5:        The frequency of Foxp3+ Treg cell activation after  107 
stimulation with pneumococcal capsular polysaccharide  
(T3P and 6B) and toxoid of pneumolysin W433F 
 
Figure-5.4.1:       One representative figure which shows the gating  124 
Strategy used for the identification of Tr1 cell frequency  
in freshly isolated tonsillar MNC 
 
Figure-5.4.2a:     Dose response curve of WT pneumococcal CCS for  125 
Tr1 cell activation 
 
Figure-5.4.2b:     Dose response curves for W433F, T3P and 6B for  126 
Tr1 cell Stimulation 
 
 Figure-5.4.3:      The frequency of Tr1 cell activation after stimulation  127 
with pneumococcal CCS 
 
Figure-5.4.4:       The frequency of Tr1 cell activation after stimulation  128 
with pneumococcal capsular polysaccharide  
(T3P and 6B) and toxoid of pneumolysin W433F 
 
Figure-5.4.5:        The frequency of Tr1 cell induction after stimulation 129  
with pneumococcal CCS 
 
Figure-5.4.6:       The frequency of Tr1 cell induction after stimulation 131 
with pneumococcal capsular polysaccharide  
(T3P and 6B) and toxoid of pneumolysin W433F  
 
Figure-6.4.1:        Foxp3+ Treg cell percentage increases upon stimulation  146 
of tonsillar MNC with WT pneumococcal CCS 
 
Figure-6.4.2:       Foxp3+ Treg cell percentage in tonsillar MNC following  147 
Stimulation by WT pneumococcal CCS 
 
Figure-6.4.3:        TGF-β production in tonsillar MNC following stimulation 148 
by pneumococcal CCS after pre-incubation with  
anti-TGF-β and anti-αvβ8 
 
Figure-6.4.4:        Foxp3+ Treg cell percentage in tonsillar MNC following 149 
xvii 
 
stimulation by pneumococcal CCS after pre-incubation with  
anti-TGF-β and anti-αvβ8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xviii 
 
List of Abbreviations 
 
ANOVA   Analysis of variance 
APC   Antigen presenting cell 
BA       Blood agar 
BALT    Bronchial-associated lymphoid tissue 
BFA            Brefeldin A 
BSA       Bovine serum albumin 
CBD          Choline binding domain 
CBP       Choline binding protein 
CbpA       Choline binding protein A 
CCS      Concentrated culture supernatants 
cfu         Colony forming units 
CO2      Carbon dioxide 
CPCV23   23-valent capsular polysaccharide vaccine 
CPS    Capsular polysaccharide 
CRP    C-reactive protein 
CTL    Cytotoxic T lymphocytes 
CTLA-4    Cytotoxic T lymphocytes associated antigen-4 
DC    Dendritic cell 
ELISA    Enzyme linked immunosorbent assay 
FACS    Fluorescence activated cell sorting 
FBS    Foetal bovine serum 
FITC    Fluorescein isothiocyanate 
Foxp3    Forkhead-box P3 
FSC    Forward scatter 
g    Centrifugal force 
g    Gram 
GALT    gastrointestinal-associated lymphoid tissue 
HBSS   Hank’s balanced salt solution 
HCl    Hydrochloric acid 
H2O2    Hydrogen peroxide 
H2SO4    Sulphuric acid 
hr    Hour 
HRP    Horse radish peroxidase 
IFN-γ    Interferon gamma 
IgA    Immunoglobulin A 
IgG   Immunoglobulin G 
IL    Interleukin 
iTreg    Inducible Treg cells 
LAG-3    Lymphocyte activation gene-3 
LBP    LPS-binding protein 
LPS    Lipopolysaccharide 
LTA   Lipoteichoic acid 
LytA    Autolysin A 
M    Molar 
mA    Milliampere 
MALT    Mucosal-associated lymphoid tissue 
MAC    Membrane attack complex 
Mg   Milligram 
min    Minute 
ml    Millilitre 
xix 
 
MNC    Mononuclear cell 
NALT    Nasopharynx-associated lymphoid tissue 
NaOH    Sodium hydroxide 
ng    Nanogram 
NK cell    Natural killer cell 
NLR    Nod-like receptor 
NP    Nasopharyngeal 
nTreg    Natural Treg cell 
OD    Optical density 
PAMP    Pathogen associated molecular pattern 
PB    Peripheral blood 
PBMC    Peripheral blood mononuclear cells 
PBS    Phosphate buffered saline 
PCV    Pneumococcal conjugate vaccine 
PdB    Genetically detoxified pneumolysin 
PE    Phycoerythrin 
pH    Power of hydrogen 
Ply    Pneumolysin 
PMN   Polymorphonuclear leucocytes 
PRR    Pathogen recognition receptor 
PsaA    Pneumococcal surface adhesion A 
PspA    Pneumococcal surface protein A 
PspC    Pneumococcal surface protein C 
rPly    Recombinant pneumolysin 
RT    Room temperature 
SDS-PAGE   Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SEM    Standard error of the mean 
SSC    Side scatter 
STGG    Skim milk, tryptone, glucose, glycerol transport medium 
TCR    T-cell receptor 
TGF-β    Transforming growth factor 
Th    T helper 
Th1    T helper 1 cell 
Th17    T helper 17 cell 
Th2    T helper 2 cell 
Th3    TGF-β-secreting T helper 3 cell 
THB    Todd-Hewitt-broth 
TLR    Toll like receptor 
Tr1    IL-10- secreting T regulatory 1 cell 
Treg    Regulatory T cell 
TSB    Tryptone soya broth 
U    Units 
URT   Upper respiratory tract 
V   Volts 
WCA    Whole cell antigen 
WHO    World Health Organization 
wt    wild type 
yr    year 
μg    Microgram 
μl    Microlitre
1 
 
 
 
 
 
 
 
 
 
 
Chapter one 
General Introduction 
 
 
 
 
 
 
2 
 
1.1 Natural immunity to Streptococcus pneumoniae 
Streptococcus pneumonia (pneumococcus) is an important human pathogen that is 
responsible for several invasive and non-invasive diseases which range in severity from 
mild otitis media to severe meningitis and pneumonia2.   Pneumococcal disease is 
particularly prevalent in high risk groups including the elderly and young children and is a 
leading cause of childhood morbidity and mortality worldwide. Pneumococcal infection is 
particularly a problem in developing countries where infection rates are higher than in 
developed countries.  
Pneumococcal transmission is through direct contact with respiratory droplets containing 
the bacteria. This can be via infected patients or healthy individuals who carry the bacteria. 
Not everyone who is a carrier will present with symptoms of infection. The bacteria can 
persist without being cleared and become part of the normal microbiota of the individual 
with 5-40% of individuals carrying the bacteria as part of their normal flora3.  Transient 
carriage is generally harmless in healthy individuals, but the longer carriage persists, the 
higher the chance of the pneumococcus being able to disseminate from the nasopharynx 
into the normally sterile respiratory tract and cause infection4. 
Colonisation by pneumococcus is a prerequisite for invasive disease, acting as the first 
point of contact between the bacteria and the host. From here the pneumococcus has the 
potential to be able to reach the lungs, blood or cross the blood brain barrier and infect the 
brain.  The primary site of pneumococcal colonisation is the nasopharynx. Dissemination of 
bacteria from the mucosal site is the cause of further severe infection such as septicaemia 
and meningitis. The colonised nasopharynx also acts as a reservoir of the bacteria allowing 
spread through the community. 
It is thought that almost all children are colonised by at least one pneumococcal serotype in 
their first couple of years of life5.  The incidence of pneumococcal colonisation has been 
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shown to decrease with age, but it is not uncommon for children to be repeatedly 
colonised with numerous serotypes6, 7. This colonisation has potential immunogenic effects, 
priming both mucosal and systemic immune responses which confer protection from 
further colonisation events and invasive disease. Colonisation at a young age provides 
immunological memory against pneumococcal antigens which may provide protective 
effects against colonisation in later life and may thus contribute to the decrease in 
colonisation events seen with age8.  
Vaccination is the most effective way of protecting against pneumococcal disease, but the 
problem has been the large number of serotypes that have to be protected against. There 
are more than 90 known serotypes and current vaccines are only effective against a small 
proportion of these9. There are 2 types of pneumococcal vaccines currently available; 
polysaccharide vaccines and protein conjugate vaccines both of which have narrow 
serotype coverage. Pneumococcal polysaccharide capsule has long been known to induce 
protective immunity. The first polysaccharide-based vaccine was commercially available 
after the end of the First World War and targeted four serotypes10.  Later, a 23-valent 
polysaccharide vaccine was licensed11.    Polysaccharide vaccines are limited in that they 
produce a T cell independent immune response and are therefore ineffective in children 
under 2 years of age who are the most vulnerable to pneumococcal colonisation4, 12. Due to 
this, protein conjugate vaccines have been developed which contain polysaccharide 
conjugated to a protein that induces a T-cell dependent response, and immunological 
memory. Protein conjugate vaccines are effective, but they are expensive and have narrow 
serotype coverage. The use of vaccines that target specific serotypes have led to a decrease 
in serotypes contained in the vaccine but has seen the emergence of different serotypes 
not contained in the vaccine13. Efforts are now being made to overcome the limitations 
faced by current pneumococcal vaccines by developing a protein-based vaccine which 
would target most, if not all serotypes14, 15. In addition to targeting many more serotypes, a 
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protein-based vaccine is thought to be commercially easy to produce and a lot cheaper 
than current vaccines12.  As such current research is focusing on the identification of 
suitable proteins for incorporation into a pneumococcal protein vaccine. 
1.2 Microbiology of Streptococcus pneumoniae 
S. pneumoniae are gram positive encapsulated cocci. They are most commonly seen in 
pairs referred to as diplococci but can also occur as short chains or as solitary cocci3, 16.  
They are non-motile facultative anaerobes with the size of individual bacterium ranges 
from 0.5-1.25 um. S. pneumoniae are catalase negative, a characteristic shared with other 
streptococci, but can be distinguished from other group A streptococci by their α-
haemolytic colonies on blood agar. Haemolysis is the breakdown of red blood cells and 
alpha haemolysis is characterised by the area of agar underneath the colony turning 
green17. 
On blood agar plates S. pneumoniae produce glistening, raised colonies which are 
approximately 1mm in diameter. Over time the colonies tend to flatten and depress due to 
the presence of an autolytic enzyme. S. pneumoniae are commonly differentiated from 
other α-haemolytic bacteria using their colony morphology as well as using several 
biochemical tests including sensitivity to optochin. S. pneumoniae is susceptible to the 
chemical optochin and will not grow in its presence18. To test optochin susceptibility, a disc 
which has been impregnated with optochin is placed on a plate which is seeded with the 
microbe being investigated. Upon incubation of the plate the bacteria will multiply to form 
visible colonies but when the microbe is sensitive to optochin there will be a halo formed 
around the disc where the bacteria has been unable to grow.  
Almost all pathogenic strains of S. pneumoniae have a polysaccharide capsule which plays a 
key role in its virulence and is the basis for serotype differentiation19. Each capsular 
polysaccharide reacts with its specific antisera causing the ‘Quelling’ or swelling reaction. 
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This describes the microscopic appearance of the pneumococcal capsule after the 
polysaccharide has combined with its specific antisera. Because of the reaction the capsule 
appears to swell hence the name. To date more than 90 different capsular serotypes of S. 
pneumoniae have been identified. 90 were originally identified 20 and a further (2/3) more 
recentlY21. 
Like other gram-positive bacteria, S. pneumoniae have a cell wall composed peptidoglycan, 
techoic acid residues and lipotechoic acid residues. The peptidoglycan layer is a thick rigid 
structure composed of several peptidoglycan layers combined22. This is one of the defining 
characteristics of a gram-positive bacteria as gram negative bacteria have a thin 
peptidoglycan layer22. Both techoic and lipotechoic acids are negatively charged which give 
them a role in binding and regulating the movement of positive ions into and out of the 
cell23. Lipotechoic acid residues are directly bound to the plasma membrane and traverse 
the peptidoglycan layer while techoic acid residues do not touch the plasma membrane23. 
1.3 Pathogenesis of Streptococcus pneumoniae 
Pneumococci can spread internally and externally from their site of colonisation the 
nasopharynx. Internal spread of bacteria leads to either invasive or non-invasive infection 
of the host, whilst external spread of bacteria via respiratory droplets leads to infection of a 
new host. Spread of bacteria within the host can occur by several different pathways. 
Bacteria can spread through into the respiratory tract, middle ear cavity, central nervous 
system (CNS) or blood stream and cause inflammatory responses in each of these locations 
leading to either mucosal infection or invasive disease.  
1.3.1 Otitis media: Otitis media is a middle ear infection that causes inflammation, redness 
and build of fluid behind the ear drum. Any age group can be affected by otitis media but 
very young children under two years of age are most at risk. Otitis media can be caused by 
several different types of bacteria but is most commonly caused by the pneumococcus24. If 
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colonised by pneumococcal bacteria and the bacteria can spread from the nasopharynx 
into the middle ear cavity by way of the Eustachian tube it will lead to otitis media.  
1.3.2 Pneumococcal pneumonia: Pneumonia is a lung disease that can begin quite 
suddenly with several symptoms including a severe chill, shortness of breath and chest 
pains. Bacterial pneumonia can be cause by several different bacteria, but pneumococcal 
pneumonia is the most common in adults. Children under 5 years of age, the elderly and 
people who are immunocompromised are most likely to experience serious complications 
if they are infected with pneumococcal pneumonia and elderly people who are infected are 
most likely to die from, this disease. Pneumococcal pneumonia is caused by the spread of 
bacteria from the nasopharynx to the lower respiratory tract. Pneumococcal infection 
triggers the accumulation of white blood cells and immune proteins in the alveoli. This 
accumulation of fluid makes it difficult for alveoli to function in the exchange of oxygen. 
1.3.3 Bacteraemia: Blood is normally a sterile environment, so any bacterium detected is 
an abnormal event. The detection of viable bacteria in the blood is known as bacteraemia. 
Bacteria can enter the blood in several different ways including during surgery, through the 
introduction of a foreign object into the body or as a complication of severe infection. In 
some cases, bacteraemia can have no symptoms whereas in others fever and other 
symptoms can be experienced, with septic shock even being possible in some instances. 
Pneumococcal bacteraemia can lead to severe complications including meningitis if the 
bacteria manage to cross the blood brain barrier. 
1.3.4 Meningitis: Meningitis is characterised by the inflammation of the lining around the 
brain and spinal cord. Bacterial meningitis is very severe, and meningitis caused by 
pneumococcal disease is one of the most common. Bacteria in the blood stream manage to 
cross the blood brain barrier and infect the cerebrospinal fluid (CSF) in the meninges. When 
this happens, bacteria can reproduce rapidly, causing severe inflammation and pressure on 
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the brain. This can lead to seizures and in the most severe cases can be fatal. Pneumococcal 
meningitis has a high mortality rate, particularly in vulnerable groups. 
1.4 Epidemiology of Streptococcus pneumoniae 
S. pneumoniae is one of the most important human pathogens worldwide causing 
pneumococcal diseases all around the world. It is a problem in children who live in 
developed as well as developing countries and it is estimated that more than a million 
children under the age of 5 die each year because of pneumococcal disease25.  The advent 
of antibiotics has reduced the number of fatalities because of pneumococcal pneumonia, 
but it is estimated that there are still 500,000 cases of pneumonia each year in the USA 
alone. Pneumococcal pneumonia is also a severe disease of the elderly and people with 
other underlying illnesses. Pneumonia is estimated to affect 1% of the western population 
with S. pneumoniae being responsible for almost half the cases of community acquired 
pneumonia (CAP) in the UK26. 
Pneumococcal disease outbreaks tend to be higher in the winter month, perhaps because 
of an increase in viral respiratory infections that are seen during these months making 
people more vulnerable to pneumococcal infection. 
S. pneumoniae is categorised based on its capsular polysaccharide. To date more than 90 
different serotypes have been identified20.  Serotypes are grouped together if they are 
antigenically related e.g. 9A, 9L, 9V whereas individual serotypes which share no antigenic 
relationship are given a different number27.  Pneumococci are naturally transformable and 
as such can exchange genetic material between strains.  
Serotype prevalence has changed over time. Since the introduction of Pneumococcal 
conjugate vaccine PCV7, the percentage of clinical isolates of vaccine serotypes (4, 6B, 9V, 
14, 18C and 23F) have decreased and other non-serotype isolates have increased. In the 
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US, vaccine serotype isolates have reduced from 55% to 5% and the non-vaccine serotype 
19A has increased substantially from 2% to 22%28. The release of PCV13 which contains 
additional serotypes including serotype 19A means that 19A is no longer increasing in 
prevalence but is still the most common clinical isolate in the US28. PCV7 was introduced as 
part of the routine vaccine schedule of many countries and a dramatic decrease in invasive 
pneumococcal disease has been observed within children vaccinated alongside a herd 
effect in children in other age groups29.  But the increase in prevalence of non-vaccine 
serotypes still means invasive pneumococcal disease is a cause for concern30. 
Resistance to serotypes of S. pneumoniae has developed across the world dramatically in 
the last 30 years31. Serotype distribution differs geographically with antibiotic resistance 
also varying greatly. But it has been reported that serotypes 6B, 6A, 9V, 14, 15A, 19F, 19A 
and 23F show the highest rates of resistance to both erythromycin and penicillin31. The 
introduction of pneumococcal conjugate vaccine PCV7 was shown to reduce penicillin 
resistance rates32, 33 but those serotypes not found in the vaccine, particularly 19A, have 
now been observed to have significant antibiotic resistance in multiple countries30, 34.  
There are several different risk factors that increase your likelihood of developing 
pneumococcal disease. Age is an important risk factor with Children under the age of 2 and 
adults over the age of 65 being high risk35. There are also many other important risk factors 
that can increase your chance if developing pneumococcal disease. People who smoke, 
who have asthma or COPD have been shown to be at increased risk in comparison to 
heathy individuals36. Alcoholism has also been associated with the development of severe 
pneumococcal disease with an estimated 50%of adult patients with pneumococcal 
pneumonia having a history of alcohol abuse37. People who suffer from HIV are 10-100 
times more likely to develop pneumococcal pneumonia and bacteraemia compared to 
someone who isn’t suffering from HIV38. 
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1.5 Pneumococcal Virulence factors 
1.5.1 Polysaccharide capsule 
The polysaccharide capsule forms the outermost layer of S. pneumoniae cells and is 
approximately 200–400 nm thick. Pneumococcal serotypes are defined by their capsule and 
it is an essential virulence factor. Although non-encapsulated strains have been associated 
with superficial infections, invasive infections are almost always associated with 
encapsulated strains39. The capsule is important for several reasons. One of these is that 
within minutes of entering the nasal cavity, S. pneumoniae cells encounter mucus 
secretions. The expression of a capsule reduces entrapment in the mucus due to its 
negative charge, thereby allowing the pneumococcus to access the epithelial surfaces40.  
Un-encapsulated mutants are unable to escape the mucosal surface and are less likely to 
establish contact with the epithelial surface and establish colonisation.  Conversely it has 
also been shown that strains of S. pneumoniae that have a larger amount of capsule are 
more likely to avoid entrapment within the mucous and more likely to evade initial 
clearance41. The capsule also acts as a defensive barrier for the bacteria by preventing the 
attachment of complement components and immunoglobulins to the bacterial cell wall19.  
This allows the bacteria to rapidly multiply before the host can clear it. 
1.5.2 Pneumococcal surface proteins 
More than 500 different surface proteins are present on S. pneumoniae which can be classified 
into four families. These families are choline binding proteins (CBP), lipoproteins, LPXTG 
proteins and non-classical surface proteins (NCSP) 42.  Both lipoproteins and LPXTG proteins 
can also be found on other gram-positive bacteria. These proteins have specific roles to 
play in different stages of pneumococcal infection. I have briefly outlined the roles of the 
different groups of pneumococcal surface proteins below. 
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1.5.3 Choline binding proteins 
A notable group of surface proteins found on S. pneumoniae are the choline binding 
proteins (CBPs), a family of proteins that share the same structural organisation43. There 
are 12 CBPs bound to the choline of the pneumococcal cell wall and many are important 
virulence factors including PspA which is a protective antigen, LytA which is an autolysin 
and is responsible for the release of pneumolysin and CbpA which is an adhesin42. They are 
attached to the bacterial surface by the conserved choline binding site which binds non-
covalently to the phosphorylcholine residues of techoic acid in the bacterial cell wall. They 
also have a biologically active site which projects from the surface of the bacteria. This 
group of proteins is characterised by the choline binding motif which is 2-10 repeats of 20 
amino acids. Choline binding proteins exert their pathogenic effects either through host 
pathogen interactions or through enzymatic mechanisms44. 
1.5.4 Lipoproteins 
Lipoproteins are universally expressed on bacterial surfaces and appear to be crucial for 
bacterial survival. Several lipoproteins can be found on Streptococcus pneumonia, which all 
contribute to its virulence. These include PsA, a divalent metal ion binding ABC transporter 
and sortases, SrtC and SrtD45. 
1.5.5 LPXTG proteins 
This group of proteins is classified by a common mechanism of covalently binding to cell 
wall peptidoglycan. This mechanism is important for allowing the colonisation of the 
nasopharynx, with pneumococcal LPTXG adhesins able to bind to host sugar or protein 
molecules46. 
1.5.6 Non-classical surface proteins 
Several surface proteins are expressed by Streptococcus pneumonia which cannot be 
classified into the categories of other surface proteins. These proteins lack classical 
features of other surface proteins and are thus categorised into a group of proteins called 
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non-classical surface proteins. 6 proteins can be found in this group, PavA, Eno, GADPH, 
6PGD, HtrA and PGK. 
1.5.7 Pneumolysin  
Pneumolysin is a cytoplasmic enzyme belonging to a family of proteins called cholesterol- 
dependent cytolysins. It can cause cytolysis by forming pores in membranes that contain 
cholesterol. Upon binding to target membranes pneumolysin undergoes a conformational 
change which allows it to be inserted within the membrane and this form a pore complex. 
It is a 53 kDa pore forming toxin which is highly conserved amongst pneumococcal 
serotypes47. Pneumolysin is released by all serotypes of S. pneumoniae upon autolytic 
degradation of the bacteria. Autolysis involves the degradation of the cell wall by an 
autolysin. The main autolysin of S. pneumoniae is LytA (Nacetyl-muramoyl-1-alanine 
amidase). LytA cell wall hydrolysis allowing the pneumolysin, which is sequestered in the 
cytoplasm of the bacteria to be released and damage the host. Pneumolysin has numerous 
biological activities and acts in different ways depending on its lytic concentration. At 
sublytic concentrations a range of effects can be observed including activation of 
complement, induction of apoptosis and the triggering of pro-inflammatory responses by 
immune cells47. At higher lytic concentrations, the toxin forms pores in the membrane of 
cells leading to direct cellular and tissue damage. Isogenic mutants of S. pneumoniae that 
do not express  have been shown to be cleared from the lungs following infection which 
suggest it has an important role to play in the virulence of the bacteria48. 
1.6 Host Immunity to Streptococcus pneumoniae 
The immune system is an incredibly complex series of systems designed to be able to 
protect the host from a vast variety of pathogens and to protect any harm coming to the 
host. It is a complex array that must be able to target and kill invading pathogens, while 
being able to recognise self-antigen to prevent accidental damage to the host. The immune 
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system can be generally classified into two very broad, but also interconnecting parts based 
on their role during host immune defences. The adaptive immune system is based around T 
and B cell responses which can recognise a huge variety of antigens in an antigen specific 
manner, enabling the specific identification and subsequent elimination of pathogens. The 
adaptive immune system also provides long term protection against pathogens in the form 
of memory B and T cells which stay in the body and can offer immediate protection if they 
encounter the same antigen later. The innate immune system on the other hand, is 
responsible for providing an immediate but non-specific response and is an essential first 
line defence against invading pathogens.  
1.6.1 Innate Immune Response 
The innate immune system is the first line of defence against microbial infection. Innate 
responses are non-specific, using a limited number of receptors and secreted proteins to 
effectively distinguish between self and non-self-antigen. It is responsible for providing the 
initial defence against the pathogen and for inducing adaptive immune responses49. The 
importance of the innate immune response is clearly demonstrated as any defects in its 
components severely hamper the host’s ability to fight infection, even when an intact 
adaptive immune response is present. 
The first response is the production of antimicrobial enzymes and peptides in blood, then 
activation of the complement system. The second phase of the innate response is 
recognition of molecules called pathogen associated molecular patterns (PAMPs), which 
are found in microbes, not host cells. The recognition of PAMPs leads to a cascade of 
several effector mechanisms responsible for the clearance if the microbe. 
Innate immune responses the pneumococcus includes the clearance of bacteria in the 
upper respiratory tract by secreted enzymes in the epithelial barrier, activation of the 
complement system leading to opsonisation of the bacteria followed by phagocytosis and 
13 
 
recognition of bacteria though pathogen associated molecular patterns (PAMPs)49. The role 
of each section of the innate response within pneumococcal infection is outlined below. 
 1.6.1.1 Breakdown of epithelium 
Epithelial barriers are the host’s first defence against invading pathogens. Failure of this 
innate immune response leads to dissemination of bacteria into areas where they can 
cause disease. For example, the breakdown of the respiratory epithelium allows bacteria to 
move into the lungs and can lead to pneumonia.  
1.6.1.2 Complement 
The complement system is a far reaching and essential part of the innate immune 
response. The complement system was first discovered in 1896 by Bordet and was named 
due to its ability to ‘complement’ the properties of antibody50.  Complement is a very 
complex network of serum proteins, both plasma and membrane associated, that can elicit 
very efficient and well-regulated immune responses against pathogens51. 
It was thought that the complement system only plays a role in the innate immune 
responses and has no role to pay in adaptive immunity. Since the 1970’s it has become 
increasingly obvious that the innate and adaptive immune responses cannot be so easily 
separated and that in fact they interconnect and overlap in many ways. This is 
demonstrated by the ability of complement to not only increase the effectiveness of the 
innate immune response but also in the way complement can influence T and B cell 
responses and so play a role in adaptive immunity52. 
The complement system is comprised of more than 30 proteins that are found in plasma 
and on cell surfaces. These proteins can be arrayed into protein cascades that begin with 
the identification of the invading pathogen and lead to either the induction of pro 
inflammatory mediators or in the opsonisation of the pathogen which ultimately leads to 
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the targeted destruction of the pathogen53. The activation of the complement system 
occurs through one of 3 pathways, the classical, lectin or alternative pathways. All 3 
pathways culminate in three broad effector pathways which enable complement to 
successfully exert its effect in host defence54. The first of these effector pathways is the 
direct lysis of targeted surfaces by the formation of membrane attack complexes (MAC). A 
MAC is a pore of approximately 10nm diameter. The formation of the pores leads to the 
targeted lysis of the cell on which it is assembled. The second is the priming of the immune 
system to generate pro inflammatory cytokines and other pro inflammatory responses and 
the third is the opsonisation of pathogen surfaces by complement opsonin’s (C4b, C3b, 
C3bi) which engage with complement receptors on the surface of phagocytes such as 
macrophages leading to the phagocytosis of the pathogen54. 
It is essential that the complement system be very tightly regulated to prevent unwanted 
damage to the host. The importance of complement as an innate immune defence against 
pneumococcal infection is well documented. People who have complement deficiencies are 
more at risk of contracting severe pneumococcal infection which is also more likely to recur 
throughout life53. Complement mediated phagocytosis is an essential innate response for 
the elimination of the pneumococcus. The complement system is triggered upon 
encountering the bacteria itself but is also activated when in the presence of specific pre-
existing antibody against the bacteria because of previous infection39.   
1.6.1.3 Pattern Recognition Receptors (PRR) 
Pattern recognition receptors act to initiate the recognition of microbes and bring about a 
response which targets the bacteria55. PRRs recognise regular patterns in microbial 
structure known at pathogen-associated molecular patterns (PAMPs) which are structures 
commonly found in many microbes but not in the hosts own cells49. Examples of PRRs are 
lipopolysaccharide (LPS), Toll-like receptors (TLRs), NOD-like receptors (NLRs) and 
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peptidoglycan.49. Recognition of microbes through PRRs leads to the recruitment of 
phagocytes such as neutrophils and macrophages to the site of infection. The phagocytes 
can clear the bacteria in several ways. Firstly, they can phagocytose the bacteria, but they 
also release a multitude of inflammatory mediators which cause the clearance of the 
bacteria. If the innate immune responses fail an acute inflammatory reaction is caused 
which can lead to host damage.  
1.6.1.4 Toll-like receptors (TLR) 
Toll-like receptors (TLRs) are a specific class of PRRs that play a key role within the innate 
immune system. 10 different TLRs have been identified in humans with TLR1, 2, 4, 5 and 6 
being found on the cell surface in the plasma membrane and TLR 7, 8 and 9 residing inside 
the cell in endosomes53.  TLRs bind different ligands and therefore become activated by 
different ligands. They are found on several different cell types including leukocytes, 
adaptive immune cells (T and B cells) and other non-immune cells such as epithelial and 
endothelial cells. As with other PRRs they recognize specific, conserved patterns within 
pathogens. Their specificity means they cannot easily be changed by evolution as they are 
recognizing molecules that are associated with a threat. They are highly specific to the 
conserved region, so they cannot mistake self-antigen for a pathogen. TLRs are responsible 
for activating immune cell responses upon recognition of these conserved repeats after a 
microbe has breached the physical barrier. Upon activation TLRs recruit adapter proteins 
which are responsible for mediating protein-protein interactions. The adapter proteins 
accumulate within the cytosol of the immune cell and are responsible for the triggering of 
signal pathways which leads to the activation of transcription factors. Ultimately this leads 
to the up regulation of genes that have a role to play in inflammatory responses such as 
cytokine production. If the TLR ligand is associated with bacteria, it could be phagocytosed, 
and its antigen presented to CD4+ T cells. 
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Pneumococcal components are recognised by different TLRs. Pneumococcal cell wall 
components including lipotechoic acid and lipoproteins are recognised by TLR255 whereas 
TLR9 can detect unmethylated CpG motifs within endosomal DNA. It has also been 
suggested that TLR2 and TLR9 are involved in the enhancement of phagocytosis of S. 
pneumoniae and intracellular killing of the bacteria by leukocytes. 
The importance of TLR2, 9 and 4 in pneumococcal disease has been demonstrated using 
mouse models. As an example, during the late stages of pneumococcal colonization TLR2-/- 
mice show reduced clearance and have been shown to have reduced levels of IL-1β and 
IL656.  
1.6.1.5 NOD-like receptors (NLR) 
There are 22 members of the NLR family in humans with the majority being cytosolic 
proteins. NOD1 and NOD2 are responsible primarily for the activation of an NF-kB-
dependent pro-inflammatory response. NOD1 acts by the recognition of peptidoglycan 
fragments that are mainly produced by gram negative bacteria whereas NOD2 is activated 
by peptidoglycan fragments of all bacteria regardless of gram status57.  Other NLRs are 
responsible for the formation of protein complexes called inflammasomes. Examples 
include NLRP1 and NLRP4 and these are activated by a wide number of stimuli. NOD2 
activation is involved in the detection of pneumococci that have been internalised by 
macrophages. During phagocytosis, S. pneumonia is degraded in macrophages leading to 
the delivery of peptidoglycan fragments into the cytosol of the host cell. This is involved in 
NOD2 activation. 
1.6.2 Adaptive immune response 
The adaptive immune response becomes very important if a pathogen can overcome the 
innate immune response. The innate immune response brings about a changed cellular 
environment and along with the continued replication of the pathogen this triggers the 
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adaptive immune response. Most pathogens can overcome the innate immune response, 
so the adaptive immune response is essential for the continued defence against them. The 
adaptive immune response can be separated into cellular immune response and antibody 
immune responses. 
Naïve T cells are T cells that have not yet encountered their specific antigen. These naïve T 
cells circulate between blood and lymphoid tissues waiting to encounter its specific 
antigen. Upon antigen recognition, naïve T cells differentiate into effector T cells that are 
specialised to perform different roles. CD8+ T cells recognise pathogens presented by MHC 
class one molecules and naïve CD8+ T cells differentiate into cytotoxic T cells, which act to 
kill infected cells. CD4+ T cells on the other hand recognise pathogen presented by MHC 
class two molecules and can differentiate into several different effector CD4+ T cells each 
with a different role. CD4+ effector subsets that have currently been distinguished are T 
helper 1 (Th1), T helper 2 (Th2), T helper 17 (Th17) and T follicular helper (Tfh) 58, 59. Also, 
there are several regulatory subsets60, 61. Effector helper T cells act to activate macrophages 
and provide help to B cells to trigger the production of antibodies. 
1.6.2.1 Cellular immunity 
1.6.2.1.1 CD4+ T cells 
CD4+ T helper cells are a critical component of the immune system and are important 
mediators of cellular immune responses. It was thought for many years that T helper cells 
existed in just 2 lineages, Th1 and Th2 cells62.  These two groups were distinguished by the 
cytokines they released with Th1 cells producing IFN-γ and Th2 cells producing IL-4, IL-5 and 
IL-13. Recent analysis revealed that further subsets including Th17 cells also exist. IL17 has 
long been appreciated as a cytokine produced by T cells as protection against some 
pathogens63. In 2000, IL17A was shown to be released by a distinct population of T helper 
cells64. Further analysis revealed that T cells could differentiate into an IL17 producing 
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population of T helper cells independently of Th1 and Th2 cell development65.  This 
established Th17 cells as a unique lineage of T helper cells. 
CD4+ T cells are important as helpers for several immune cells including B cells, CD8 T cells 
and macrophages as well as having a role in the regulation of immune responses to control 
autoimmunity and adjust the magnitude and persistence of responses. Dysregulation of 
Th1, Th2 and Th17 cell differentiation can lead to severe immunopathology. If a Th1 
response is too excessive it has been associated with numerous autoimmune diseases and 
inflammatory diseases66 . Excessive Th2 responses are associated with allergic diseases and 
asthma67. It has been shown that Th17 responses are incredibly strong pro inflammatory 
responses and any reaction against self-antigen leads to severe autoimmune disease68. 
1.6.2.1.2 T cell activation 
T cell development occurs in the thymus. Following T cell development, the mature naïve T 
cell will leave the thymus and circulate throughout the body. Some will continue to 
circulate while others will enter lymphoid tissue. Like all T cells, T helper cells express the T 
cell receptor (TCR) which consists of a constant and variable region. The variable region is 
responsible for determining which antigen the T cell responds to.  
The TCR of CD4+ T cells has a high affinity for MHC class 2 which is found on the cell surface 
of Antigen Presenting Cells (APCs) such as dendritic cells and macrophages. During an 
immune response an APC such as a dendritic cell can endocytose the antigen which is then 
processed into peptide fragments before forming a complex with MHC class 269. The APC 
will travel to the site of infection and is able to present the antigen bound to the MHC class 
2 to CD4+ T cells which express the specific TCR against the peptide- MHC complex which 
causes the T cell to activate70.  
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Upon recognition of antigen bound to an APC by T helper cells, The TCR in complex with 
CD3 binds to the peptide-MHC complex. CD4 acts as a co-receptor which specifically 
recognises MHC class 2 and this also binds to the MHC class 2 molecule, but in a different 
section71. These interactions allow the two cells to be brought closely together which 
allows intracellular kinases present of the TCR, CD3 and CD4 to phosphorylate each other 
and become active. This activates intracellular T helper cell pathways which are commonly 
referred to as signal 172. When the same antigen is then subsequently encountered by 
memory T cells these same TCR pathways are activated.  
Upon completion of signal 1, a second signal is given known as signal 2. Signal 2 is a 
protective signal which prevents the T cell from responding to self-antigen. If signal 2 is not 
activated during the initial exposure of the T cell to antigen, the T cell presumes it is auto-
reactive and becomes anergic73. This means the cell will not respond to any antigen in the 
future even if both signal 1 and signal 2 are received. Signal 2 involves an interaction 
between CD28 on the CD4+ T cell and CD80 and CD86 on the APC74. CD80 and CD86 are co-
stimulatory molecules which activate the CD28 receptor. 
After activation using signal 1 and signal 2, the T cell is then able to proliferate. 
Proliferation occurs by the release of IL2 which acts upon T cells in an autocrine fashion. 
The IL2 can bind the T helper cell that is secreting it or other, neighbouring T helper cells via 
the IL2 receptor and thus proliferation and clonal expansion of the T helper cells is driven75.  
A T helper cell, which has been both activated and proliferated then, becomes a T helper 0 
(Th0) cell that is able to secrete IL2, IL4 and IFN gamma. Th0 cells will then be differentiated 
into Th1, Th2 or Th17 cells depending on the cytokine environment76.  
The activation of T cells has to be tightly controlled to prevent the accumulation of a 
massive amount of activated T cells. This is achieved through a negative feedback loop 
involving CTLA-4 which acts to inhibit intracellular signalling77. CTLA-4 is a cell surface 
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protein and is expressed by the T cell upon activation. CTLA-4 binds to CD80 and CD86 on 
the surface of the antigen-presenting cell with a much higher affinity than CD28, the co-
receptor protein involved in signal 2 production. When CTLA-4 is bound to CD80 and CD86 
the activation of T cells is halted78.  
1.6.2.2 Effector T cells 
1.6.2.2.1 Th1/Th2 cells 
Th1 cells are one of the lineages of T helper cells and they promote a cellular response to 
protect the host against intracellular pathogens. Th1 cells are characterised by the 
secretion of IFN gamma, IL2, IL10 and TNF alpha and beta79. Th1 cells cause the activation 
of macrophages and the proliferation of cytotoxic T cells which ultimately leads to the 
phagocytosis and destruction of the invading pathogen. Their cytokine profile is one of the 
main ways of differentiating Th1 cells from other T helper cell subsets, but they can also be 
distinguished by their specific cell surface receptors which include IFN-γ R2, CCR5, and 
CXCR3 and IL-12 R β280. These receptors are essential for interaction with the cytokines 
that drive the differentiation of Th1 cells from naïve T cells including IL-27, IL-12 and IFN 
gamma. Th1 cells are critical for the clearance of intracellular pathogens but their over 
expression has been shown to be associated with autoimmune diseases including 
inflammatory bowel disease and multiple sclerosis79.  
The differentiation of naïve T cells to Th1 cells begins with IL27 signalling. This induces 
STAT1- dependent expression of T-bet which is a Th1 specific transcription factor and is the 
master regulator of Th1 cells81. T-bet promotes the expression of IFN-γ and IL-12 R β2. Il12 
R β2 is then able to heterodimerize with IL-12 R β1 and form a functional IL12 receptor 
complex. This leads to the increase in IFN-γ expression58. 
21 
 
Th2 cells offer protection against extracellular pathogens by mediating the activation and 
maintenance of antibody mediate immune responses. Th2 cells produce numerous 
cytokines including IL-4, IL-5, IL-6, IL-9, IL-13 and IL-25 which cause antibody production, 
activation of eosinophils and inhibit macrophage function, making their protective 
responses phagocyte independent59. The cytokines produced by Th2 cells also act to 
counteract Th1 cell responses. 
The effects of Th2 cell cytokines is seen on many different cell types throughout the body. 
They can stimulate and recruit specialised immune cells such as basophils and eosinophils 
to the site of infection or in response to allergic or toxic antigen82. This causes the induction 
of mucous production and airway hyper responsiveness. Th2 cells are also responsible for 
the class switching of B cells to IgE. When over responsiveness of Th2 cells occur, allergies 
become exacerbated and Th2 cells have also been implicated in the onset of asthma and 
other allergic inflammatory diseases67.  
Th1 cells and Th2 cells have a mutually exclusive relationship. When one is present the 
other isn’t present. This is because they each secrete cytokines that inhibit the activation 
and differentiation of the other.  Secretion of IFN-y by Th1 cells inhibits development of 
Th2 cells and secretion of IL-4 and IL-10 by Th2 cells inhibits Th1 cell development.  
1.6.2.2.2 Th17 cells 
Recently a new class of T helper cell has been discovered: Th17 cells. Th17 cells exhibit 
effector functions that are distinct from Th1 and Th2 cells. The characteristic cytokines 
found upon Th17 activation are IL-17A, IL-17F, IL-22 and IL-23. These effector cytokines can 
be produced very quickly upon infection at mucosal sites. IL-17A and IL-17F act through the 
IL-17 receptor (IL-17R) which is composed of two subunits IL-17RA and IL-17RC. In doing so 
they promote the induction of pro-inflammatory cytokines and chemokines83. The IL-17 
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receptor is found ubiquitously so the release of IL-17 can cause the stimulation of a variety 
of cell types.  
IL-17A and IL-17F are the best-defined cytokines secreted by Th17 cells and are important 
in mediating and inducing pro-inflammatory responses to bacteria. It is responsible for the 
recruitment of neutrophils leading to the clearance of bacteria. IL-17 acts on epithelial and 
endothelial cells as well as a subset of monocytes to produce pro inflammatory cytokines 
and chemokines and this leads to the rapid recruitment of neutrophils84. 
1.6.2.2.2.1 Th17 cells and pneumococcal infection 
Th17 cells are shown to be important against several mucosal infections. They also appear 
to have a particularly important role in pneumococcal clearance 85, 86.  Th17 cells are 
responsible for the clearance of the pneumococcus by the recruitment of neutrophils and 
macrophages, and Treg cells act to regulate the Th17 cell response87, 88. This regulation is 
important to prevent an uncontrolled influx of leukocytes which could cause tissue damage 
and could allow the bacteria to disseminate in to the blood stream. However, studies 
suggest that the pneumococcus, like many other mucosal pathogens, can manipulate this 
system and induce Treg cells, which mean it is not cleared from the nasopharynx, and a 
sustained carriage state is reached.  
Several studies have shown that Th17 cells are important in the clearance of the 
pneumococcus from the nasopharynx in order to prevent colonisation89. Upon stimulation 
by anti-pneumococcal antigens, CD4+ T cells in the tonsils undergo a greater response than 
those in the periphery. This suggests that CD4+ T cells are sequestered in the tonsil which 
makes sense, as from this position they would be more likely to encounter pneumococcal 
antigen and be able to quickly mount an immune response to clear infection90. A study by 
Lu et al showed that IL-17 was produced upon in vitro stimulation with pneumococcal 
antigens and that this enhanced level of IL-17 led to a greater level of phagocytic killing86. 
23 
 
Several other studies have also shown increases in IL-17 production by CD4 T cells upon 
stimulation with pneumococcal antigens91.  
1.7 Regulatory T cells 
1.7.1 Classification 
The immune system must be tightly controlled to prevent undesirable side effects which 
could be caused by immune cells. An uncontrolled immune response can lead to severe 
host tissue inflammation which can cause more harm than the infection. Regulatory T cells 
are a fundamental component of a healthy immune system and have been implicated as 
having a role to play during microbial infection, allergy, autoimmunity, tumours and 
transplantation92. They act to balance effector responses to prevent pro-inflammatory 
responses to self-antigen. They have also been implicated as important in mucosal 
immunity. It is well documented that a deficiency in Treg frequency or number, or a defect 
in their function can lead to inflammation and/or autoimmune disease. Over the years 
several populations of CD4+ Treg cells have been identified. These include Foxp3+ 
regulatory T cells, Th3 cells and Type 1 regulatory T cells (Tr1)93. 
 A naturally occurring suppressive subset of T cells was first described in the 1970’s94. 
However due to a series of negative results the hypothesis was rejected. The “suppressor T 
cell” hypothesis was revived by studies showing that a subset of CD4+ T cells which express 
CD25 are essential for control of autoreactive T cells in vivo95.  It was shown that depletion 
of CD25+ T cells in adult mice led to the development of various autoimmune diseases 
including gastritis95. This work led to the classification of a naturally occurring CD4+CD25+ 
subset of Treg cells. Recently, the discovery of a transcription factor which is expressed on 
this cell type, the forkhead-winged helix transcription factor forkhead box P3 (FoxP3), has 
allowed this cell type to be distinguished from other CD4+CD25+ T cells96.  
24 
 
1.7.2 Foxp3+ Treg cells 
Foxp3+ Treg cells have an important role in the prevention of auto immune disease and in 
the maintenance of immune tolerance. Dysfunction of Foxp3+ Treg cells through, for 
example a mutation in Foxp3, can cause fatal autoimmune disease.  Foxp3+ Treg cells can 
be broadly classified into two subsets, naive Tregs (nTregs) and inducible Tregs (iTregs). 
nTregs mature in the thymus and make up 5-10% of the peripheral CD4+ T cell 
population97. nTregs are thought to be the population of Treg cells responsible for 
maintaining self-tolerance98. iTregs are thought to acquire their suppressor activity through 
activation of CD4+CD25-FoxP3- T cells in the periphery upon stimulation by an antigen. 
Activation of iTregs occurs in the presence of TGF-β199. It is thought that iTregs could have 
a particularly important role to play at mucosal surfaces where there is an abundance of 
TGF-β1. TGF-β1 isn’t required for the differentiation of nTregs but does seem important in 
promoting their survival in the periphery99. 
1.7.2.1 Identification of Foxp3+ Treg cells  
As well as the presence of Foxp3 there are several characteristic markers of Foxp3+ Tregs. 
Foxp3+ Tregs are CD4+CD25+CD127low and looking for these markers allows the 
identification of this cell type100. Naïve and inducible Tregs can be distinguished by the 
presence or absence of CD45RO and CD45RA. nTregs are characterised by their expression 
of CD45RA and low levels of FoxP3. iTregs are characterised by the expression of CD45RO 
and high levels of FoxP390. 
1.7.2.2 Mechanisms of suppression 
Foxp3+ Treg cells use the αβTCR for antigen recognition and are restricted by MHC-II 
molecules as with other CD4+ T cells101. It is thought that there are 2 mechanisms by which 
Treg cells exert their suppressive effects. The contact dependent method involves CTLA-4 
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on the Treg cell and CD80/86 on the effector T cell102. CTLA-4 is expressed at high levels on 
CD4+CD25+ Treg cells and it is thought that the CTLA-4 interacts with the CD80/86 on the 
effector T cell to decrease effecter T cell function. Immunosuppressive cytokines are also 
important in Treg associated suppression. IL-10 and TGF-β released by Treg cells are 
responsible for down regulating MHC II and co-stimulatory molecules on dendritic cells 
which affects their ability to present antigens and so stops the activation of CD4+ T cells102. 
1.7.3 Type 1 regulatory T cells (Tr1) 
Type 1 regulatory T (Tr1) cells are an inducible subset of regulatory T cells that play a role in 
promoting and maintaining tolerance103. One of the main ways of identifying Tr1 cells has 
been through their cytokine profile. Tr1 cells are characterised mainly by high expression of 
IL-10. They also express minimal amounts of IL-4 and IL-17 which allows them to be 
distinguished from Th2 and Th17 cells respectively which express significantly higher levels 
of their respective cytokine98. They express a low amount of IL-2 but again the levels are 
not significant, so they can be distinguished from Th1 cells which express these cytokines in 
much higher level98.  
The original study that led to the discovery of IL-10 producing Tr1 cells began in the late 
eighties104. Tr1 cells were discovered in the peripheral blood of patients with severe 
combined immunodeficiency (SCID) with long term mixed chimerism after HLA-mismatched 
fetal liver hematopoietic stem cell transplant (HSCT) 104.  The SCID patients developed long 
term tolerance to stem cell allografts which suggested there was something regulating 
immune cells. Isolated cells did not show the same cytokine profile as Th1 or Th2 cells 
which suggested a unique cell type was responsible for the immune cell regulation.  A few 
years later Groux et al demonstrated that Tr1 cells, producing high amounts of IL10, are a 
distinct subset of CD4+ T cells that are antigen specific and show strong 
immunosuppressive activity105.  
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Tr1 cells can control the activation of naive and memory T cells and suppress Th1 and Th2 
cell mediated immune responses. The suppressive effects of Tr1 cells are reversed by 
blocking antibodies against IL-10, showing that the inhibitory capacity of Tr1 cells is mainly 
mediated through production of IL-10. They also kill myeloid cells by the secretion of 
Granzyme B98. 
1.7.3.1 Identification of Tr1 cells 
Tr1 cells are induced when CD4+ T cells are activated by antigen in the presence of IL-10106. 
It had been difficult to distinguish these cells from other cell types, relying on 
characterisation using its unique cytokine profile. Tr1 cells are distinguished from Th1 cells 
by expression of minimal IL4 and down regulation of GATA3 expression1. Tr1 cells lack IL17 
and express low levels of RORC which distinguishes them from TH17 cells. Low levels of IL2 
and IFN gamma which distinguishes them from CD25+Foxp3+ Treg cells. It has recently 
been shown that there are cell surface markers characteristic of Tr1 cells which allow for 
them to be differentiated from other regulatory T cells1. Tr1 cells are CD4+CD49b+LAG3+1. 
This ability to differentiate Tr1 cells from other cells means further study of this cell type is 
possible. 
1.7.3.1.1 IL-10 
IL-10 is an immunomodulatory cytokine that plays an essential role in regulation of the 
immune system in a variety of ways. It is responsible controlling inflammatory responses by 
down regulating inflammatory cytokines, induces tolerance and is important in the down 
regulation of other immune responses107. IL10 is indispensable for driving the 
differentiation of Tr1 cells but other cytokines are also involved. 
During infection IL10 inhibits the activity of a variety of different cell types including Th1 
cells and macrophages. These cells are essential for the clearance of pathogens but can also 
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be responsible for causing tissue damage which is why they must be regulated108. For this 
reason, IL10 can be responsible for inhibiting clearance of pathogens and preventing 
inflammation associated immunopathology. 
IL10 was first described as a cytokine produced by Th2 cells which acted to inhibit Th1 cell 
responses, but it is now known that IL10 is produced by several other cell types including 
macrophages, dendritic cells and various subsets of CD4+ and CD8+ T cells109. IL10 regulates 
T cell responses with many of the effects being indirect and occurring via the direct effect 
of IL10 on macrophages108. IL10 inhibits MHC class 2 and costimulatory molecule B7-1/B7-2 
expression on macrophages which limits their production of pro inflammatory cytokines 
and chemokines110. IL10 can also directly act on CD4 T cells, inhibiting their proliferation 
and the production of numerous cytokines including IL2, IL4 and IL5110. This allows IL10 to 
directly regulate Th1 and Th2 responses. 
1.7.3.1.2 CD49b/LAG-3 
LAG-3 is a protein antigen expressed on T cells and NK cells after cell activation. It is a CD 
antigen given the name CD223111. The expression of LAG3 on the surface of activated T cells 
is upregulated by IL2, IL7 and IL12 and its expression leads to the production of IFN-γ.  LAG-
3 has also been shown to be expressed on activated B cells but not when the B cell is 
activated solely by a TLR agonist112.  LAG-3 expression on B cells could therefor serve as a 
marker for B cells that have been activated by T cells.  
LAG-3 is a multifunctional protein and can affect a variety of different cell types. LAG 3 is a 
ligand for MHC class 2 and the interaction between LAG3 and MHC class 2 controls CD4+ T 
cell responses and leads to the down regulation of antigen specific CD4+ T cell proliferation 
and cytokine secretion113.  
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LAG-3 is cleaved into 2 fragments which affects its function. A 54-kDa fragment, which 
includes the extracellular domain and a 16-kDa peptide containing the transmembrane and 
cytoplasmic domains. The 54 kDa fragment is released from the cell surface as soluble LAG-
3 and it appears to cause the increase in T cell activation114.  
LAG-3 has been shown to be important for maximal function of regulatory T cells. 
Antibodies against LAG-3 have been shown to inhibit suppression by induced Treg cells 
both in vitro and in vivo115. LAG-3 knockout mice have been shown to have regulatory T 
cells with reduced regulatory function115.  
CD49b (cluster of differentiation 49b) is a protein encoded by the CD49b gene. CD49b is the 
α2 integrin subunit of very late activation antigen 2 (VLA-2)1. Integrins are integral 
membrane glycoproteins composed of an alpha and a beta subunit and are found on a 
variety of cell types including T cells and NK cells116. 
1.8 Role of regulatory T cells in pneumococcal disease 
Nasopharyngeal colonisation is very common in young children before natural immunity 
can develop. In the UK colonisation in children less than 3 years of age is between 40-
50%117 but in African children this can reach 90-100%118, 119. By the age of 3 most children 
have developed natural immunity against specific pneumococcal antigens. This natural 
immunity is responsible for the clearance of the pneumococcus from the nasopharynx 
before carriage status can be achieved. However, despite this natural immunity carriage 
can still occur throughout life and it is thought that Treg cells could have a role in this. 
Due to the success of vaccines targeted to the polysaccharide capsule of the 
pneumococcus, it has classically been thought that protection against it was due to an 
antibody-based response120. However, more and more publications are now suggesting an 
important role for CD4+ T cell immunity in protection against the pneumococcus. MHC-II 
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knockout mice which lack the ability to induce cell-mediated immunity through the 
presentation of antigen show prolonged carriage 120 suggesting CD4+ T cells have an 
important role to play in pneumococcal carriage rather than antibody-based responses. 
In a recent study by Zhang et al, adenoidal cells from children who tested positive for 
pneumococcal carriage were found to contain higher numbers of Foxp3+ Treg cells when 
stimulated with pneumococcal whole cell antigen than those taken from children that 
tested negative90. The Treg cells present are of a memory phenotype suggesting they have 
been induced by a previous colonisation event. This association between carriage state and 
the increased number of Treg cells in the nasopharynx suggests that colonisation with the 
pneumococcus leads to the promotion of pneumococcus specific Treg cells. As well as this, 
the depletion of these cells before stimulation with whole cell antigen led to an increase in 
CD4+ T cell proliferation and the re-introduction of the Treg cells suppressed this effect121. 
This suggests that these memory Treg cells present in the nasopharynx have a potent 
inhibitory effect on CD4 T cell proliferation and may contribute to the persistence of 
carriage seen in young children. The next step in this story is to try and work out what 
specific component or components are responsible for the induction of Treg cells in the 
nasopharynx. 
There have been several studies that have looked at different pneumococcal components 
to see how they affect colonisation and how they alter CD4+ T cell responses. The aim of 
this research is to try and identify components which could be used to inform the design of 
a novel vaccination strategy. Ideally a mucosal vaccine would contain several different 
protein antigens as this would increase its effectiveness across all pneumococcal serotypes. 
Protein antigens that have been looked at include pneumococcal surface protein A (PspA), 
pneumococcal surface adhesin A (PsaA), Choline binding protein A (CbpA) and 
pneumolysin47.  
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Intranasal immunisation of mice using killed whole cell pneumococci and cholera toxin 
adjuvant conferred protection against experimental colonisation. This protection was 
dependent on CD4+ T cells120. In addition to this, immunisation with cholera toxin B subunit 
together with pneumococcal surface adhesin A (PsaA) was enough to provide protection 
against colonisation with the pneumococcus122. This suggests PsaA could be important for 
colonisation. It has also been demonstrated that a fusion conjugate containing cell wall 
polysaccharide, Pneumolysin and PsaA delivered alongside cholera toxin nasally protected 
mice against experimental colonisation123. 
Another study showed that D39 deficient in PspA and the D39 deficient in PspC (CbpA) 
have a reduced capacity to colonise the nasopharynx124. A Pneumolysin deficient mutant 
also had a reduced capacity to colonise the nasopharynx although this was to a lesser 
extent125. 
Pneumolysin has been shown to be essential for maintaining long term asymptomatic 
carriage in the nasopharynx126. Upon administration of a Wild type WT strain carriage was 
maintained for 28 days whereas after administration of PLN-A (pneumolysin deficient 
mutant) carriage was cleared between 7-14 days after infection. Another study has shown 
that stimulation of adenoidal MNCs with Ply or F433 leads to proliferation of CD4 T cells85. 
From these studies it is suggested that a variety of pneumococcal proteins appear to play a 
role in the colonisation of the nasopharynx. The next step in the story is to work out how 
they can do this. 
Several papers have suggested that pneumococcal components can suppress allergic 
airways disease and are able to do this through the induction of Treg cells127. Using a 
mouse model of allergic airways disease, Thorburn et al identified that type 3 
polysaccharide (T3P) and Pneumolysin when administered together caused an increase in 
Treg cell numbers in the lungs when compared to a control group127.  
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There is overwhelming evidence showing that Treg cells and Th17 cells have important 
roles to play in many mucosal infections. These cell populations have a key role in the 
outcome of these infections but whether they have a positive or negative effect appears to 
depend on the pathogen.  With regards to pneumococcal infection, Treg cells appear to be 
important for carriage of the pneumococcus in the nasopharynx and have been shown to 
be responsible for supressing CD4+ T cell responses which would lead to the clearance of 
the bacteria from its site of colonisation. Further research is necessary to look at which 
specific components and what mechanisms are used to induce antigen specific Treg cells in 
the nasopharynx of individuals. 
1.9 Role of regulatory T cells in pathogen persistence 
Studies90, 128, 129suggest that the pneumococcus, like many other mucosal pathogens, can 
manipulate the immune system and induce Treg cells, allowing the pathogen to persist and 
not be cleared from the nasopharynx. This allows the carriage of the bacteria and its spread 
to other individuals in the community. 
Foxp3+ Treg cells are essential for protecting against inflammation mediated tissue damage 
but they also suppress immune responses which are necessary for the clearance of the 
bacteria to prevent pathogen persistence130. Effector T cells, in particular Th17 cells, are 
responsible for the clearance of the bacteria but if with no regulation, they would cause 
severe tissue damage. Treg cells can inhibit the action of important adaptive immune cells 
including macrophages and T and B lymphocytes which promotes an environment prefect 
for the carriage of the bacteria. This is why an equilibrium must be reached. To allow Treg 
numbers to promote pathogen clearance while at the same time protecting from 
inflammation associated damage caused by uncontrolled effector cell proliferation and 
action130. 
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Treg cells can affect a wide range of host immune cells including CD4+ and CD8+ T cells, B 
cells and antigen presenting cells such as dendritic cells and macrophages130. Treg cells act 
by inhibiting proliferation and cytokines of effector cells.  They inhibit the production of 
antibody and reduce the ability of APCs to stimulate T cell responses by inhibiting the 
expression of co-stimulatory molecules and inflammatory cytokines involved in APC 
responses130. 
1.9.1 Bacteria 
IL-17A and IL-22 produced by Th17 cells are important against Klebsiella pneumoniae 
infection. K. pneumoniae is a gram negative opportunistic pathogen that causes acute 
pneumonia131. During infection there are measurable levels of IL-17A and IL-22 which act to 
recruit neutrophils to the lungs and decrease the bacterial burden. IL-22 has been shown to 
have a role in preventing the dissemination of bacteria from the lungs to the spleen where 
it can do even more damage. So the IL-22 is important for the augmentation of barrier 
defences131. 
Mycobacterium tuberculosis is the pathogen that causes tuberculosis. It is estimated that 
approximately one third of the world population is infected with M. tuberculosis and 
people infected have a high morbidity and mortality. During M. tuberculosis infection the 
bacteria is phagocytosed by macrophages but the cell wall prevents fusion with the 
lysosome131. This means the bacterium is protected and can divide. Th1 cells are essential 
during M. tuberculosis infection as they directly act to get rid of the bacteria.  Th17 cells are 
also important, although in an indirect way, as they are responsible for the recruitment of 
Th1 cells132. So, in this case the role of Th17 cells is not a primary role but is nevertheless 
important and as such is being targeted in vaccine development strategies. Studies133, 134 
have shown that during M. tuberculosis infection there are a high number of FoxP3+ cells in 
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the lungs of mice and humans which suggests that Treg cells have a role to play in the 
persistent nature of the infection.  
Helicobacter pylori is a gram negative pathogen that infects the gastric mucosa84. It is 
associated with the development of ulcers and cancers. IL-17A produced by Th17 cells is 
essential to the inflammation that is seen during H. pylori infection. Th1, Th17 and Treg 
cells all have a role to play during H. pylori infection and the outcome of the infection 
depends on how these cells are balanced135. There are several papers documenting the 
relative importance of Th17 and Th1 cell responses to H. pylori infection. Some papers 
argue that IFN-γ produced by Th1 cells is implicated in the pathology associated with the 
infection, whereas others show that IL-17 neutralization reduces gastric inflammation 
associated with this infection implicating Th17 cells as the main subset associated with 
inflammation. A study by Flach et al compared the importance of four different cytokines 
and showed that only the neutralisation of IL-17 was associated with an increase in H. 
pylori colonisation136 .  This strongly suggests that Th17 cells are more important for 
protection against H. pylori than Th1 cells. H.pylori infection can persist for decades in the 
gut of individuals despite a robust immune response from the host. It has been shown that 
this is since antigen specific CD4+CD25+ FoxP3+ Treg cells accumulate in the gastric mucosa 
of people who are infected with H. pylori. The bacterium can actively skew the immune 
response towards producing Treg cells and thereby suppresses Th17 driven immunity137. In 
doing so the inflammation associated with the infection is prevented but bacteria are 
persisting in the gut. So, the Treg response protects the gut against exaggerated 
inflammation but in turn allows the bacterial burden to increase. This can lead to chronic 
infection and can be the cause of the development of gastric cancer138. This fine balance 
would need to be considered by anyone hoping to produce a vaccine against this infection 
as by skewing the immune response towards one or the other subsets of T cells could have 
disastrous outcomes. 
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Bordetella pertussis is the cause of severe respiratory disease which can often be 
complicated by secondary infections which can lead to death in young children. Challenge 
with B. pertussis induces both Th1 and Th17 cell responses. IFN-γ is produced to coincide 
with the peak of infection and IL-17 is detected before IFN-γ and continues until the 
infection is cleared139. B. pertussis specific Th1 cells are associated with the recovery from 
this infection but during the acute phase of infection the antigen specific Th1 cell response 
is suppressed by pathogen specific Treg cells. This allows persistence of infection. However, 
the absence of a strong Treg cell response led to an increase in inflammatory cytokines and 
extensive damage to lung tissue. This suggests that perhaps Treg cell induction is important 
to prevent the over enthusiastic Th1 cell response. Once again this highlights the delicate 
balance between T helper cells and Treg cells. 
1.9.2 Fungi 
Candida albicans causes oropharyngeal candidiasis (OPC) which is a biofilm-like infection of 
the oral mucosa. IL-17 mediated recruitment of neutrophils is important for host defence 
against C. albicans. When mice that are deficient in the IL-17 receptor are infected with C. 
albicans there is decreased survival seen when compared to a wild type control showing 
that Th17 cells are important during infection140. During C. albicans infection there is an 
unexpected interplay between Th17 cells and Treg cells with both seeming to be important 
for providing protective immunity. Mice which lack T and B cell responses are very 
susceptible to OPC infection. Transfer of Th17 cells to these mice isn’t enough to protect 
against infection but co transfer of Treg cells and Th17 cells confers protection through an 
enhancement of Th17 cell responses140. So, the Treg cells appear to be boosting rather than 
suppressing the Th17 cell response. 
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1.9.3 Virus 
During Herpes Simplex Virus 2 (HSV-2) infection, which causes genital herpes, the removal 
of Treg cells causes an increase in virus associated inflammation and increases mortality. 
The viral load is also dramatically increased upon the removal of Treg cells141. Infection of 
the cornea due to Herpes simplex virus 1 (HSV-1) induces early induction of IL-17 and IL-23. 
Knockout mice which lack the IL-17 receptor see reduced recruitment of neutrophils during 
early infection which leads to damage to the cornea following infection with HSV-1. 
1.9.4 Parasite 
Plasmodium falciparum is the parasite that causes human malaria. During malarial infection 
increased numbers of Treg cells have been found in both human and mouse malaria 
infection. In mouse models of malaria, it was shown that Tregs act to supress CD4+ T cell 
responses and in doing so cause in increase in the parasite load. In human infection it has 
also been shown that higher numbers of Treg cells are associated with increased parasite 
load and development of infection. A study conducted among Gambian children who had 
malaria and those who were healthy (control) showed that Treg cells were unable to 
control inflammation during acute and severe infection which suggests they may be 
overwhelmed by the parasite142. Later in infection Treg cells may be important in down 
regulating inflammatory responses when the parasite is already well on its way to being 
cleared by the immune response. But suppression too early in infection would hamper the 
responses needed to clear the infection and allow the parasite burden to increase once 
more. 
Toxoplasma gondii is an obligate intracellular parasite that causes toxoplasmosis. In a 
mouse model, expansion of Treg cells protects the host against fatal immune pathology. 
Following infection there is a natural collapse in Treg cell numbers which allows a 
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potentially fatal infection to take hold. Increasing the number of Treg cells prevents this 
from happening.143 
1.10 Antibody responses against Streptococcus pneumoniae 
1.10.1 B cells 
B cells develop from stem cells that originate in bone marrow. B cell development occurs in 
several stages, each marked by the expression of different gene patterns and different 
arrangements of the immunoglobulin H chain and L chain gene loci144.  B cells can either 
undergo positive or negative selection. Positive selection occurs through antigen 
dependent signalling involving the pre- B cell receptor and the B cell receptor. If the B cell 
receptors do not bind to their ligand, B cell development ceases. Negative selection occurs 
when the BCR binds to self-antigen and allows for tolerance of self-antigen145. 
Immature B cells move from the bone marrow to the spleen where they pass through 2 
transitional stages of development before undergoing the final stage of development. 
Upon entry to the spleen B cells are considered T1 B cells (transitional stage 1) but whilst in 
the spleen they transition to T2 B cells (transitional stage 2). T2B cells differentiate into 
either follicular B cells or marginal zone B cells depending on signals received through the 
BCR and other receptors. Upon differentiation they are now considered to be full mature 
naïve B cells146.  
Activation of B cells occurs in secondary lymphoid organs such as the spleen and lymph 
nodes. In the secondary lymphoid organs, the B cells receive constant supply of antigen via 
circulating lymph. B cell activation begins with the binding of antigen to the BCR. The 
antigen can be free antigen or antigen presented by APCS such as dendritic cells or 
macrophages. Activation of B cells is enhanced through the activity of another surface 
receptor on B cells, CD21. CD21 forms a complex with surface protein CD19 and CD81 
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which is collectively known as the B cell co-receptor complex145. If an antigen that is tagged 
with C3 (complement component) the C3 fragments ligates with the CD21 which 
transduces a signal through CD19 and CD81, lowering the activation threshold of the cell 
and thus enhancing B cell activation147.  
T cell dependent antigens as the name suggests are antigens that induce B cell antibody 
responses with the help of T cells. B cell responses to these antigens take several days but 
the antibodies produced have a higher affinity and functional versatility than B cells 
responses generated from T cell independent activation148.  
When a T cell dependent antigen binds the BCR, it is endocytosed, degraded and presented 
to T cells as fragments of peptide in a complex with MHC class 2. T helper cells that are 
specific to the same antigen and thus were activated by the same antigen recognise and 
bind the MHC class 2-peptide complex through the TCR. Following the binding of the TCR to 
the MHC class 2-peptide complex, a surface protein, CD40L and cytokines including IL4 and 
IL21 are expressed. CD40L is a co-stimulatory factor for B cell activation and binds the B cell 
surface receptor CD40 leading to B cell proliferation as well as sustaining T cell growth and 
proliferation. Cytokines derived from T cells bind to cytokine receptors on B cells also 
promote B cell proliferation. Upon receipt of these signals a B cell is considered active149.  
Upon activation B cells undergo a 2-step differentiation process which yield both short 
lived plasmablasts, responsible for immediate protection and long-lived plasma cells and 
memory B cells which allow protection for a much longer period. The first step is called the 
extrafollicular response and occurs within the secondary lymphoid tissue, outside the 
lymphoid follicles. During this step B cells can proliferate, may switch between classes of 
immunoglobulin and differentiate into plasmablasts which produce antibodies for 
immediate protection but are weak150. During the second step, B cells migrate into the 
lymphoid follicles and form a germinal centre, a specialised area where B cells undergo 
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extensive proliferation and immunoglobulin class switching. B cells are helped by T cells 
(mainly Tfh cells) which are localised within the germinal centre and the result is the 
production of high affinity memory B cells and long-lived plasma cells. The plasma cells 
secrete large amounts of antibody and generally localise within the bone marrow150.  
T cell independent antigens such as polysaccharide and unmethylated CPG DNA can induce 
a humoral response without the need for T helper cell interactions. The B cell response to T 
cell independent antigen is very rapid but the antibodies produced tend to be of a lower 
affinity and have less functional versatility compared to antibodies produced by T cell 
dependent activation151.  
Additional signals are still required for B cells to complete activation, but they do not 
receive them from T cells. Instead, B cells are activated by TLR’s or repeating epitopes on 
bacterial cell walls. B cells activated by these antigens further proliferate in secondary 
lymphoid tissue but not in lymphoid follicles and no germinal centre is formed152.  
Memory B cells are activated upon the binding of their target antigen. Upon binding of the 
antigen, endocytosis occurs to allow the memory B cell to engulf the antigen. The antigen is 
degraded before peptide fragments form a complex with MHC class 2 which can then be 
presented to T cells. T helper cells which recognise the same antigen as the memory B cell, 
recognise the MHC class 2-peptide complex and bind to them leading to a signal cascade 
that ends with B cell activation and proliferation51. 
1.10.2 B cells and Streptococcus pneumoniae 
When pneumococcal capsular polysaccharide activates naïve B cells they are able to 
differentiate into IgM+ memory B cells which can produce IgM specific to the 
pneumococcal antigen without any additional T cell help being required153. During latter 
stages of infection pneumococcal specific IgM+ B cells can differentiate into pneumococcal 
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specific IgG+ or IgA+ memory B cells126. IgA is recognised as being important against 
pneumococcal infection as it is commonly found at mucosal sites such as the nasopharynx, 
and after mucosal infection, IgA is detected in the nasopharynx126. In both mouse models 
and clinical studies, a deficiency in IgA lead to bacterial persistence in the nasopharynx and 
the increased likelihood of recurrent infection154, 155. 
IgM+ B cells are also an important humoral defence against pneumococcal infection. It has 
consistently been shown that patients with low levels of IgM+ memory B cells are more 
prone to develop recurrent respiratory infections
156
. Mouse models have shown that when 
B cells that produce IgM are depleted, response against pneumococcal polysaccharide are 
severely impaired
157
. These studies, and more not mentioned here, suggest IgM and IgM+ 
memory B cells play a key part in humoral immune responses against pneumococcus.  
1.11 Mucosal immune system 
The mucosal immune system is part of the adaptive immune system and is responsible for 
activating antigen specific T and B cells. The mucosal immune system is commonly referred 
to as the MALT (mucosal associated lymphoid tissue) and MALTs are distributed widely 
throughout the mucosal surfaces of the body. They are named based on their location for 
examples gut associated lymphoid tissue (GALT) and nasopharynx associated lymphoid 
tissue (NALT)
51. Mucosal surfaces are prone to infection as they are thin permeable layers 
designed for their specific purpose. For example, the gut is designed for food absorption, 
the lungs for gas exchange and the eyes and nose for sensory activities. As such these sites 
are vulnerable to Infection and are commonly the route for infectious agents to enter the 
body
51. 
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1.11.1 Nasopharynx-associated lymphoid tissue (NALT) 
Human nasopharynx-associated lymphoid tissue (NALT) includes tonsils and adenoids. The 
tonsils and adenoids are part of a ring of lymphoid tissues known as Waldeyer’s ring in the 
nasopharynx158. This is an important and unique inductive site for B cell responses. Both 
tonsils and adenoids are large clusters of mucosal lymphoid tissue which are an important 
site of immune induction. They are ideally located to be exposed to both airborne and 
alimentary antigen159.  During childhood they can often become enlarged due to 
hypertrophy or infections which can lead to their removal to relieve airway blockage.   
Tonsils and adenoids contain four specialized lymphoid compartments participating in the 
immune functions of these organs, namely the reticular crypt epithelium, the extrafollicular 
area, the mantle zones of lymphoid follicles and the follicular germinal centres (GCs) 160.  
Tonsils and adenoids resemble lymph nodes but have no afferent lymph. Instead antigen is 
transported to T and B cell areas by antigen presenting cells such as dendritic cells160. 
Dendritic cells are found in abundance in extrafollicular areas and are often surrounded by 
T cells, particularly CD4+ T cells. Various types of these cells including naïve (CD45RA+), 
memory (CD45RO+) and recently activated (CD25+) are found and can produce both a 
primary and secondary immune response159.  
Adenotonsillar tissue differs from peripheral blood in that B cells are the predominant 
lymphocyte population found here. The main T cell population found in adenotonsillar 
tissue is CD4+ T cells with a low percentage of CD8+ T cells161.   
1.11.2 Consequences of adenotonsillectomy 
During this study adenotonsillar tissue was collected from patients who underwent routine 
adenotonsillectomy. Reasons for surgery were mainly recurrent infections or sleep 
disorders162 163. It is still questionable as to what the effects of removing tonsils are, 
particularly with regards to the mucosal immune response in the upper respiratory tract. 
Given that one of the main reasons for surgical removal of adenotonsillar tissue is due to 
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recurrent infections it is surprising that there have been reports of increased risk of 
nasopharyngeal colonisation by respiratory pathogens after adenotonsillectomy162. It has 
been shown that removal of tonsils has only a very small effect on reduction of symptoms 
associated with upper respiratory tract infections, with sore throats and the associated 
absence from school being reduced marginally163. 
It has also been shown that adenotonsillectomy seems to increase the levels of 
pneumococcal carriage, particularly when the surgery occurs at a very young age. The 
pneumococcal polysaccharide specific antibody response is also reduced which certainly 
indicated that adenotonsillar tissue is a crucial site involved in immune responses against 
the pneumococcus in children162.  
1.13 Pneumococcal Vaccines 
1.13.1 History 
The first successful case of pneumococcal vaccination occurred over a hundred years ago in 
1911 when British physician Sir Almroth E. Wright and colleagues vaccinated several 
thousand gold mine workers in South Africa with a crude whole-cell heat-killed 
pneumococcal vaccine164. This vaccine was developed from circulating strains of the 
bacteria with no regard at all for serotype specificity as at this time it was unknown that the 
pneumococcus had so many serotypes. Between 1923 and 1929 Avery and Heidelberger 
conducted work which showed that the polysaccharide capsule of the bacteria was the 
basis of the different pneumococcal serotypes and that this capsule could be important for 
the immunogenicity of the bacteria. In 1930 Thomas Francis Jr and William S Tillett injected 
pure pneumococcal polysaccharide into individuals recovering from pneumococcal 
pneumonia and discovered that the polysaccharide injected was able to induce specific 
antibody against the serotype used165. Developments in polysaccharide technology and the 
outbreak of World War II led to the development of a quadrivalent (serotypes 1, 2, 5 and 7) 
pneumococcal vaccine at a US Arm Air Force technical school in South Dakota10. In 1947 E.R 
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Squibb & Sons obtained a License in the USA to distribute two different formulations of a 
hexavalent pneumococcal polysaccharide vaccine containing different polysaccharides. One 
was aimed at adults and contained polysaccharides for serotypes 1, 2, 3, 5, 7 and 8. The 
other was for use in children and contained polysaccharide for serotypes 1, 4, 6, 14, 18 and 
19. At around the same time as pneumococcal polysaccharide vaccine developments, 
antibiotics were being introduced. Post war doctors preferred to use antibiotics to treat 
pneumococcal infection and as such interest in the development and use of vaccines faded. 
Little more would be achieved in the field of pneumococcal vaccine development until the 
1970’s10. 
1.13.2 Pneumococcal polysaccharide vaccine (PPSV) 
Antibiotic therapy as a method of treating pneumococcal disease was shown to be 
inadequate as it still maintained a high mortality rate. This along with the emergence of 
antibiotic resistant strains of the pneumococcus led to a resurgence in interest for the 
development of a pneumococcal polysaccharide vaccine166. A 14 valent pneumococcal 
polysaccharide vaccine was approved in 1977, containing 50 µg of purified polysaccharide 
capsule from serotypes 1,2, 3, 4, 6, 8, 9, 12, 14, 19, 23, 25, 51 and 56167.  This vaccine was 
recommended for use in children 2 years or older who had other chronic health problems 
and therefore had an increased risk of being infected by the pneumococcus and for people 
older than 50. This vaccine contained serotypes that were effective against a proportion of 
invasive pneumococcal diseases but not all. It was recognised that a vaccine targeting a 
wider range of serotypes was needed which led to the development of a 23 valent vaccine 
(PPSV23) which was introduced in 1983 and contained 25 µg of capsular polysaccharide 
from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 
20, 22F, 23F, and 33F11, 168. PPSV23 has very good efficacy in immunocompetent adults and 
older children and is effective against most invasive pneumococcal serotypes169. 
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Serotype selection for inclusion in the vaccine was based on their prevalence worldwide. 
This differs from region to region with some serotypes being present in certain 
geographical regions. In developed countries PPSV23 provides coverage against up to 90% 
of invasive pneumococcal infections164. In Britain for example, severe pneumococcal 
infections are between 80-90% likely to be caused by serotypes covered by the vaccine170. 
However, this isn’t the case in certain developing countries where protection offered by 
PPSV23 isn’t as effective. A study in Malaysia showed that 71% of invasive pneumococcal 
diseases are caused by serotypes contained in the vaccine which leaves 29% of invasive 
infections being caused by serotypes that aren’t protected against171. This highlights the 
limitations of this vaccine in its restriction of only protecting against certain serotypes. 
1.13.3 Pneumococcal conjugate vaccine (PCV) 
Despite the success of pneumococcal polysaccharide vaccines, it soon became clear they 
had several short comings. The biggest problem is that they are very poorly immunogenic 
in children under 2 years of age and this age group is one of the most vulnerable to 
pneumococcal infection172.  This was a problem that clearly needed to be overcome, and a 
solution was found in the form of a protein conjugate vaccine in which pneumococcal 
polysaccharide is conjugated to a protein to improve its immunogenicity. The process of 
using a conjugate protein in a vaccine wasn’t new. It had already been used in haemophilus 
vaccine with the first protein conjugated vaccines to be licensed in the USA being for 
Haemophilus influenza type b (Hib)173.  
Several different protein candidates were trialled for use in a pneumococcal protein 
conjugate vaccine. At first, a tetra-valent conjugate vaccine was prepared with outer 
membrane protein complex of Neisseria meningitides; which showed good immunogenicity 
in 31 toddlers as well as 62 infants in Finland174. A subsequent tetravalent vaccine 
conjugated with diphtheria toxoid was also found to induce a good memory response175. 
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Finally, a penta-valent (6B,14,18,19F,23F)176 and a hepta-valent (4,6B,9V,14,18C,19F and 
23F) polysaccharide vaccine conjugated to a nontoxic form of diphtheria toxin CRM197 were 
found to induce a good antibody response in infant and toddlers177. A large-scale safety and 
efficacy trial of the hepta-valent vaccine (PCV7) conjugated to CRM197 was carried out in 
Northern California, USA; which included 37,868 children in a randomly selected double 
blinded trial178. The vaccine was a success with both safety and efficacy being reported as 
excellent. It was shown that if 3 doses of the vaccine were given at 2-month intervals 
starting at 2 months of age followed by a booster dose at age 2 the vaccine would 
effectively protect children from pneumococcal disease178. Based on this success PCV7 was 
licensed in 2000 and is found on the routine immunisation schedule of children in the USA 
where it is administered in a 3-dose schedule followed by a booster between the ages of 
12-15 months179. Other studies led to the inclusion of PCV7 on to the vaccination schedule 
of children in European countries and by 2007 more than 70 countries were licensed to use 
it180. Its use in the USA has seen the rates of invasive pneumococcal disease fall from 97 to 
24 cases per 100,000. The vaccine also reduced the incidence of pneumococcal disease 
seen in unimmunised individuals, perhaps as a direct result of herd immunisation29. 
 Despite the success of PCV7 there have been some issues. The use of this vaccine has been 
associated with serotype replacement in which serotypes contained in the vaccine 
decrease in incidence but are replaced by those not found in the vaccine181 182. The most 
important example of this is serotype 19A which was not in the vaccine as it was the ninth 
leading cause of invasive pneumococcal disease in the USA. After PCV7 was introduced it 
became the number one leading cause of invasive pneumococcal disease in the USA28. 
Serotype 19A also became the leading cause of invasive pneumococcal disease after PCV7 
vaccination in Australia, Canada and many European countries33, 183, 184. Serotype 
replacement highlights the need to develop a broad ranging vaccine that is affective against 
all pneumococcal serotypes as opposed to just a select few12. Currently 10 valent (1, 4, 5, 
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6B, 7F, 9V, 14, 18C, 19F and 23F) and 13 valent (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 
and 23F) pneumococcal conjugate vaccines are used185. Children and infants are routinely 
vaccinated with pneumococcal conjugate vaccines and this has led to a decrease in invasive 
pneumococcal diseases caused by serotypes contained within the vaccine186. There has also 
been a herd effect of vaccination which has seen a decrease in invasive pneumococcal 
disease in older children and adults187 188, 189.This is down to reduced transmission of 
bacteria within the community due to decreased levels of pneumococcal carriage. 
1.13.4 Immune mechanisms of PPSV and PCV 
The immune mechanisms of PPSV and PCV differ. PPSV works by inducing antibodies 
specific to the polysaccharide contained in the vaccine, which induce phagocytosis through 
activation of compliment and opsonisation of bacteria168.  B cell receptors on B cells 
recognise repeating epitopes found in pneumococcal capsular polysaccharide which 
activates the B cell to convert to plasma cells which secrete antibody specific to the 
polysaccharide. This process is T cell independent as it occurs without any T cell 
intervention.190. 
PCV also stimulate B cell receptors in a way that is identical to that of PPSV, but they also 
have an additional mechanism of action. The vaccine is composed of capsular 
polysaccharide conjugated to a protein carrier. The capsular polysaccharide activated the B 
cell response while the protein carrier causes an induction of T cell responses. The protein 
is processed by antigen presenting cells (APC) and is then presented to CD4+ T helper cells. 
The T cell response enhances the primary antibody response and provide a stronger 
secondary response through the induction of both memory B and T cells191. The immune 
mechanisms of PCV are much stronger than those of PPSV and are much more effective in 
infants and the elderly. Its ability to induce memory B and T cells is also a huge advantage 
46 
 
which provides enhancement of the immune response if a subsequent infection occurs or 
upon receiving a booster dose of the vaccine191. 
1.13.5 Advantages and disadvantages of PPSV and PCV 
PPSV23 was successful in controlling pneumococcal disease in adults but was limited by its 
poor immunogenicity in young children. New born children are one of the most at risk 
groups for pneumococcal disease, but they have B cells which respond very poorly to the 
polysaccharide antigens contained within the vaccine192. Despite maturation of the immune 
system over the first two years of life, the protective effects of this vaccine remain poor. On 
top of this no memory response is induced so re-vaccination of children does not cause an 
enhancement of the immune response193.   To effectively protect against pneumococcal 
disease using this vaccine, it is necessary to re vaccinate periodically due to the lack of 
memory response. However, there is evidence that immune tolerance is developed upon 
repeated exposure194. There is also no protection offered against mucosal infection which 
means it offers little protection against nasopharyngeal carriage of the bacteria and thus 
does not protect against the spread of the bacteria or against its progression from non-
invasive to invasive infection. 
Pneumococcal conjugate vaccines offer better protection against pneumococcal disease 
than polysaccharide vaccines. They provide a much stronger immune response and are 
effective in infants, young children, elderly people and those who are immunodeficient. It 
also induces mucosal immunity which confers protection against pneumococcal carriage195.  
This ability to inhibit nasopharyngeal colonisation is a key advantage of the conjugate 
vaccine over the polysaccharide vaccine as protection against nasopharyngeal colonisation 
limits the bacteria’s progression to an invasive infection and reduces the chance of 
transmission from person to person. In this way the pneumococcal conjugate vaccine offers 
herd immunity within a community196, 197. 
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A disadvantage of the conjugate vaccine is its high price. This makes them unrealistic for 
global use. The countries in which pneumococcal diseases burden is highest cannot afford 
the expense of including PCV13 as part of their vaccination programmes. PCV13 also 
includes fewer serotypes than PPSV23. This means fewer serotypes are protected against 
many of which are responsible for invasive pneumococcal disease in at-risk groups of 
individuals. However, despite its disadvantages, PCV13 is still the best available option for 
protection against pneumococcal disease, particularly in young children. 
1.13.6 Development of protein-based vaccines 
Why there is a need to develop a protein based pneumococcal vaccine? Over 90 serotypes 
of S. pneumoniae exist and there is huge variation between which serotypes affect 
different regions20. Current pneumococcal conjugate vaccines are very effective at 
conferring protection against serotypes included in the vaccine, but they are very complex 
and incredibly expensive to make. In addition, they do not provide protection against 
serotypes not included in the vaccine. In contrast to this protein pneumococcal vaccines 
have the potential to provide protection against all serotypes which would prevent other 
serotypes replacing ones that are protected against.  
For a protein-based vaccine to be effective against pneumococcus, ideally it should be able 
to induce specific antibody and CD4+ T cell including IL17A dependent immune responses. 
Antibodies against pneumococcal proteins are important for clearance of bacteria through 
the promotion of opsonophagocytosis and recent evidence shows that CD4+ T cell 
responses have an important role to play in protection against pneumococcal infection47. 
CD4+ T cell responses have been implicated in pneumococcal carriage. A protein based 
pneumococcal vaccine could potentially be used alone or in combination with current 
capsule polysaccharide-based vaccines to broaden their current protection. 
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A stand-alone protein vaccine has the potential to be both cheaper and less complex to 
produce than current pneumococcal conjugate vaccines. However, it would need to be able 
to demonstrate its effectiveness at achieving the same level of success as a PCV. Of course, 
its effects would be broader in range which could potentially outweigh any slight reduction 
in efficacy. Alternatively, one or more pneumococcal proteins could be added to a PCV 
which could lead to a broadening of coverage and minimise new serotypes emerging to 
replace ones included in the vaccine. It would have to be tested to ensure the addition of 
the proteins did confer a greater benefit than just the PCV alone. 
1.13.6.1 Current research into pneumococcal protein-based vaccines 
Widespread use of 7 valent PCV led to emergence of disease caused by non-vaccine 
serotypes28. New formulations of the vaccine, containing 10 and 13 serotypes have recently 
been licensed but the same issue of serotype replacement is likely to occur. The cost of 
producing conjugate vaccines is high, making them difficult to implement worldwide as 
developing countries cannot afford to use them. With the risk of serotype replacement still 
likely to occur, vaccine research has moved to looking at protein candidates that would be 
protective against all serotypes of S. pneumoniae as opposed to just a few. A protein 
pneumococcal vaccine could provide protection against all serotypes of S. pneumoniae in a 
single formulation which would have numerous benefits including reduced manufacturing 
costs and elimination of the issue of serotype replacement. A cheaper vaccine would be 
more accessible to developing countries, whose populations are more at risk from 
pneumococcal infection anyway. 
The next generation research for pneumococcal vaccine is focussed on the creation of a 
vaccine containing several conserved proteins that can induce broader immunity to protect 
against infection by S. pneumoniae. Over 20 pneumococcal proteins have been identified 
49 
 
which produce protective antigens against the pneumococcus including pneumococcal 
surface protein A (PspA) and pneumolysin (Ply) 198. 
Pneumolysin is a highly conserved protein which causes the formation of pores in cell 
membranes containing cholesterol. Ply is in the cytoplasm of S. pneumoniae but is released 
by autolysis199. Ply is a major virulence factor, exerting its effect on different cell types 
including immune cells and epithelial cells. Antibodies against Ply can be found in humans 
who have been colonised by S. pneumoniae and these antibodies have been shown to 
passively protect mice that have been challenged with pneumococci200. Pneumolysin in its 
purified form is highly toxic and as such wouldn’t be suitable for use in a vaccine targeted 
to humans. However, Ply can be detoxified which involves its genetic or chemical 
modification to remove its haemolytic activity201. Recently a detoxified genetic mutant of 
Ply (PlyD1) has been developed which has been used in mouse models and has shown 
some protection is conferred to the mice involved202. 
Ply has been studied in mouse models and in natural infections in humans. It has been 
shown to induce both adaptive and innate immune responses and antibodies against 
Pneumolysin have been found in individuals infected with S. pneumoniae200, 203.  There is 
limited genetic variation of Pneumolysin between different serotypes of S. pneumoniae 
which suggests it may be a suitable target for inclusion in a vaccine204. 
1.14 TGF-β 
The Transforming Growth Factor Beta (TGF-β) superfamily consists of many different 
proteins including the TGF-beta proteins, Bone Morphogenetic Proteins (BMPs), Growth 
Differentiation Factors (GDFs), Activins and Inhibins205. Transforming growth factor beta 
(TGF-β) is a multifunctional cytokine that is expressed in 3 different isoforms TGF-β 1-3206.  
TGF-β is secreted by many different cell types has several roles including a role in regulating 
proliferation, differentiation, adhesion and migration207. TGF-β molecules are proposed to 
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act as cellular switches that regulate processes such as immune function. Many cell types 
have TGF beta receptors and as such can be either positively or negatively regulated by 
TGF-β207. TGF-β exists in an inactive or latent form and must be activated to be able to 
exert its suppressive effect205.  
Secreted TGF-β is cleaved into a latency associated peptide (LAP) and a mature TGF-β 1 
peptide. In its latent state TGF-β is composed of TGF-β 1 homodimer, a LAP homodimer 
and a TGF-β 1 binding protein. In its active form is composed of TGF-β 1 homodimer205. 
1.14.1 Latent TGF-β 
TGF-β 1, 2 and 3 are all synthesized intracellularly as precursor molecules. After synthesis 
the TGF-β molecules are secreted as part of an inactive complex comprising of an N-
terminal latency-associated peptide (LAP) and a mature TGF-β monomer at the C terminal. 
Homodimers of TGF-β and LAP interact in a non-covalent manner forming a complex 
known as small latent complex (SLC)208. LAP is then covalently linked to one of three latent 
TGF-β binding proteins (LGBTs) to form a larger complex called a large latent complex (LLC) 
which is then secreted out of the cell into the extracellular matrix209. 
The LLC will then remain in the extracellular matrix in an inactive state and requires further 
processing to release the active TGF-β product210. The presence of TGF-β in an inactive 
complex allow for the closer regulation of TGF-β signalling, as many cells express TGF-β 
receptors, but it is not always beneficial for TGF-β to be exerting an effect. TGF-β present in 
its latent state allows it to quickly be cleaved to its active state under the right conditions. 
The ubiquitous expression of TGF-β and its receptor suggest that its regulation must be 
complex and multifactorial but one of the most important mechanisms of preventing the 
effect of TGF-β is by stopping the release of the TGF-β molecule. 
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1.14.1.1 Enzyme mediated TGF-β activation: 
For TGF-β to become activated, the TGF-β molecule must be cleaved form the LAP and 
LTBP in the LLC. Within a lab, TGF-β can be activated within a sample by lowering the pH to 
2.0 for a short period of time. This method will activate all the TGF-β present in a sample211. 
There are other in lab methods which can be used to activate TGF-β but transient 
acidification is the most effective212. 
TGF-β can be activated by surface receptors and protease activity. Proteases are able to 
release the LLC from the tissue matrix213, 214. When the LLC is free of the matrix, the LAP can 
bind to surface receptors and undergo a conformational change or be further acted upon 
by proteases to release TGF-β212. 
1.14.1.2 Receptor mediated TGF-β activation: 
Receptors for LAP as part of the LLC have recently been characterised which allow cells to 
hold latent TGF-β on their surface which can then be activated and delivered to its own or 
other cells TGF-β receptors215, 216. An example of this is seen with macrophages which bind 
latent TGF-β which has either been produced by the macrophage itself or has come from 
the environment. The macrophage then activates the latent TGF-β which allows it to bind 
to its TGF-β receptor217. Regulatory T cell activity through TGF-β is thought to involve the 
binding of latent TGF-β to one cell, which is then activated and delivered to other cells, 
allowing the suppression of other T cells218-220.  
Several surface binding proteins for LAP have been identified including multiple αV 
containing integrins. These receptors are found on the surface of many different cell types 
involved in the repair of wounds and inflammation including dendritic cells, endothelial 
cells and myofibroblasts212.  
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αvβ6 was the first alpha containing integrin to be implicated in TGF-β activation. LAPs 
contain an RGD motif which is recognized by the majority of alpha containing integrins. 
αvβ6 activates TGF beta 1 by binding to the RGD motif present in LAP β1 and LAP β3. When 
bound TGF-β is liberated from its latent complex221. 
In mouse models where the integrin αVβ8 is knocked out on their dendritic cells, 
autoimmunity and colitis are seen. These dendritic cells become unable to induce the 
activation of Treg cells, an effect which is reversed if active TGF-β is added222, 223.  
1.14.2 Signalling pathways 
TGF-β signalling occurs through a heterotetrameric receptor complex which comprises of a 
type 1 receptor dimer and a type 2 receptor dimer. The receptors within the complex are 
serine/threonine kinase receptors with a cysteine rich extracellular domain, a 
transmembrane domain and a serine/threonine rich domain. Signalling begins with the 
binding of TGF-β ligand to a TGF-β type 2 receptor224. This binding leads to the rotation of 
the receptors to allow the exposure of the cytoplasmic kinase domains. The type 2 receptor 
then catalyses the phosphorylation of the serine residues of the type 1 receptor225. The 
type 2 receptor bound depends on the TGF-β ligand as there are different type 2 receptors 
for each class of ligand.  
1.14.3 Smad pathway 
Smads are a class of intracellular signalling proteins that mediate the signalling of members 
of the TGF-β superfamily. Smads can be classified into three distinct groups based on their 
roles in TGF-β signal transduction. These groups are receptor regulated Smads (R-Smads), 
common partner Smads (Co-Smads) and inhibitory Smads (I-Smads)225. The 
phosphorylation of the type 1 receptor leads to the recruitment of R-Smads. In most cell 
types Smad 2 and Smad 3 are recruited and phosphorylated. In other cells Smad 1 and 
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Smad 5 can be activated depending on which type 1 receptor is expressed by the cell225. 
When the R-Smad protein has been activated it associated with the Co-Smad, Smad 4226. 
This R-Smad/Co-Smad complex is then translocated into the nucleus of the cell where it is 
responsible for the regulation of gene expression. I-Smads prevent R-Smads from 
interacting with the TGF-β receptor or compete with Co-Smads to prevent the generation 
of the R-Smad/Co-Smad complex. I-Smads play a key role in the regulation of TGF-β 
signalling by negative feedback227. 
1.14.4 TGF-β and regulatory T cells 
TGF-β and Treg cells are both important in the control of immune responses and in the 
maintenance of immune homeostasis. TGF-β appears to play a role as an effector cytokine 
involved in the immunosuppressive function on Treg cells.  
TGF-β 1 has a role in the induction of both inducible Tregs which have an inhibitory role 
and Th17 cells which are responsible for the production of numerous pro-inflammatory 
cytokines including IL17A228. 
There are several mouse models that have been established which allow the investigation 
of the role of TGF-β in immune regulation. TGF-β -/- mice allowed the realisation of how 
important TGF-β 1is in immune system regulation. The mice in this model develop a rapid 
wasting syndrome which leads rapidly to death229.  Transgenic mice that have an impaired 
TGF-β signalling pathway show an increased susceptibility to the induction of disease, 
although it is not as severe as disease seen in TGF-β -/- mice230. Mice can survive for several 
months without developing severe disease. This can be explained by TGF-β acting on 
multiple cell types. So TGF-β can still influence some cells but not others. So, mice show a 
susceptibility to the induction of allergic and autoimmune responses without developing 
spontaneous autoimmune disease. 
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1.15 Integrins 
Integrins are transmembrane receptors that act as a bridge for interactions between two 
cells or between cells and the extracellular matrix231. Integrins are responsible for triggering 
chemical pathways which pass information about the exterior of the cell into the interior of 
the cell. In this way the chemical composition or the mechanical nature of the cell can be 
monitored, and events triggered at the cell surface can be rapidly responded to231. At least 
18 alpha and 8 beta subunits have been identified in humans, which combine to form 24 
different integrins. 
Integrins possess no enzymatic activity which makes them different to other signalling 
receptors. Their signalling is reliant on cross talk with other signalling pathways, in 
particular, growth factor (GF) signalling pathways232. 
The two main functions of integrins are in the attachment of the cell to the extracellular 
matrix and in signal transduction from the extracellular matrix to the cell233. They do play a 
role in various other biological activities including cell migration and immune 
patrolling234.The integrin αvβ8 has been shown to have a role to play in the activation of 
TG-β 1235. In this thesis we have explored the role of the integrin αvβ8 in the activation of 
TG-β and therefore in the activation of Foxp3+ Treg cells. 
 1.15.1 TGF-β and the integrin αvβ8 in the development of Treg cells 
TGF-β plays a fundamental role in the development of Treg cells and has a role in the 
induction of both induced and natural Tregs236. In addition to roles in Treg cell 
development, TGF-β plays an important role in the functional ability of Treg cells to 
suppress T cell responses. As already discussed, TGF-β exists in an inactive state that must 
be activated in order for it to bind to its receptor and exert a suppressive effect. TGF-β 
activators include a variety of proteases and cell surface molecules which are able to alter 
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latent TGF-β to enable the active state to bind to its receptor237. Foxp3+ Treg cells have 
been shown to be able to activate TGF-β via the expression of the integrin αvβ8 and on 
activated Treg cells, this integrin is upregulated235. If Treg cells lack the expression of αvβ8 
they become completely unable to suppress T cell mediated inflammatory responses235. 
1.16 Aims/Objectives of this Thesis 
The aims of this thesis are as follows 
1. To investigate the frequency of Foxp3+ Treg cells in NALT and PBMC in both 
children and adults. 
2. To investigate the frequency of Tr1 cells in NALT and PBMC samples in 
children and adults. 
3. To investigate whether stimulation using Pneumococcal concentrated 
culture supernatant (CCS) with and without pneumolysin and capsular 
polysaccharide can activate Foxp3+ Treg cells. 
4. To investigate if the toxoid of pneumolysin W433F and purified capsular 
polysaccharides T3P and 6B can activate Foxp3+ Treg cells in tonsillar MNC. 
5. To investigate whether stimulation using pneumococcal CCS with and 
without the pneumolysin and capsular polysaccharide can activate Tr1 cells 
in tonsillar MNC. 
6. To investigate if the toxoid of pneumolysin W433F and purified capsular 
polysaccharides T3P and 6B can activate and induce Tr1 cells in tonsillar 
MNC.  
7. To investigate the role of TGF-β in he activation of Foxp3+ Treg cells and the 
role of the integrin αVβ8 
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Chapter 2 
Materials and Methods 
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2.1 Subjects and Samples 
2.1.1 Subjects  
Samples used in this study were collected from children and adult patients undergoing 
adenoidectomy and/or tonsillectomy due to upper airway obstruction or tonsillitis, 
attending Alder Hey Children’s Hospital and Royal Liverpool and Broadgreen University 
Hospitals. Patients who had any known immunodeficiency were excluded from the study. 
The study was approved by the local ethics committee (Liverpool Paediatric Research Ethics 
Committee) and written informed consent was obtained from each patient or their legal 
guardians as appropriate. 
2.1.2 Patients Samples 
2.1.2.1 Adenotonsillar Tissues 
Immediately after surgery, adenotonsillar tissue was transferred into a 25ml universal tube, 
containing 10-15ml of Hank’s Balanced Salt Solution (HBSS) (Sigma Aldrich, UK) 
supplemented with 10μg/ml gentamycin (Sigma) and 1% L-glutamine (Sigma Aldrich). The 
tissue was then transported to the laboratory ready for processing. 
2.1.2.2 Peripheral Blood 
25 ml universal tubes containing heparin (LEO Pharma, UK), an anticoagulant, were used to 
collect 2-5 ml of blood prior to surgery. This was then transported to the laboratory, ready 
for processing on arrival. 
2.1.2.3 Nasopharyngeal Swabs 
Nasopharyngeal swabs were collected into a sterile vial containing 1ml Skim milk- 
Tryptone-Glucose-Glycerine (STGG) broth. Before the operation (while patient was 
anaesthetised), the nasopharyngeal swab sample was collected using a sterile Dryswab™ 
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(Medical Wire & Equipment, UK). The swab was then inoculated into a vial containing 
STGG, before transportation to the laboratory, where it was stored in a -80°C freezer ready 
for analysis at a later date. 
2.1.2.4 Saliva 
Before surgery, a sample of saliva was collected with a sterile ‘Oracol’ sponge swab 
(Malvern Medical Developments Limited, UK). The absorbent sponge swab was placed in 
the mouth and left for approximately one minute to allow absorbance of saliva. Once 
saturated, the saliva swab was placed into a test tube and transported to the laboratory. 
Upon arrival at the laboratory the saliva swab was placed in a 20 ml syringe and the saliva 
was forced out of the swab into a 1.5 ml eppendorf tube. This was then immediately stored 
in a -80°C freezer ready for analysis later. 
2.2 Processing of Samples 
2.2.1 Isolation of mononuclear cells from adenotonsillar tissue 
All processing of adenotonsillar tissue samples occurred within a class II safety cabinet to 
prevent any contamination of cells. Adenotonsillar tissue was washed with 5 ml of HBSS 
two to three times to ensure the sample was clean and ready for processing.  15-20 ml of 
HBSS was added into a sterile petri dish and the adenotonsillar tissue was transferred into 
the dish. Using fresh sterilised scalpel and forceps the tissue was mashed for several 
minutes to release the cells into the media. The media containing the cells was carefully 
passed through a 70 µm filter (BD biosciences, USA) into a fresh universal tube. In some 
instances, where a blockage of the filter occurred, several filters were used. Cells were then 
layered on top of 15-20 ml Ficoll-Paque™ PREMIUM (GE Healthcare Life Sciences, UK) using 
a Pasteur pipette. This was done very slowly with the universal held at a slight angle to 
prevent the filtrate mixing with the ficoll. The sample was centrifuged at 400 x g for 30 
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minutes with the brake set to 1. After centrifugation a clear interface layer of cells was 
formed which was then transferred using a Pasteur pipette into a fresh universal tube. This 
was topped up to 45 ml with sterile PBS solution (Sigma, UK) before being centrifuged at 
400 x g for 10 minutes. The supernatant was then poured off into a waste bottle and the 
pellet was re-suspended using a vortex. Cells were re-suspended in 3-5 ml of sterile RPMI-
1640 culture medium with HEPES (Sigma-Aldrich, UK) supplemented with 10% heat 
inactivated Foetal Bovine Serum (FBS) (Sigma), 1% L-glutamine (Sigma), streptomycin 
(50μg/ml) and penicillin (50U/ml) (Sigma-Aldrich) and counted using an automatic cell 
counter. (BioRad, UK). After counting, each cell suspension was adjusted to contain 4x106 
cells/ml concentrations. 
2.2.2 Collection of blood serum and isolation of peripheral blood mononuclear cells 
(PBMCs) 
Peripheral blood samples were centrifuged at 400 x g for 10 minutes to allow collection of 
serum. Serum was collected in approximately 500 µl aliquots in 1.5 ml eppendorf tubes and 
stored at -80°C. Following serum collection, the PBMC’s were isolated.  To do this, 
Peripheral blood was carefully layered onto 10 ml Ficoll Paque™ PREMIUM (GE Healthcare 
Life Sciences, UK). Gradient centrifugation of the sample at 400 x g for 30 minutes allowed 
the collection of the mononuclear cell layer which was then washed with sterile PBS 
(Sigma) at 400 x g for 10 minutes. The cells were then re-suspended in 1 ml RPMI-1640 
culture medium with HEPES (Sigma-Aldrich, UK) supplemented with 10% heat inactivated 
FBS (Sigma), 1% L-glutamine (Sigma), streptomycin (50μg/ml) and penicillin (50U/ml) 
(Sigma-Aldrich); and counted in an automated cell counter (BioRad). Cells were then 
further re suspended in culture medium and the concentration adjusted to 4 x 106 cells/ml. 
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2.3 Pneumococcal concentrated culture supernatant (CCS) 
The strain used in this study was Streptococcus pneumoniae encapsulated type 2 strain D39 
(NCTC7466)238. An isogenic pneumolysin deficient mutant (Ply-/-) was also used239. 
Concentrated pneumococcal culture supernatant (Pneumococcal CCS) was prepared from 
these strains following a method outlined previously240. Optimal dose concentrations were 
determined prior to cell stimulation to be 1 µg/ml. 
2.3.1 Preparation of pneumococcal CCS 
 Bacterial frozen stocks were cultured overnight on blood agar plates (Fisher Scientific, UK) 
(37°C, 5% CO2). After about 18 hours, typical α-haemolytic colonies of S. pneumoniae were 
observed. Several colonies were then used to inoculate Todd Hewitt Broth (THB) (Oxoid, 
UK) containing 5% yeast extract which was then cultured overnight (37°C, 5% CO2). The 
following day, the optical density of the culture was measured at 620nm and then this was 
checked every 30 minutes until exponential phase of growth was reached (OD of 0.4-0.5 at 
620nm). The broth culture was centrifuged at 3000 x g for 30 minutes and the supernatant 
removed. The supernatant was then passed through a 0.45 µm filter followed by a 0.2 µm 
filter. Concentration of the pneumococcal culture supernatant was then achieved by 
centrifuging the sample at 3000 x g for 30 minutes in a Vivaspin15 concentrator (Sartorius 
Stedim Biotech, Germany). This process was repeated several times to ensure that the 
sample was concentrated tenfold. Samples were then aliquoted into 1.5 µl microcentrifuge 
tubes and stored at -80°C until use.  
2.3.2 Measurement of protein concentration in pneumococcal CCS. 
The protein concentration of pneumococcal CCS was measured using the Bradford protein 
assay and involved the use of Bradford protein dye reagent (Sigma) following 
manufacturer’s instructions. The principle of this assay is to compare sample dilutions 
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against a known standard curve in order to work out the concentration of your sample. The 
standard curve used is a Bovine Serum Albumin (BSA) standard curve. A stock 
concentration of 2 mg/ml of BSA was serially diluted (two-fold) in sterile PBS five times to 
give the BSA curve. Samples were diluted serially (ten-fold) three times. 5 µl of sample or 
BSA standard was added to the appropriate well of a 96-well Costar plate and 250 µl of 
Bradford reagent was then added. The plate was incubated in the dark for 5 minutes before 
absorbance was read at 595nm using the ThermoElectron MultiSkan (Opsys MR, Thermo 
labsystems, UK). A standard curve was produced from the readings of the BSA dilutions and 
this was used to work out the concentrations of the samples using DeltasoftPC microplate 
reader software. (Biometallics Inc., USA). 
 
Figure 2.3.1: Standard curve of Bradford protein assay 
Pneumococcal CCS Concentration (mg/ml) 
Concentration used to 
simulate cells 
D39 WT 0.641 1µg/ml 
Ply-/- 0.733 1µg/ml 
 
Table 2.3.1: Concentration of Pneumococcal CCS measured by Bradford protein assay 
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2.4 Western Blotting 
2.4.1 Principle of the assay 
This method is a widely accepted analytical technique in which proteins are separated on 
sodium dodecyl phosphate- polyacrylamide gels (SDS-PAGE), according to their molecular 
weight. These proteins are then transferred into a nitrocellulose or PVDF membrane. Non-
specific binding is blocked with bovine milk (skimmed) protein, before the target protein is 
detected using antibodies specific to the target protein. A primary antibody is added which 
is specific the target protein before the addition of a secondary antibody specific to the 
primary antibody. The Secondary antibody commonly labelled with horseradish peroxidase 
or alkaline phosphatase cleaves a chemiluminescent agent to provide luminescence in 
proportion to the amount of protein present241. 
2.4.2 Western Blotting of Pneumococcal CCS 
To confirm the presence of pneumolysin in the WT and absence of Pneumolysin in the Ply-
/- mutant strain western blotting was used. This involved the following a multi-step process 
which is outlined below. 
2.4.2.1 Gel Electrophoresis 
Samples were prepared by diluting 1:2 using Laemmli reducing Buffer242 before being 
heated on a heat block at 100°C for 5 min. The gel was loaded into the tank before the 
addition of running buffer into the middles and side of the chamber. The comb was gently 
removed to prevent any tearing of the gel. 20 μl of prepared WT, Ply-/- and Cap -/- 
pneumococcal CCS and 5 μl of precision plus protein kaleidoscope ladder (Bio-Rad, UK) 
were loaded into the wells using long sample loading tips. Electrodes were connected 
between the tank and the power pack and run for 1 hr at a constant 250v in 50mA. 
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2.4.2.2 Protein Transfer by Western blotting 
The gel was removed from the tank after gel electrophoresis and carefully placed in 
transfer buffer. The stacking gel was gently cut from the resolving gel using a sharp scalpel. 
The transfer of the protein was performed using a Transblot TurboTM transfer system 
(BioRad) into a 0.2µm nitrocellulose membrane (Transblot turbo transfer pack). Protein is 
transferred using electroblotting which involves the use of a current to pull the protein 
from the gel onto the nitrocellulose membrane. The gel was placed onto a nitrocellulose 
membrane which was then placed onto the bottom ion reservoir (anode) stack. The top ion 
reservoir (cathode) stack is then placed on top of the gel and a constant current of 25v in 
1000mA was applied for 10 minutes. 
2.4.2.3 Detection of Pneumolysin (Ply) proteins in pneumococcal CCS 
Following transfer of the protein, the nitrocellulose membrane was blocked with 5% 
skimmed milk in TBS containing 0.05% Tween20 (TBS-T) for 2 hr at room temperature (RT). 
The membrane was then washed 3 times in TBS-T before the addition of rabbit anti-Ply 
(diluted 1:10000 in blocking solution) was added. Next, the membrane was incubated at 
room temperature for 2 hours before being washed 5 times in TBS-T. The membrane was 
then incubated with secondary antibody, donkey anti-rabbit IgG-HRP (diluted 1:10000 in 
blocking solution) for 1 hour at room temperature. Following incubation, the membrane 
was washed 5 times with TBS-T and then once in PBS before the addition of substrate to 
the membrane. The substrate was prepared by adding 1:1 volume of chemiluminescence 
reagent A and B (BioRad).  The substrate and membrane were incubated for 5 minutes in 
the dark at room temperature before the removal of excess substrate at which point the 
membranes were imaged using the Chemi-DocXRS system (BioRad) 
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Figure 2.4.2.3 Western blot analysis of pneumococcal CCS Nitrocellulose membrane 
blotted with pneumococcal CCS were immunostained with rabbit anti-Ply antiserum 
showing that pneumolysin is present in D39 WT and absent in Ply-/- 
 
2.5 Analysis of immune cells by Flow Cytometry 
2.5.1 Principle of test 
Flow cytometry is a laser-based technology which allows the measurement and analysis of 
both physical and chemical characteristics of single cells within a fluid as they pass through 
a focussed laser beam. Flow cytometry allows the measurement of a cells size, granularity 
and fluorescence. As the cells within a fluid suspension pass through the interrogation 
point of the flow cytometer, light is scattered in all directions. Light scattered in the 
forward direction or forward scatter (FSC) represents the size of the cells with larger cells 
being represented by a higher forward scatter signal. Light scattered in a sideways direction 
or side scatter (SSC) represents the granularity of cell. More granular cells are shown to 
have a higher side scatter signal. Within a sample containing a mixed population of cells, 
FSC and SSC allow the distribution of different subsets of cells. As well as FSC and SSC, flow 
cytometry can be used to measure the fluorescence of a cell. Cells which are fluorescently 
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labelled and are then excited by the laser, emit light of varying wavelengths which allow 
further characterisation of the cell243-245. 
Flow Cytometric analysis in this project was carried out using the BD FACS Calibre (BD 
Biosciences). Different subsets of lymphocytes were defined with multiple parameters, 
including FSC and SSC based gating. Fluorescence emissions of different fluorochromes 
were measured at different wavelengths; FITC or Alexafluor488 in FL1 at 519nm, PE in FL2 
at 578nm, PerCPCy5.5, PECy5 or PECy7 in FL3 at 695nm, and APC or Alexafluor660 in FL4 at 
660nm. Data was acquired with Cell Quest software (BDBiosciences) and analysed with 
WinMDI 2.9 software 
2.5.2 Intracellular cytokine staining  
2.5.2.1 Principle of intracellular cytokine staining 
Cytokine production is an important part of the immune response. Specific cytokines are 
rapidly produced and secreted upon cellular activation by the correct stimulus under the 
correct conditions. Cytokines play an important role in many different pathways including 
the induction and activation of different T cell subsets246. 
Intracellular cytokine staining (ICS) is a very widely used flow cytometry-based assay which 
is used to detect cytokines within the endoplasmic reticulum after cell stimulation. During 
ICS, cells are activated using either a specific peptide or a non-specific mix. After activation 
cells are incubated with a protein transport inhibitor such as Brefeldin A (BFA), by which 
the accumulated cytokines are retained within the endoplasmic reticulum of the cell. 
Cells are then washed before being stained with specific antibodies to cell surface markers 
(e.g. CD3, CD4 or CD8). Finally, cells are fixed, and cell membrane was permeabilised before 
the addition of antibodies specific to the cytokine that to be detected. 
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2.5.2.2 Identification of regulatory T cells  
To detect the presence of Foxp3+ regulatory T cells and Tr1 cells, cells were stained with 
antibodies specific to each cell type. Immediately after sample processing, 500 µl of cells 
from adenotonsillar tissue diluted to 4x106, or 500 µl of cells from peripheral blood diluted 
to 2x106 were added to wells of a 48-well flat bottom culture plates (Corning Inc., USA). 
BFA was added and the plates were incubated at 37°C for 4 hours. Intracellular staining of 
cells using anti-Foxp3 or anti-IL-10 antibodies allowed the identification of these cells for 
Foxp3+ T regulatory cells or IL10-producing Tr-1 cells in both adenotonsillar tissue and 
peripheral blood. 
2.5.3 Staining procedure 
2.5.3.1 Foxp3+ Treg cell staining 
Foxp3+ Treg cells have an important role in the prevention of auto immune disease and in 
the maintenance of immune tolerance. Foxp3+ Treg cells possess several surface markers 
which can be used to distinguish them from other cell types. These include CD25, CTLA-4, 
CD103 and CD39. Foxp3+ Treg cells also express the intracellular transcription factor Foxp3 
and this is a marker specific to both thymic and peripheral Foxp3+ Treg cells. 
To determine the presence of Foxp3+ Treg cells, after the 4-hour incubation with BFA, 
adenotonsillar MNC were harvested from the plates into 1.5 ml Eppendorf tubes and 
washed with FACS staining buffer (0.02% PBS-BSA) by centrifugation at 600 x g for 8 
minutes. After washing, 5 µl of PeCy7 (BD Bioscience) conjugated CD4 was added to each 
sample and before they were incubated at 4°C for 30 minutes. Cells were then washed 
using 1 ml of FACS staining buffer, followed by centrifugation at 600 x g for 8 minutes. 350 
µl of fixation/permeabilisation buffer was added to each sample and they were incubated 
for 30 minutes at room temperature. Cells were then washed, followed by centrifugation at 
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600 x g for 8 minutes in permeabilisation buffer before the addition of 15 µl of Alexafluor 
647 (BD Bioscience) conjugated Foxp3 to each sample. This was incubated at room 
temperature for a further 30 minutes, followed by a final wash step using 1 ml of 
permeabilisation buffer per sample for 8 minutes at 600 x g. The final step was the addition 
of 500 µl of FACS staining buffer to each tube ready for FACS analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.3.1. A representative figure which shows the gating strategy used for the identification 
of Foxp3+ Treg cells (CD4+Foxp3+) in freshly isolated tonsillar MNC. 
R1 highlights the lymphocyte population, defined using typical FSC and SSC. Within the lymphocyte 
population the CD4+ cells are then defined in R2. Finally, the Foxp3+ Treg cells are identified by the 
gating of the CD4+ population (R2) and the positive staining of Foxp3. This CD4+Fox3+ cell 
population is defined as the frequency of Treg cells and is shown as a percentage 
 
2.5.3.2 Tr1 cell staining procedure  
Tr1 cells are a suppressive subset of regulatory T cell which exert their effect mainly though 
the production of IL10. Tr1 cells can be identified by the co expression of surface markers 
CD49b and Lag 3 and the high expression of IL101.  This is the combination of markers I was 
staining for to identify a cell population as being Tr1 cells.  
To detect Tr1 cells, after incubation with BFA, adenotonsillar MNC were harvested from the 
plates into 1.5 ml Eppendorf tubes and washed with FACS staining buffer (0.02% PBS-BSA) 
by centrifugation at 600 x g for 8 minutes. After washing, 20 µl of Alexafluor 647 (BD 
Bioscience) conjugated CD49b, and 5 µl of PeCy7 (BD Bioscience) conjugated CD4 was 
R2 
R1 
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R1 
R2 R3 
(a) (b) (c) 
(d) (e) 
added to each sample and tubes were incubated at 4 degrees for 30 minutes. 
Adenotonsillar MNC or PBMC were then washed using 1 ml of FACS staining buffer at 600 x 
g for 8 minutes. 350 µl of fixation/permeabilisation buffer was added to each sample and 
tubes incubated for 30 minutes at room temperature. Cells were then washed in 
permeabilisation buffer followed by centrifugation at 600 x g for 8 minutes, before the 
addition of 5 µl of APC (BD Bioscience) Conjugated IL10 and 20 µl of PE (R&D Systems) 
conjugated LAG3 to each sample. This was incubated at room temperature for a further 30 
minutes followed by a final wash step using 1 ml of permeabilisation buffer per sample, 
followed by centrifugation for 8 minutes at 600 x g. The final step was the addition of 500 
µl of FACS staining buffer to each tube ready for FACS analysis. 
Figure 2.5.3.2. A representative figure which shows the gating strategy used for the identification 
of Tr1 cell frequency in freshly isolated tonsillar MNC and PBMC.  
The lymphocyte population is highlighted in R1, using the typical FSC and SSC configuration. (b) 
Within the lymphocyte population the CD4+ cells are defined in R2. (c) R3 then highlights the cells 
within R2 which are both CD49b+ and LAG3+ and are therefore defined as Tr1 cells. (d) IL10 positive 
cells within the CD4+ lymphocyte population. (e) In order to confirm the cells in R3 are Tr1 cells they 
are then gated against IL10. 
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2.5.4 Activation of regulatory T cells 
2.5.4.1 Foxp3+ Treg cells 
2.5.4.1.2 Cell stimulation 
500 µl of tonsillar MNC suspension at a concentration of 4 x 106 was stimulated for 3 days 
and kept in an incubator at 37°C in 5% CO2. After 3 days, 0.5 µl of a protein transport 
inhibitor, Brefeldin A (BFA) was added to each sample before further incubation at 37°C in 
5% CO2 for 4 hours. The incubation was then stopped, the plate wrapped in cellophane and 
left in the fridge overnight. 
2.5.4.1.3 Cell harvest and staining 
The following morning cells were harvested from the plated into 1.5 ml Eppendorf tubes 
and washed with FACS staining buffer (0.02 %PBS-BSA) by centrifugation at 600 x g for 8 
minutes. After washing 50 µl of a master mix containing 20 µl of CD25 and 5 µl of CD4 were 
added to each sample and incubated at 4°C for 30 minutes. Cells were then washed using 1 
ml of FACS staining buffer at 600 x g for 8 minutes. 350 µl of fixation/permeabilisation 
buffer was added to each sample and incubated for 30 minutes at room temperature. Cells 
were then washed in permeabilisation buffer followed by centrifugation at 600 x g for 8 
minutes before the addition of 50 µl of a master mix containing 15 µl of Foxp3 was added 
to each sample. This was incubated at room temperature for a further 30 minutes followed 
by a final was step using 1 ml of permeabilisation buffer per sample for 8 minutes at 600 x 
g. The final step was the addition of 500 µl of FACS staining buffer to each tube ready for 
FACS analysis. 
2.5.4.2 Activation of Tr1 cells 
2.5.4.2.1 Cell stimulation 
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500 µl of tonsillar MNC suspension at a concentration of 4 x 106 was stimulated for 3 days 
and kept in an incubator at 37°C in 5% CO2. After 3 days 0.5 µl of a protein transport 
inhibitor, Brefeldin A was added to each sample before further incubation at 37°C in 5% 
CO2 for 4.5 hours. The incubation was then stopped, the plate wrapped in cellophane and 
left in the fridge overnight. 
2.5.4.2.2 Cell harvest and staining 
The following morning cells were harvested from the plate into 1.5 ml Eppendorf tubes and 
washed with FACS staining buffer (0.02%PBS-BSA) by centrifugation at 600 x g for 8 
minutes. After washing 50 µl of a master mix containing 20 µl of CD49b, 20 µl of LAG3 and 
5 µl of CD4 were added to each sample and incubated at 4 degrees for 30 minutes. Cells 
were then washed using 1 ml of FACS staining buffer at 600 x g for 8 minutes. 350 µl of 
fixation/permeabilisation buffer was added to each sample and incubated for 30 minutes 
at room temperature. Cells were then washed at 600 x g for 8 minutes in permeabilisation 
buffer before the addition of 50 µl of a master mix containing 5 µl of IL10 was added to 
each sample. This was incubated at room temperature for a further 30 minutes followed by 
a final was step using 1 ml of permeabilisation buffer per sample for 8 minutes at 600 x g. 
The final step was the addition of 500 µl of FACS staining buffer to each tube ready for 
FACS analysis. 
2.5.4.3 Induction of Tr1 cells 
2.5.4.3.1 Principle of MACS separation 
MACS cell separation allows cells which have a certain marker to be isolated from a cell 
population. This can be either positive selection to obtain a pure cell population or negative 
selection to remove a cell type from the whole cell population.  
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The cells which are to be depleted are magnetically labelled with specific microbeads which 
bind to specific target molecules. In this case, with CD45RO beads and CD25 beads. The 
cells are then passed through a MACS LD column which is placed within magnetic field of a 
MACS cell separator. The unlabelled cells which do not express the target molecule run 
straight through the column and are collected into a tube. This depleted cell population 
does not contain cells expressing the target molecule. The magnetically labelled cells which 
express the target molecule are retained on the column. 
2.5.4.3.2 Depletion for induction of Tr1 cells 
To remove any pre-existing activated Tr1 cells, CD45RO+ cells were first depleted from the 
cell culture. CD45RO is expressed on several different cell types. It is found on both 
memory CD4+ and CD8+ T cells as well as being present on CD4+ effector T cells, 
macrophages and monocytes. The depletion of CD45RO+ cells produces a naïve cell 
population allowing the analysis of naïve CD4+ T cells by flow cytometry.  
2.5.4.3.3 Magnetic labelling and depletion of CD45RO 
Approximately 50 x 106 cells were taken from the pure cell mix and re-suspended in 400 µl 
(80µl/107 cells) of depletion buffer (0.5% PBS BSA). To this 100µl (20µl/107 cells) of 
CD45RO magnetic beads (Miltenyi Biotech) were added. The cell suspension was 
thoroughly vortexed followed by incubation at 4 degrees for 15 minutes. Following 
incubation, cells were washed with 10 ml (2 ml/107 cells) of depletion buffer at 400 x g for 
10 minutes. The cell pellet formed was re-suspended in 250µl (50µl/10 cells) before 
magnetic separation was carried out. The MACS LD column (Miltenyi Biotech) was placed 
inside the magnetic groove of the magnet and primed by the addition of 2 ml of depletion 
buffer, with acre being taken to avoid bubbles. The cell suspension was then added to the 
column carefully and allowed to pass through. This process could take some time 
depending on the number of CD45RO cells present in the sample. After all the cell 
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suspension had passed through the column, 2 ml of depletion buffer was passed through 
the column. The collected CD45RO- T cells collected by this process were then re 
suspended in RPMI medium to a concentration of 4 x 106 cells/ml. Analysis of these cells 
through stimulation using pneumococcal antigens and FACS analysis was performed 
following techniques described previously for non-depleted lymphocytes.  
2.6 Enzyme-Linked Immunosorbent Assay (ELISA) for measurement of 
cytokine production in cell culture supernatant 
2.6.1 Principle of assay  
Enzyme Linked Immunosorbent Assay (ELISA) is a highly sensitive biochemical assay 
technique designed for detecting and quantifying substances. The basis of the test is to use 
antibodies and colour change to identify a specific substance.  The assay involves the use of 
a specific monoclonal antibody to coat a microtiter plate. When the sample which is being 
analysed is added to the plate, the specific antibody that has coated the plate will capture 
the protein of interest. A second monoclonal antibody is then added to the plate which is 
specifically designed for detection. The detection antibody is labelled with biotin to allow 
the subsequent binding of a streptavidin conjugated enzyme. Throughout the addition of 
each antibody and enzyme, the plate is washed which allows for the removal of any 
unbound protein. The final step is the addition of substrate which causes a colour change 
proportional to the amount of protein bound. A standard curve is created which allows the 
concentration of the specific protein in the sample to be determined247, 248.  
2.6.2 Measurement of IL-10 
In vitro production of IL-10 in adenotonsillar MNC cultures was measured using the human 
IL-10 ELISA Ready-Set-Go® set (eBioscience, UK) following manufacturer’s instructions. 
Capture antibody in coating buffer was used to coat 96-well Costar plates (Corning). The 
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plates were sealed and left overnight at 4°C. The following morning the plate was washed 5 
times with PBS-T using a plate washer. After washing, plates were blotted on absorbent 
paper to remove any residual buffer. 5 x concentrated assay diluent was diluted to 1 x 
assay diluent by mixing with 4 parts dH20. Each well was blocked using 200 µl of 1 x assay 
diluent. The plate was then incubated for 1 hour at room temperature. During the 
incubation period the samples and the highest concentration of the standard were 
prepared. The highest concentration of the standard (500 pg/ml) was prepared by adding 5 
µl human IL-10A recombinant protein into 10 ml of 1 x assay diluent. Samples were 
prepared by diluting 1:20 in 1x assay diluent. When the incubation was over 100 µl of 
samples and standards were added to the plate. The standards were prepared in duplicate 
starting from the highest concentration at the top followed by 2-fold serial dilution to give 
a total of 16 standards. The plate was incubated for 2 hours at room temperature. During 
the incubation detection antibody was prepared by adding 44µl of purified anti-human IL-
10 Biotin to 11 ml of 1 x assay diluent (1:250 dilution) At the end of the incubation period 
the plate was washed 5 time using PBS-T before the addition of 100 µl of detection 
antibody to each well. The plate was incubated for 1 hour at room temperature before 
being washed 5 times with PBS-T. 100 µl of Avidin-HRP (diluted 1:250) was added to each 
well before incubation for 30 minutes at room temperature. The plate was washed 5 times 
with PBS-T before the addition of 100 µl of TMB substrate solution to each well. The plate 
was then incubated in the dark for 15 minutes at room temperature before the addition of 
50 µl of stop solution (1M H2SO4). The final step was the reading of the plate at 450 nm 
using a plate reader. The concentration (pg/ml) was calculated using the standard curve 
generated using DeltasoftPC software (Biometallics). 
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2.6.3 Measurement of TGF-B 
In vitro production of TGF-β in adenotonsillar MNC cultures was measured using the human 
TGF-β ELISA Ready-Set-Go® set (eBioscience, UK) following manufacturer’s instructions. 
Capture antibody in coating buffer was used to coat 96-well Costar plates (Corning). The 
plates were sealed and left overnight at 4 °C. The following morning the plate was washed 
5 times with PBS-T using a plate washer. After washing, plates were blotted on absorbent 
paper to remove any residual buffer. 5 x concentrated assay diluent was diluted to 1 x 
assay diluent by mixing with 4 parts dH20. Each well was blocked using 200 µl of 1 x assay 
diluent. The plate was then incubated for 1 hour at room temperature. During the 
incubation period the samples and the highest concentration of the standard were 
prepared. The highest concentration of the standard (500pg/ml) was prepared by adding 5 
µl human TGF-β recombinant protein into 10 ml of 1 x assay diluent. Samples were 
prepared by diluting 1:20 in 1 x assay diluent. When the incubation was over 100 µl of 
samples and standards were added to the plate. The standards were prepared in duplicate 
starting from the highest concentration at the top followed by 2-fold serial dilution to give 
a total of 16 standards. The plate was incubated for 2 hours at room temperature. During 
the incubation detection antibody was prepared by adding 44 µl of purified anti-human 
TGF-β Biotin to 11 ml of 1 x assay diluent (1:250 dilution) At the end of the incubation 
period the plate was washed 5 time using PBS-T before the addition of 100 µl of detection 
antibody to each well. The plate was incubated for 1 hour at room temperature before 
being washed 5 times with PBS-T. 100 µl of Avidin-HRP (diluted 1:250) was added to each 
well before incubation for 30 minutes at room temperature. The plate was washed 5 times 
with PBS-T before the addition of 100 µl of TMB substrate solution to each well. The plate 
was then incubated in the dark for 15 minutes at room temperature before the addition of 
50 µl of stop solution (1M H2SO4). The final step was the reading of the plate at 450 nm 
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with a plate reader. The concentration (pg/ml) was calculated using the standard curve 
generated using DeltasoftPC software (Biometallics). 
2.7 Statistical Analysis  
Data were analysed using GraphPad Prism version 5.  Initially data was tested for normality 
using D’Agostino and Pearson omnibus normality test. Analysis of data that did not pass the 
normality test was then done using non-parametric tests while the data that did pass the 
normality test was analysed using parametric tests. Differences between two groups, for 
example adults and children, were analysed by Student’s t (parametric) or Mann-Whitney 
(non-parametric) test. Differences between paired samples for example stimulated tonsillar 
MNC or stimulated blood samples and unstimulated control cells, were analysed by paired t 
(parametric) or Wilcoxon matched-pairs signed rank (non-parametric) test.  
A p value of <0.05 was taken as a level of statistical significance.    
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Chapter 3 
Characterisation of Foxp3+ T regulatory and 
Type 1 regulatory T cells in Human Nasal 
Associated Lymphoid Tissue and Peripheral 
Blood Mononuclear Cells  
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3.1 Introduction 
Regulatory T cells have been shown to have an important role to play in the modulation of 
different immune responses during auto immune diseases, tumours, transplantation and 
allergy249. They have also recently emerged as being key players in immune regulation 
during microbial infection250. They are important in the control of excessive effector 
immune responses which if allowed to continue unchecked, could lead to severe host 
tissue and cellular inflammation and end up causing more harm than the initial bacterial 
infection. There are several populations of regulatory T cell including CD8+ regulatory T 
cells and CD4+ regulatory T cells. Of the CD4+ Treg cells populations that have been 
identified include Foxp3+ regulatory T cells, Th3 cells and Type 1 regulatory cells (Tr1)251-253.  
(Figure 3.1) 
 
 
 
 
 
 
Figure 3.1 Different subsets of Treg cells. The naturally occurring CD4+CD25+FOXP3+ Treg (nTreg) 
cells are generated in the thymus, whereas three different subsets of inducible Treg (iTreg) cells can 
be generated in the periphery: (i) FOXP3+Treg cells, (ii) CD4+FOXP3− IL-10–producing Tr1 cells and 
(iii) TGF-β-expressing TH3 cells. (From: Regulatory T cells and immune regulation of allergic diseases: 
roles of IL-10 and TGF-β
254
) 
A naturally occurring suppressive subset of T cells was first described in the 1970’s94. 
However due to a series of negative results the hypothesis was rejected. The “suppressor T 
cell” hypothesis was revived by studies showing that a subset of CD4+ T cells which express 
CD25 are essential for control of autoreactive T cells in vivo95.  It was shown that depletion 
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of CD25+ T cells in adult mice led to the development of various autoimmune diseases 
including gastritis95. This work led to the classification of a naturally occurring CD4+CD25+ 
subset of Treg cells. Recently, the discovery of a transcription factor which is expressed on 
this cell type, the forkhead-winged helix transcription factor forkhead box P3 (FoxP3), has 
allowed this cell type to be distinguished from other CD4+CD25+ T cells96.  
3.1.1 Foxp3+ Treg cells 
Foxp3+ Treg cells are the most well studied, and therefore the easiest to categorise. They 
can be natural (nTreg) or inducible (iTreg). (Figure 3.1) nTregs become mature in the 
thymus and make up approximately 5-10% of the circulating peripheral CD4+ T cell 
population255. nTregs are produced in the thymus and subsequently migrate to the 
peripheral blood where they remain, monitoring self-antigen256.  iTregs acquire their 
suppressive activity upon their activation by antigen in the periphery and are specific to the 
antigen, which activates them.  nTregs are thought to have an important role to play in 
maintaining self-tolerance whereas iTregs are thought to be more important at mucosal 
surfaces where they are more likely to encounter foreign antigen.  
Foxp3+ Treg cells possess several surface markers which can be used to distinguish them 
from other cell types. These include CD25, CTLA-4, CD103 and CD39. Foxp3+ Treg cells also 
express the intracellular transcription factor Foxp3 and this is a marker specific to both 
thymic and peripheral Foxp3+ Treg cells. 
Foxp3+ Treg cells use the αβTCR for antigen recognition and are restricted by MHC-II 
molecules as with other CD4+ T cells101. It is thought that there are 2 mechanisms by which 
Treg cells exert their suppressive effects. The contact dependent method involves CTLA-4 
on the Treg cell and CD80/86 on the effector T cell102. CTLA-4 is expressed at high levels on 
CD4+CD25+ Treg cells and it is thought that the CTLA-4 interacts with the CD80/86 on the 
effector T cell to decrease effecter T cell function. Immunosuppressive cytokines are also 
79 
 
important in Treg associated suppression. IL-10 and TGF-β released by Treg cells are 
responsible for down regulating MHC II and co-stimulatory molecules on dendritic cells 
which affects their ability to present antigens and so stops the activation of CD4+ T cells102. 
3.1.2 Tr1 cells 
Tr1 cells were first described by Roncarolo et al in 1997 who showed a Foxp3- CD4+ T cell 
subset, which suppressed antigen specific T cell responses, which prevented colitis105. Tr1 
cells are not as well studied as Foxp3+ Treg cells. They were initially identified based on 
their cytokine profile. This allows them to be distinguished from other regulatory and 
effector T cells. They express high levels of IL-10, small amounts of IL4 and IL17 which allow 
them to be distinguished from Th2 and Th17 cells, and a low level of IL2 which distinguishes 
them from Th1 cells98. More recently it has been shown that Tr1 cells can be identified by 
the co expression of surface markers CD49b and LAG-3 and the high expression of IL-101. 
This is the combination of markers I was looking for during this experiment to identify a 
population as being Tr1 cells.  
The original study that led to the discovery of IL-10 producing Tr1 cells began in the late 
eighties104. Tr1 cells were discovered in the peripheral blood of patients with severe 
combined immunodeficiency (SCID) with long term mixed chimerism after HLA-mismatched 
fetal liver hematopoietic stem cell transplant (HSCT)104.  The SCID patients developed long 
term tolerance to stem cell allografts which suggested there was something regulating 
immune cells. Isolated cells did not show the same cytokine profile as Th1 or Th2 cells 
which suggested a unique cell type was responsible for the immune cell regulation.  A few 
years later Groux et al demonstrated that Tr1 cells, producing high amounts of IL10, are a 
distinct subset of CD4+ T cells that are antigen specific and show strong 
immunosuppressive activity105.  
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Tr1 cells can control the activation of naive and memory T cells and suppress Th1 and Th2 
cell mediated immune responses. The suppressive effects of Tr1 cells are reversed by 
blocking antibodies against IL-10, showing that the inhibitory capacity of Tr1 cells is mainly 
mediated through production of IL-10. They also kill myeloid cells by the secretion of 
Granzyme B98. 
3.1.3 Nasopharynx associated lymphoid tissue 
The lymphoid tissue found in the nasal mucosa is known as nasopharynx associated 
lymphoid tissue (NALT) and is part of the mucosal associated lymphoid tissue 
(MALT)257Human NALT includes tonsils and adenoids 258.  Both tonsils and adenoids are 
large clusters of mucosal lymphoid tissue which are an important site of immune induction. 
They are ideally located to be exposed to both airborne and ingested antigen159. It is 
common during childhood for them to become enlarged and inflamed due to recurrent 
infections. This can lead to their removal.  
Tonsils and adenoids contain four specialized lymphoid compartments participating in the 
immune functions of these organs, namely the reticular crypt epithelium, the extrafollicular 
area, the mantle zones of lymphoid follicles and the follicular germinal centres (GCs) 160. 
Tonsils and adenoids resemble lymph nodes but have no afferent lymph. Instead antigen is 
transported to T and B cell areas by antigen presenting cells such as dendritic cells160. 
Dendritic cells are to be found in abundance in extrafollicular areas and are often 
surrounded by T cells, particularly CD4+ T cells. Various types of these cells including naïve 
(CD45RA+), memory (CD45RO+) and recently activated (CD25+) are found and can produce 
both a primary and secondary immune response159.  
Adenotonsillar tissue differs from peripheral blood in that B cells are the predominant 
lymphocyte population found here. The main T cell population found in adenotonsillar 
tissue is CD4+ T cells with a low percentage of CD8+ T cells being found161.   
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In this study we aimed to study the numbers of Foxp3+ Treg and Tr1 cells in nasopharynx-
associated lymphoid tissue (NALT) and peripheral blood and identify any differences in 
numbers between the two compartments. We also aimed to study the numbers of these 
cells and any differences between adult and children samples.  
3.2 Aims of the study 
In this chapter we have investigated: 
1) The frequency of Foxp3+ Treg cells in NALT and PBMC in both children and 
adults 
2) The frequency of Tr1 cells in NALT and PBMC samples in children and adults. 
 
3.3 Experimental Design:  
To determine the frequency of Foxp3+ Treg and Tr1 cells within NALT and peripheral blood, 
freshly isolated MNC from tonsil samples and PBMC samples were stained with 
fluorescently labelled antibodies to specific cell surface and intracellular markers. For 
detection of Foxp3+ Treg cells, cells were stained with CD4 and Foxp3. For detection of Tr1 
cells, cells were stained with CD4, CD49b, LAG3 and IL10. Cells were then analysed by flow 
cytometric analysis on a FACSCalibur. 
3.3.1 Human subjects and samples 
Samples of Tonsillar tissue were obtained from children undergoing routine 
adenotonsillectomy between the ages of 2-16 years of age. All children involved in the 
study gave their permission to be involved through informed consent of their parent or 
guardian.  
3.3.2 Detection of Foxp3+ Treg cells 
Mononuclear cells (MNCs) were isolated from samples of tonsillar tissue and peripheral 
blood by ficoll gradient centrifugation. These freshly isolated cells were then stained with 
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CD4 and incubated in the dark for 20 minutes at room temperature (RT). Cells were 
centrifuged at 600 x g for 8 minutes before the addition of 350 µl of 
fixation/permeabilisation buffer. Cells were incubated at 4°C for 30 minutes followed by 
further centrifugation at 600 x g for 8 minutes. Cells were then incubated with Foxp3 for 30 
minutes in the dark at RT. Permeabilisation buffer was then added before centrifugation at 
600 x g for 8 minutes. Finally, cells were re suspended ready for FACS analysis on the 
FACSCalibur. A lymphocyte gate was set based on typical FSC/SSC characteristics and 
Foxp3+ Treg cells were expressed as the percentage of CD4+ cells which stained positively 
for Foxp3 (Figure 1). The data gathered from flow cytometric analysis was then analysed 
using WinMDI. 
3.3.3 Detection of Tr1 cells 
Freshly isolated MNCs from both tonsillar tissue and peripheral blood samples were stained 
for the detection of Tr1 cells. Cells were initially stained for surface markers, followed by 
intracellular markers. For staining of the surface markers, CD4 and CD49b were added to 
the cells before they were incubated in the dark for 20 minutes at room temperature. Cells 
were then centrifuged for 8 minutes at 600 x g before the addition of 350 µl of 
fixation/permeabilisation buffer and incubation at room temperature for 30 minutes. 
Fluorescently labelled IL-10 and LAG-3 were then added to the cells before incubation at RT 
in the dark for 30 minutes. Cells were centrifuged before the addition of 1 ml of 
permeabilisation buffer. Finally, cells were once again centrifuged before being re 
suspended in FACS buffer ready for FACS analysis on the FACSCalibur. The FACS data 
gathered was then analysed using WinMDI. 
3.3.4 Statistical analysis 
Data were analysed using GraphPad Prism version 5.  Differences between two groups, for 
example adults and children, were analysed by Student’s t (parametric) or Mann-Whitney 
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(non-parametric) test. Differences between paired samples, for example stimulated tonsil 
and stimulated blood samples, were analysed by paired t (parametric) test.  
A p value of <0.05 was taken as a level of statistical significance.    
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3.4 Results 
3.4.1 The frequency of Foxp3+ Treg cells in tonsillar MNC and PBMC samples 
The frequency of Foxp3+ Treg cells in tonsillar MNC and PBMC was shown by the staining 
of cells using markers specific for this cell type. A combination stains against surface marker 
CD4 and the intracellular transcription factor Foxp3 were used. Cells that were CD4+Foxp3+ 
were concluded to be Foxp3+ Treg cells. A representative figure showing gating strategy 
can be seen in figure 3.4.1a. Figure 3.4.1b shows that the mean frequency of Foxp3+ Treg 
cells in children’s tonsillar MNC (10.4%) was significantly higher than in PBMCs (4.6%) and 
that the mean frequency of Foxp3+ Treg cells in adult tonsillar MNC (6.8%) was significantly 
higher than in PBMCs (4.6%) 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.1a. A representative figure which shows the gating strategy used for the identification 
of Foxp3+ Treg cells (CD4+Foxp3+) in freshly isolated tonsillar MNC and PBMC.  
(a) PBMC sample (b) Tonsillar sample. R1 highlights the lymphocyte population, defined using typical 
FSC and SSC. Within the lymphocyte population the CD4+ cells are then defined in R2. Finally, the 
Foxp3+ Treg cells are identified by the gating of the CD4+ population (R2) and the positive staining of 
Foxp3. This CD4+Fox3+ cell population is defined as the frequency of Treg cells and is shown as a 
percentage 
 
R1 
R2 
R1 
R2 
(a) 
(b) 
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Figure 3.4.1b (a) The frequency of Foxp3+ Treg cells in children tonsillar MNC and PBMC 
The frequency of Foxp3+ Treg cells is shown to be significantly higher in tonsillar MNC compared to 
PBMC. (10.4% in tonsillar tissue samples and 4.6% in peripheral blood samples). (p=<0.0001, n = 
15). Mean + SEM are shown *p<0.05, **p<0.01, ***p<0.001 (b)The frequency of Foxp3+ Treg cells 
in adult tonsillar MNC and PBMC. The frequency of Foxp3+ Treg cells is shown to be significantly 
higher in tonsillar MNC compared to PBMC. (6.8% in tonsillar tissue samples and 4.6% in peripheral 
blood samples). (p= 0.0115, n = 9). Mean + SEM are shown *p<0.05, **p<0.01, ***p<0.001. 
 
3.4.2 The frequency of Tr1 cells in tonsillar MNC and PBMC samples 
The frequency of Tr1 cells in tonsillar MNC and PBMC samples was shown by the staining of 
a combination of surface and intracellular markers. Cells were stained using CD4, CD49b, 
LAG-3 and IL-10. CD4+CD49b+LAG-3+ cells which were also shown to produce high levels of 
the intracellular cytokine IL10 were concluded to be Tr1 cells. A representative figure 
showing the gating strategy used can be found in figure 3.4.2a. Figure 3.4.2b shows that 
the mean frequency of Tr1 cells in children tonsillar MNC (6.25%) is significantly higher than 
in PBMC (2.2%). Figure 3.4.2c shows that the mean frequency of Tr1 cells in adult tonsillar 
MNC (0.97%) is significantly higher than in PBMC (0.33%) 
 
 
(a) (b) 
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Figure 3.4.2a A representative figure, which shows the gating strategy, used for the identification 
of Tr1 cell frequency in freshly isolated tonsillar MNC and PBMC.  
The lymphocyte population is highlighted in R1, using the typical FSC and SSC configuration. (b) 
Within the lymphocyte population the CD4+ cells are defined in R2. (c) R3 then highlights the cells 
within R2 which are both CD49b+ and LAG3+ and are therefore defined as Tr1 cells. (d) IL10 positive 
cells within the CD4+ lymphocyte population. (e) In order to confirm the cells in R3 are Tr1 cells they 
are then gated against IL10. 
 
 
 
 
 
 
 
Figure 3.4.2b (a)The frequency of Tr1 cells in children tonsillar MNC and PBMC The frequency of 
Tr1 Treg cells is shown to be significantly higher in tonsillar MNC compared to PBMC. (6.25% in 
tonsillar MNC and 2.2% in PBMC) (p=0.0262, n = 7). Mean + SEM are shown *p<0.05, **p<0.01, 
***p<0.001. (b)The frequency of Tr1 cells in adult tonsillar MNC and PBMC The frequency of Tr1 
Treg cells is shown to be significantly higher in tonsillar MNC compared to PBMC. (0.97% in tonsillar 
MNC and 0.33% in PBMC) (p= 0.0002, n = 7). Mean + SEM are shown *p<0.05, **p<0.01, 
***p<0.001. 
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3.4.3 Foxp3+ Treg cell frequency is higher in children tonsillar MNC samples than in adult 
tonsillar MNC and PBMC samples  
The frequency of Foxp3+ Treg cells was measured in both children and adult tonsillar MNC 
and PBMC to allow a comparison between age groups. The frequency of Foxp3+ Treg cells 
was measured by staining with CD4 and Foxp3. Figure 3.4.3b shows that the mean 
frequency of Fox3+ Treg cells in PBMC is no different to in adult samples (4.6% vs 4.6%).  
However, in tonsillar MNC the mean percentage of Foxp3+ Treg cells is significantly higher 
in children samples (10.4%) compared to adult samples (6.8%). (Figure 3.4.3b)  
 
 
 
 
 
 
 
 
Figure 3.4.3 Frequencies of Foxp3+ Treg cells in adult and children tonsillar MNC and PBMC 
(a)The frequency of Foxp3+ Treg cells in tonsillar MNC is shown to be higher in children than in 
adults (10.4% in children and 6.8% in adults) (p= 0.0017) Mean + SEM are shown *p<0.05, **p<0.01, 
***p<0.001. (b) The frequency of Foxp3+ Treg cells in PBMC is shown to be the same in both adults 
and children (4.6% for both) 
 
3.4.4 Tr1 cell frequency is higher in children tonsillar MNC samples than in adult tonsillar 
MNC and PBMC samples 
The frequency of Tr1 cells was measured in both children and adult tonsillar MNC to see if 
any difference in cell numbers was observed in different age categories. Tr1 cells were 
identified by the staining of CD4, CD49b, LAG-3 and IL-10. A representative example of the 
cell staining, and gating strategy is shown in figure 4. Figure 3.4.4 shows the mean 
percentage of Tr1 cells in both children and adult tonsillar MNC samples. The mean 
(a) (b) 
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(0.97%) 
 
 
 
 
 
 
 
 
Figure 3.4.4 Frequencies of Tr1 cells in adult and children tonsillar MNC and PBMC samples 
(a)The frequency of Tr1 cells in tonsillar MNC is shown to be higher in children than in adults (6.25% 
in children and 0.97% in adults) (p= 0.0117) Mean + SEM are shown *p<0.05, **p<0.01, ***p<0.001. 
(b) The frequency of Tr1 cells in PBMC is shown to be higher in children than in adults (2.2% in 
children and 0.33% in adults) (p= 0.0477) Mean + SEM are shown *p<0.05, **p<0.01, ***p<0.001. 
 
 
3.5 Discussion 
Data showing frequencies of Tr1 cells in human peripheral blood is limited, and there is 
currently no data showing frequencies of Tr1 cells in human tonsillar tissue or showing any 
kind of pattern or relationship between the mucosal nasopharyngeal compartment and the 
systemic compartment. Data showing the relationship between Foxp3+ Treg cell frequency 
in the NALT and peripheral blood and the differences seen with age is also limited.  
It has been suggested that Treg cells may have an important role to play in mediating the 
persistence of pneumococcal carriage in the NALT. As such, it is hypothesised that an 
increased frequency of Treg cells would be observed in tonsillar MNC compared to PBMC. 
In this study several experiments have been performed to analyse the frequencies of both 
Foxp3+ Treg and Tr1 cells in adult and children tonsillar MNC and PBMC.  
(a) (b) 
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I have shown that adult and children paired tonsillar MNC samples, there are fewer Foxp3+ 
Treg cells in PBMC samples compared to in tonsillar MNC. (Figure 3.4.1b, Figure 3.4.1c). 
This suggests that the mucosal compartment of the nasopharynx, which is the location of 
tonsillar tissue, is more exposed to pathogenic antigen than the systemic system where 
PBMCs are found. The systemic compartment is a usually sterile site, whereas the 
nasopharynx is a site of microbial colonisation, so it is consistent with the hypothesis that 
an increased exposure to microbes in the nasopharynx leads to an increase in T regulatory 
cells.  
We have also shown that the frequency of both Foxp3+ Treg cells in tonsillar MNC and 
PBMC changes with age. Children samples show much higher frequencies of Foxp3+ Treg 
cells compared to adult samples (Figure 3.4.3). Young children are frequently exposed to 
pneumococcus which remains in the nasopharynx without being cleared. It is thought that 
almost all children are colonised by at least one pneumococcal serotype in their first couple 
of years of life5.   The incidence of pneumococcal colonisation has been shown to decrease 
with age, but it is not uncommon for children to be repeatedly colonised with numerous 
serotypes6, 129. Colonisation at a young age provides immunological memory against 
pneumococcal antigens which may provide protective effects against colonisation in later 
life and may thus contribute to the decrease in colonisation events seen with age259. 
These findings suggest that Foxp3+ Treg cells may be responsible for the persistence of 
carriage seen in young children as a direct result of the activation of Treg cells. Local 
colonisation occurs within the nasopharynx, so exposure to microorganisms is increased in 
this compartment when compared to other compartments such as the peripheral blood. A 
colonisation event could lead to the activation of antigen specific Treg cells which prevent 
the clearance of the bacteria from the nasopharynx and thus contribute to the persistent 
carriage of the microbe90. 
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It was shown the numbers of Tr1 cells was higher in tonsillar MNC compared to PBMC in 
both children and adults (Figure 3.4.2b, Figure 3.4.2c). Tr1 cells are thought to differ from 
naturally occurring Foxp3+ Treg cells that emerge from the thymus in that they are induced 
from naïve cells when stimulated by antigen in an IL-10 dependent process106. They have 
typically been shown to exist in much lower frequencies than Foxp3+ Treg cells, with 
research mainly being in peripheral blood samples260. To the best of my knowledge this is 
the first research to investigate Tr1 cells numbers in tonsillar samples of healthy adults and 
children and to compare Tr1 cell frequencies in 2 separate compartments, the NALT and 
PBMCs. The pattern of results observed is the same as that seen with Foxp3+ Treg cells, 
with much higher frequencies observed in the nasopharynx, where colonisation occurs, 
compared to the peripheral blood which is a sterile site that doesn’t encounter pathogenic 
stimulation. This could suggest that Tr1 cells are also activated or primed by colonisation 
events by the pneumococcus. Tr1 cells could play a similar role in inhibiting the clearance 
of the bacteria from the nasopharynx and could play a role in the spread of the bacteria 
through persistence of carriage. 
Tr1 cells were also shown to be found in higher numbers in children samples, where an age 
associated decrease in cell frequency was observed which inversely correlated with an 
increase in age (Figure 3.4.4) Again, the number of colonisation events and the length of 
carriage by pneumococcus has been shown to decrease with age40. The adult samples we 
processed were shown to have a lower percentage of Tr1 cells present compared to the 
children samples. Tr1 cells could therefore have a role to play in the persistence of carriage 
seen in children and the lower frequency in adults could be due to the lack of Tr1 cells 
which allows the clearance of the bacteria. 
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3.6 Summary 
The results gathered here show that that there are significantly higher numbers of Foxp3+ 
Treg and Tr1 cells in tonsillar MNC than PBMC in both children and adults. This may explain 
the persistence of carriage which is seen in the nasopharynx. The numbers of Foxp3+ Treg 
and Tr1 cells is significantly higher in tonsillar MNC from children samples compared to 
adult samples which could be down to the amount of exposure experienced in early 
childhood inhibiting the successful clearance of the bacteria from the nasopharynx.  
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Chapter 4 
Foxp3+ Treg cell activation by Pneumococcal 
Antigens in Human Nasopharynx-Associated 
Lymphoid Tissues  
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4.1 Introduction 
The results presented in chapter 3 show that there are significant numbers of Foxp3+ Treg 
cells present in freshly isolated human tonsillar tissue. We hypothesise that stimulation 
using pneumococcal protein antigens may be able to activate Foxp3+ Treg from freshly 
isolated tonsillar MNC. 
Pneumococcus is a major cause of invasive infectious diseases worldwide, with high 
morbidity and mortality, particularly in the elderly and very young children261. 
Pneumococcus is harmless when it is at its natural site of colonisation, the nasopharynx, 
but if it is able to move to other areas of the body such as the lungs or brain it can cause a 
wide range of serious diseases4. Colonisation of the upper respiratory tract is harmless in 
individuals who are otherwise fit and healthy. But in at-risk individuals such as children 
under 2 and the elderly the consequences of colonisation can be much more severe. Given 
that invasive disease cannot occur without colonisation, it has been suggested that a 
vaccine that targets the nasopharynx and reduces carriage rates would be effective in 
preventing the spread of bacteria through the community and would reduce the risk of 
invasive disease 
Pneumococcus has a wide variety of virulence factors which contribute to its successful 
colonisation and infection on individuals. These include the polysaccharide capsule, 
Pneumolysin and a variety of surface proteins. The polysaccharide capsule is currently used 
in vaccines against pneumococcus but does have limitations with its narrow serotype 
coverage and expense. Recently a number of pneumococcal proteins have been 
investigated for their potential inclusion in a pneumococcal vaccine including pneumolysin 
and choline binding protein A (CbpA).12.  
Pneumococcal polysaccharide capsule is approximately 200-400 nm thick and forms the 
outer layer of pneumococcus. Strains of pneumococcus that are lacking in the capsule are 
avirulent and do not cause disease39. The capsule acts to reduce the entrapment of bacteria 
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in mucosal secretions and acts as a defensive barrier against the binding of complement 
and other component s which would lead to the phagocytosis of the bacteria19.  
 
Pneumolysin is cholesterol dependent cytolytic pore forming toxin which is expressed 
almost universally by all known clinical isolates of pneumococcus47.  Upon binding to cell 
membranes, pneumolysin undergoes a conformational change which leads to its insertion 
in the membrane and the formation of pores. Pneumolysin can activate complement 
components and also acts through its pore forming ability to directly cause tissue and 
cellular damage.  Clinical isolates which have been found to not express pneumolysin have 
been shown to be successfully cleared from the lungs suggesting the pneumolysin has an 
important role in the pathogenicity of pneumococcus262. 
Previous studies have shown that pneumolysin and its toxoids are able to produce 
protective immunity against both colonisation of pneumococcus and invasive disease240. 
Animal models have shown that mucosal immunisation of the nasopharynx using 
pneumococcal antigens such as pneumolysin may induce protection against both invasive 
disease and nasopharyngeal carriage120, 263. A reduction in carriage would protect against 
the spread of bacteria and reduce the likelihood of at-risk individuals developing invasive 
disease.  
Pneumococcal protein antigens have been shown to induce protection against 
pneumococcus of multiple different serotypes240, 264, 265.  If they could be used in a 
successful vaccine that would target all serotypes, the cost of the vaccine would be 
significantly cheaper than those currently produced, and their effectiveness would also be 
much more far reaching. Currently only specific serotypes are targeted and although 
protection against these is good, new serotypes tend to emerge as dominant serotypes. A 
vaccine containing a combination of pneumococcal protein antigens or a mix of 
polysaccharide and proteins could be used to confer protection to more pneumococcal 
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serotypes and would provide wider protection. Also, as protein antigen induced antibody 
response is T cell dependent, it is likely to be effective in both children and adults.   
Previous studies have shown that pneumococcal proteins may be involved in the activation 
of Foxp3+ Treg cells in tonsillar tissue90.  Regulatory T cells have an inverse relationship 
with effector T cells and this relationship is finely balanced to allow the effective clearance 
of bacteria without severe adverse inflammation occurring to host tissue129. Pneumococcal 
whole cell antigen (WCA) has been shown to promote an increased number of Foxp3+ Treg 
cells in tonsillar tissue which suggests there is a pneumococcal component which has an 
effect on numbers of this cell type90.  To create a successful mucosal vaccine against 
pneumococcus it is therefore important to understand the relationship between regulatory 
T cells in tonsillar issue and pneumococcus. 
Several different pneumococcal proteins have been studied as potential targets for 
vaccines47, 123, 124, 126. Amongst these, is pneumolysin, a highly conserved protein which 
causes the formation of pores in cell membranes containing cholesterol. Ply is in the 
cytoplasm of S. pneumoniae but is released by autolysis199. Ply is a major virulence factor, 
exerting its effect on different cell types including immune cells and epithelial cells. 
Antibodies against Ply can be found in humans who have been colonised by S. pneumoniae 
and these antibodies have been shown to passively protect mice that have been challenged 
with pneumococci200. Pneumolysin in its purified form is highly toxic and as such wouldn’t 
be suitable for use in a vaccine targeted to humans. However, Ply can be detoxified which 
involves its genetic or chemical modification to remove its haemolytic activity. Recently a 
detoxified genetic mutant of Ply (PlyD1) has been developed which has been used in mouse 
models and has shown some protection is conferred to the mice involved202. PlyD1 has 
been used in phase 1 human studies and has shown to be safe as well as immunogenic in 
adults that were involved in the trials 
96 
 
Ply has been studied in mouse models and in natural infections in humans. It has been 
shown to induce both adaptive and innate immune responses and antibodies against 
Pneumolysin have been found in individuals infected with S. pneumoniae200, 203. There is 
limited genetic variation of Pneumolysin between different serotypes of S. pneumoniae 
which suggests it may be a suitable target for inclusion in a vaccine204. 
Pneumolysin has been shown to be essential for maintaining long term asymptomatic 
carriage in the nasopharynx126. Upon administration of a WT strain carriage was maintained 
for 28 days whereas after administration of PLN-A (pneumolysin deficient mutant) carriage 
was cleared between 7-14 days after infection. Another study has shown that stimulation 
of adenoidal MNCs with Ply or F433 leads to proliferation of CD4 T cells85.  
Capsular polysaccharide has been used to vaccinate against pneumococcus since the early 
1900’s, initially as polysaccharide only vaccines and then in the form of polysaccharide 
conjugate vaccines10, 166, 167. They confer a great deal of protection against the serotypes 
included in the vaccines, but other serotypes are still able to cause disease and have been 
shown to increase in prevalence to replace those protected by the vaccine182, 194. 
Furthermore, they are expensive to produce.  
Several papers have suggested that pneumococcal components can suppress allergic 
airways disease and are able to do this through the induction of Treg cells. Using a mouse 
model of allergic airways disease, Thorburn et al identified that type 3 polysaccharide (T3P) 
and Pneumolysin when administered together caused an increase in Treg cell numbers in 
the lungs when compared to a control group127. This increase in Treg cells wasn’t seen 
when the pneumolysin and the T3P were administered separately127. It has also been 
demonstrated that a fusion conjugate containing cell wall polysaccharide, Pneumolysin and 
PsaA delivered alongside cholera toxin nasally protected mice against experimental 
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colonisation123. This combination of polysaccharide and protein could be a promising 
combination for a vaccine against pneumococcus.  
4.2 Aims of the study 
In this chapter we have investigated: 
1. Whether stimulation using pneumococcal CCS with and without pneumolysin or 
capsular polysaccharide can activate Foxp3+ Treg cells  
2. If the toxoid of Pneumolysin, W433F and purified capsular polysaccharide T3P and 
6B can activate Foxp3+ Treg cells in tonsillar MNC. 
4.3 Experimental Design:  
Tonsillar MNC were stimulated using pneumococcal CCS and other pneumococcal antigens 
to see if they were able to activate Foxp3+ Treg cells. To assess the ability of the antigens to 
activate Foxp3+ Treg cells, freshly isolated tonsillar MNC were stimulated for 3 days before 
intracellular staining and FACS analysis. Foxp3+ Treg cell responses after stimulation were 
analysed using the measurement of Foxp3 expression. 
4.3.1 Human subjects and samples 
Samples of Tonsillar tissue were obtained from children undergoing routine 
adenotonsillectomy between the ages of 2-16 years of age. Any individual who had been 
exposed to antibiotics for three weeks prior to surgery or were suffering from severe 
infection or immunodeficiency were excluded from the study. All children involved in the 
study gave their permission to be involved through informed consent of their parent or 
guardian.  
4.3.2 Pneumococcal concentrated culture supernatant (CCS) 
For some of the experiments performed in this chapter, Pneumococcal CCS was prepared 
and used to stimulate stimulation of tonsillar MNC. Pneumococcal CCS was prepared from 
the encapsulated type 2 strain D39 (NCTC7466)238 of S. pneumonia and its isogenic 
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mutants, one of which was deficient in capsule (Cap-/-) and one of which was deficient in 
Pneumolysin (Ply -/-) 200. Pneumococcal CCS was used to stimulate tonsillar MNC for three 
days, after which the frequency of Foxp3+ Treg cells was analysed by intracellular cytokine 
staining and FACS analysis. The Pneumococcal CCS was prepared following the method 
outlined previously by Zhang et al (ref). Bacterial frozen stocks were cultured overnight on 
blood agar plates (Fisher Scientific, UK) (37°C, 5% CO2). After approximately 18 hours, 
typical α-haemolytic colonies of S. pneumoniae were observed which were then used to 
inoculate Todd Hewitt Broth (THB) (Oxoid, UK) containing 5% yeast extract. This broth was 
then cultured overnight (37°C, 5% CO2). The following day, the optical density of the 
culture was measured at 620nm and then this was checked every 30 minutes until 
exponential phase of growth was reached (OD of 0.4-0.5 at 620nm). To collect the 
supernatant, the broth culture was centrifuged at 3000 x g for 30 minutes and the 
supernatant removed. This was then passed through a 0.45 µm filter followed by a 0.2 µm 
filter before the final stage of the concentrating process. The pneumococcal culture 
supernatant was concentrated by centrifuging the sample at 3000 x g for 30 minutes in a 
Vivaspin15 concentrator (Sartorius Stedim Biotech, Germany). This process was repeated 
several times to ensure that the sample was concentrated tenfold. Samples were then 
aliquoted into 1.5 µl microcentrifuge tubes and stored at -80°C until use. The Bradford 
protein assay was used to determine the concentration of the prepared pneumococcal CCS 
and the appropriate volume and concentration was then used to stimulate tonsillar MNC in 
my experiments.  
4.3.3 Foxp3+ Treg cell harvesting, staining and analysis 
4.3.3.1 Cell stimulation 
500 µl of tonsillar MNC suspension at a concentration of 4 x 106 was stimulated for 3 days 
and kept in an incubator at 37°C in 5% CO2. After 3 days, 0.5 µl of a protein transport 
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inhibitor, Brefeldin A (BFA) was added to each sample before further incubation at 37°C in 
5% CO2 for 4 hours. The incubation was then stopped, the plate wrapped in cellophane and 
left in the fridge overnight. 
4.3.3.2 Cell harvest and staining 
The following morning cells were harvested from the plated into 1.5 ml Eppendorf tubes 
and washed with FACS staining buffer (0.02 %PBS-BSA) by centrifugation at 600 x g for 8 
minutes. After washing 50 µl of a master mix containing 20 µl of CD25 and 5 µl of CD4 were 
added to each sample and incubated at 4°C for 30 minutes. Cells were then washed using 1 
ml of FACS staining buffer at 600 x g for 8 minutes. 350 µl of fixation/permeabilisation 
buffer was added to each sample and incubated for 30 minutes at room temperature. Cells 
were then washed in permeabilisation buffer followed by centrifugation at 600 x g for 8 
minutes before the addition of 50 µl of a master mix containing 15 µl of Foxp3 was added 
to each sample. This was incubated at room temperature for a further 30 minutes followed 
by a final was step using 1 ml of permeabilisation buffer per sample for 8 minutes at 600 x 
g. The final step was the addition of 500 µl of FACS staining buffer to each tube ready for 
FACS analysis. 
4.3.3.3 Foxp3+ Treg cell staining 
Foxp3+ Treg cells have an important role in the prevention of auto immune disease and in 
the maintenance of immune tolerance. Foxp3+ Treg cells possess several surface markers 
which can be used to distinguish them from other cell types. These include CD25, CTLA-4, 
CD103 and CD39. Foxp3+ Treg cells also express the intracellular transcription factor Foxp3 
and this is a marker specific to both thymic and peripheral Foxp3+ Treg cells. 
To determine the presence of Foxp3+ Treg cells, after the 4-hour incubation with BFA, 
adenotonsillar MNC were harvested from the plates into 1.5 ml Eppendorf tubes and 
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washed with FACS staining buffer (0.02% PBS-BSA) by centrifugation at 600 x g for 8 
minutes. After washing, 5 µl of PeCy7 (BD Bioscience) conjugated CD4 was added to each 
sample and before they were incubated at 4°C for 30 minutes. Cells were then washed 
using 1 ml of FACS staining buffer, followed by centrifugation at 600 x g for 8 minutes. 350 
µl of fixation/permeabilisation buffer was added to each sample and they were incubated 
for 30 minutes at room temperature. Cells were then washed, followed by centrifugation at 
600 x g for 8 minutes in permeabilisation buffer before the addition of 15 µl of Alexafluor 
647 (BD Bioscience) conjugated Foxp3 to each sample. This was incubated at room 
temperature for a further 30 minutes, followed by a final wash step using 1 ml of 
permeabilisation buffer per sample for 8 minutes at 600 x g. The final step was the addition 
of 500 µl of FACS staining buffer to each tube ready for FACS analysis. 
4.3.4 Statistical analysis 
Data were analysed using GraphPad Prism version 5.  Differences between two groups, for 
example adults and children, were analysed by Student’s t test. Differences between paired 
samples for example stimulated tonsil and stimulated blood samples, were analysed by 
paired t (parametric) or Wilcoxon matched-pairs signed rank (non-parametric) test.  
A p value of <0.05 was taken as a level of statistical significance.    
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R1 
R2 
4.4 Results 
4.4.1 Gating strategy for Foxp3+ Treg cells 
Foxp3+ Treg cells were defined as CD4+Foxp3+ cells when stained using intracellular 
staining (Figure 4.4.1). The lymphocyte population was defined in R1 using the typical FSC 
and SSC distribution (A). Within the lymphocyte population, CD4+ cells were then gated 
within R2 (B).  Foxp3+ Treg were then defined from the CD4+ T cells as a percentage of 
Foxp3+ cells in (c). 
 
 
 
 
 
Figure 4.4.1. A representative figure which shows the gating strategy used for the identification of 
Foxp3+ Treg cells (CD4+Foxp3+) in freshly isolated tonsillar MNC  
R1 highlights the lymphocyte population, defined using typical FSC and SSC (A). Within the 
lymphocyte population the CD4+ cells are then defined in R2 (B). Finally, the Foxp3+ Treg cells are 
identified by the gating of the CD4+ population (R2) and the positive staining of Foxp3. This 
CD4+Fox3+ cell population is defined as the frequency of Treg cells and is shown as a percentage in 
CD4+ T cell (C). 
 
4.4.2 Determination of optimal doses of pneumococcal CCS to be used for the activation 
and induction of Foxp3+ Treg cells in human tonsillar MNC 
D39 WT pneumococcal CCS and its isogenic mutants deficient in either pneumolysin (Ply -/-
) or capsular polysaccharide (Cap -/-) were used in experiments looking at the activation of 
Foxp3+ Treg cells. To determine the optimal dose of pneumococcal CCS to use, a dose 
response curve of WT pneumococcal CCS was created. The protein concentration of 
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pneumococcal CCS was measured using the Bradford protein assay and involved the use of 
Bradford protein dye reagent (Sigma) following manufacturer’s instructions. The principle 
of this assay is to compare sample dilutions against a known standard curve to work out 
the concentration of your sample. The standard curve used is a Bovine Serum Albumin 
(BSA) standard curve. A stock concentration of 2 mg/ml of BSA was serially diluted (two-
fold) in sterile PBS five times to give the BSA curve. Samples were diluted serially (ten-fold) 
three times. 5 µl of sample or BSA standard was added to the appropriate well of a 96-well 
Costar plate and 250 µl of Bradford reagent was then added. The plate was incubated in 
the dark for 5 minutes before absorbance was read at 595nm using the ThermoElectron 
MultiSkan (Opsys MR, Thermo labsystems, UK). A standard curve was produced from the 
readings of the BSA dilutions and this was used to work out the concentrations of the 
samples using DeltasoftPC microplate reader software. (Biometallics Inc., USA). Figure 4.4.2 
summarises the results and shows that the optimal protein concentration of pneumococcal 
CCS to use for Foxp3+ Treg cell activation is 1 µg/ml. A concentration of 0.5 µg/ml does not 
stimulate Foxp3+ Treg cells much more than a negative unstimulated control and higher 
concentrations appear to have a toxic effect on the cells. 1 µg/ml is the concentration of 
pneumococcal CCS that was used for all Foxp3+ Treg cell activation experiment. 
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Figure 4.4.2. Dose curve of WT pneumococcal CCS for the stimulation of Foxp3+ Treg cells 
Stimulation of Foxp3+ Treg cells with WT pneumococcal CCS shows the optimal protein 
concentration to be 1 µg/ml.  
 
4.4.3 Determination of optimal doses of W433F, T3P and 6B to be used for the activation 
of Foxp3+ Treg cells in human tonsillar MNC 
The toxoid of pneumolysin W433F and purified capsular polysaccharide types T3P and 6B 
were used in experiments looking at the activation of Foxp3+ Treg cells. To determine the 
optimal concentrations to use for these experiments, dose response curves for all three 
were made. Figure 4.4.3 shows the dose curves for W433F (a), T3P (b) and 6B (c) 
respectively.  The dose curve for pneumolysin toxoid W433F shows the optimal dose for 
stimulation is 10 ng/ml (n=2). For both T3P and 6B the optimal dose for stimulation is 
1µg/ml (n=2). These optimum concentrations were used in all experiments looking at the 
activation of Foxp3+ Treg cells by W433F, T3P and 6B. 
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Figure 4.4.3 Dose response curves for W433F, T3P and 6B for Foxp3+ Treg cell stimulation 
(a)The percentage of Foxp3+ Treg cell activation by W433F is shown to be optimal at 10 ng/ml with 
higher concentrations seeming to have a toxic effect on the cells. (b) The frequency of Foxp3+ Treg 
cell activation by T3P is shown to be optimal at 1µg/ml with higher concentrations seeming to have 
a toxic effect on the cells. (c) The frequency of Foxp3+ Treg cell activation by 6B is shown to be 
optimal at 1µg/ml with higher concentrations seeming to have a toxic effect on the cells.  
 
4.4.4 Stimulation of tonsillar MNC with pneumococcal CCS deficient in pneumolysin (Ply) 
or capsular polysaccharide show lower Treg cell activation compared to stimulation with 
wild type pneumococcal CCS 
Freshly isolated tonsillar MNC were stimulated using WT, Ply-/- and Cap-/- pneumococcal 
CCS in order to determine whether the absence of specific key pneumococcal virulence 
factors (pneumolysin and capsular polysaccharide) had an effect on the activation of 
Foxp3+ Treg cells. Pneumococcal CCS was used to stimulate freshly isolated tonsillar MNC 
at a concentration of 1 µg/ml as outlined in figure 4.4.2. Figure 4.4.4 shows that D39WT 
pneumococcal CCS stimulation of tonsillar MNC leads to the activation of significantly more 
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Foxp3+ Treg cells (9.47%) compared to the unstimulated negative control (4.86%). When 
Ply-/- CCS and Cap -/- CCS is used for stimulation the percentage of Foxp3+ Treg cell 
activation is significantly lower (6.42% and 6.36% respectively) 
 
 
 
 
 
 
 
 
Figure 4.4.4 The frequency of Foxp3+ Treg cell activation after stimulation with pneumococcal CCS 
The frequency of Foxp3+ Treg cells is shown to be significantly higher in tonsillar MNC upon 
stimulation with WT CCS compared to unstimulated negative control (4.86% for the negative control 
and 9.47% when stimulated with WT CCS). (p = 0.0156, n = 6). Ply -/- CCS shows significantly less 
activation compared to the WT CCS (6.42% compared to 9.47%) (p = 0.0233, n = 6). Cap -/- CCS 
shows significantly less activation compared to WT CCS (6.36% compared to 9.47%) (p = 0.0042 n = 
6) Mean + SEM are shown *p<0.05, **p<0.01, ***p<0.001. 
 
4.4.5 Activation of Foxp3+ Treg cells in tonsillar MNC by pneumolysin toxoid W433F and 
purified capsular polysaccharide (T3P and 6B)  
Results from stimulation of freshly isolated tonsillar MNC with pneumococcal CCS deficient 
in key pneumococcal virulence factors suggest that pneumococcal pneumolysin and 
polysaccharide capsule may be important for the activation of Foxp3+ Treg cells in human 
tonsillar MNC (Figure 4.4.4). To confirm this, human tonsillar MNC were stimulated using 
purified toxoid of pneumolysin (W433F) and capsular polysaccharide types T3P and 6B.  
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Freshly isolated tonsillar MNC were stimulated with W433F, T3P and 6B. Data shown in 
figure 4.4.5 shows that compared to a medium control with no stimulation (5.28%), the 
stimulation of cells with W433F elicited an increase in Foxp3+ Treg cells (7.41%). The 
stimulation of tonsillar MNC with both T3P and 6B also showed an increase in Foxp3+ Treg 
cells (7.78% and 7.65%) compared to the unstimulated medium control (5.28%). Tonsillar 
MNC were also stimulated using a combination of W433F and T3P and W433F and 6B. The 
stimulation of tonsillar MNC with W433F and T3P shows significantly more Foxp3+ Treg cell 
activation (8.72%) compared to an unstimulated control (5.28%) but there is no significance 
when compared to just W433F and T3P alone. The combination of 6B and W433F shows no 
significance in Foxp3+ Treg cell activation compared to a negative control or to W433F or 
6B alone.  
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Figure 4.4.5 The frequency of Foxp3+ Treg cell activation after stimulation with pneumococcal 
capsular polysaccharide (T3P and 6B) and toxoid of pneumolysin W433F  
(a)The frequency of Fox3+ Treg cells after stimulation with purified pneumococcal capsular 
polysaccharide T3P is significantly higher when compared to an unstimulated negative control 
(7.78% compared to 5.28%, p = 0.0065, n = 9). The frequency of Foxp3+ Treg cells after stimulation 
with W433F is significantly higher when compared to an unstimulated negative control (7.41% 
compared to 5.28%, p = 0.0037). Stimulation using a combination of T3P and W433F shows a 
significant increase in Foxp3+ Treg cell frequency compared to a negative control (8.72 compare to 
5.28, p = 0.0115, n = 9) but no significant difference compared to T3P and W433F alone. (b) The 
frequency of Fox3+ Treg cells after stimulation with purified pneumococcal capsular polysaccharide 
6B is significantly higher when compared to an unstimulated negative control (7.65% compared to 
5.28%, p = 0.0007, n = 9). The frequency of Foxp3+ Treg cells after stimulation with W433F is 
significantly higher when compared to an unstimulated negative control (7.41% compared to 5.28%, 
p = 0.0037). A combination of 6B and W433F does not show any significant increase compared to a 
negative control or compared to 6Bcap and W433F alone. Mean + SEM are shown *p<0.05, 
**p<0.01, ***p<0.001. 
 
4.5 Discussion 
There is limited data about the role of regulatory T cells and their relationship with 
pneumococcus during colonisation of the nasopharynx. Data relating to human samples is 
particularly limited. A previous study showed the pneumococcal whole cell antigen (WCA) 
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was able to induce Foxp3+ Treg cell proliferation in tonsillar MNCs which suggests there are 
pneumococcal protein/s which could have a role to play in the induction of these cells90. 
Currently, it remains unclear which pneumococcal proteins may have a role in the 
activation or induction of regulatory T cells in in human nasopharynx-associated tissue 
(NALT). The identification of such protein/s would be useful information to further our 
understanding on the role of Treg in pneumococcal carriage and on novel vaccination 
strategies against pneumococcal disease. 
As previously mentioned, current pneumococcal vaccines target pneumococcal 
polysaccharide capsule. These vaccines have proven to be effective at protecting 
individuals against serotypes included in the vaccine. Currently there are over 90 known 
serotypes of pneumococcus, each classified based on their different polysaccharide 
capsules. Current conjugate vaccines target 7 or 13 of these but this still leaves a gap with 
the clear majority of serotypes not being included in the vaccine, largely due to the high 
cost and technical complexity of producing vaccines with more serotypes included.  
This has led to pneumococcal vaccine research becoming more focussed on identifying 
pneumococcal proteins which could be included in a vaccine that would then be effective 
against all known serotypes266, 267. Pneumococcal proteins including pneumolysin and 
choline binding protein A have been studied to see if they could be used in a vaccine240. 
This study has shown that in human tonsillar tissue, pneumolysin is able to activate pre-
existing Foxp3+ regulatory T cells. Given that pneumolysin is a key virulence factor of 
pneumococcus, it is important to understand the interactions between it and cells of the 
immune system. Before it could be included in a vaccine it would be necessary to 
understand exactly how pneumolysin affects the delicate balance of the immune system. 
Regulatory T cells are important for preventing the uncontrolled expression of effector T 
cells which if unchecked could lead to severe host inflammation so understanding how 
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these cells are activated is very important. Regulatory T cells have also been shown to be 
important in the carriage of pneumococcus and in causing the persistence of bacteria in the 
nasopharynx90, 126.   
In this study we investigated the importance of pneumolysin and capsular polysaccharide in 
the activation of Foxp3+ Treg cells. My first experiment involved the use of pneumococcal 
CCS with and without pneumolysin and capsule to determine their importance in Foxp3+ 
Treg cell activation. D39 WT strain of pneumococcal CCS showed significantly higher 
activation of Foxp3+ Treg cells compared to both mutant strains used. The first mutant 
strain was pneumolysin (Ply) deficient (Ply -/-) and the second was capsule deficient (Cap -
/-). These initial results suggested that both pneumolysin and capsular polysaccharide could 
be important for the activation of Foxp3+ Treg cells.  
After the initial findings using pneumococcal CCS I wanted to look at whether purified 
capsular polysaccharide and the toxoid of pneumolysin, W433F, could activate Foxp3+ Treg 
cells compared to a negative control. My results show that W433F and purified capsular 
polysaccharide are able to activate pre-existing Foxp3+ Treg cells to significantly higher 
levels compared to an unstimulated negative control. Two different types of capsular 
polysaccharide were used, T3P and 6B and both were shown to activate Foxp3+ Treg cells 
compared to the negative control. Capsular polysaccharide is currently used in 
pneumococcal vaccines and we know it is effective at preventing pneumococcal disease. In 
my results, pneumolysin has been shown to be effective at activating Foxp3+ Treg cells.   
The pre-existing Foxp3+ Treg cells detected in tonsillar tissue are likely to be those which 
are primed due to previous pneumococcal colonisation events in the nasopharynx. The 
ability of both W433F and both capsular polysaccharides used to activate these cells 
suggests that both the polysaccharide capsule and pneumolysin are able to activate these 
cells and therefore play a role in the carriage of pneumococcus in the nasopharynx.  
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The ability of pneumolysin to activating pre-existing Foxp3+ Treg cells suggests that this 
pneumococcal protein does specifically influence the immune response generated in 
response to pneumococcal exposure. Understanding the precise mechanism of these 
interactions and its effects on other immune cells is key to further research, which aims to 
include this protein in any future vaccines. It is interesting to note that pneumolysin is as 
effective at capsular polysaccharide at activation of Foxp3+ Treg cells and that the 
combination of both capsular polysaccharide and pneumolysin does not lead to enhanced 
Foxp3+ Treg cell activation. Capsular polysaccharide is already effective at providing 
protection against pneumococcal disease and if pneumolysin is as effective, it could be 
even more successful in conferring protection due to its presence on all known clinical 
pneumococcal isolate. In addition to this, my research has focussed on the interactions 
between pneumococcus and Foxp3+ Treg cells in the nasopharynx. Given that the 
nasopharynx is the site of pneumococcal colonisation, that prolonged carriage of the 
bacteria leads to spread throughout the community and that disease cannot occur without 
colonisation, the nasopharynx could be a potential target for a future vaccine that directly 
works at the mucosal site rather than through the blood. Again, it is important to 
understand the balances and intricacies of how any potential vaccine would work and how 
it would affect the hosts’ natural response, but this is certainly an interesting and 
potentially rewarding area of research which could have very fruitful results in the future. 
The overall findings in this study support the hypothesis that both pneumococcal 
polysaccharide and pneumococcal proteins have an important role in the activation of 
Foxp3+ Treg cells in the nasopharynx. They suggest that in the mucosal tissue of the 
nasopharynx pneumolysin and capsular polysaccharide can influence these regulatory cells, 
which leads to persistence of carriage and the delay in pneumococcal clearance. 
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4.6 Summary 
The results presented in this study suggest certain pneumococcal components may have a 
role in the activation of Foxp3+ T regulatory cells in human NALT. Data suggests that both 
Pneumolysin and capsular polysaccharide are both able to activate Foxp3+ Treg cells and as 
such they may contribute to the carriage of pneumococcus in the nasopharynx.  
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Chapter 5 
Tr1 cell activation and induction by 
Pneumococcal Antigens in Human 
Nasopharynx-Associated Lymphoid Tissues  
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5.1 Introduction 
The results presented in chapter 1 show that tonsillar tissue contains significant numbers of 
type 1 regulatory (Tr1) cells. This chapter aims to determine whether specific 
pneumococcal components such as pneumolysin and capsular polysaccharide can activate 
or induce Tr1 cells in tonsillar MNC.  
Pneumococcus is major cause of morbidity and mortality worldwide, particularly amongst 
at risk groups including the very young, the elderly and people who are 
immunocompromised with approximately 1 million children under the age of 5 years of age 
dying annually2. Carriage of the bacteria in the nasopharynx is common, especially in young 
children who are regularly in contact with one another. At the site of colonisation, the 
bacterium is usually harmless and doesn’t cause disease. However, if it can move from the 
nasopharynx into other areas of the body such as the lungs or brain it can cause serious 
infection such as meningitis, septicaemia and pneumonia and is also responsible for many 
otitis media in young children2.  In addition, carriage of the bacteria within the nasopharynx 
is an important source of the spread of infection within a community, with carriage rates 
reaching 90% in young children4. Given that colonisation is a pre-requisite for disease and 
carriage of the bacteria allows it to be spread throughout the community, a vaccine that 
targets the site of colonisation, the nasopharynx, could be an effective strategy in reducing 
the spread of bacteria and in preventing invasive disease240.  
The activation of CD4+ T cells in response to antigenic stimulation results in the generation 
of effector CD4+ T cells which can then exert their effects at the site of the pathogen 
invasion. As well as the activation of effector cells, memory cells are also produced upon 
stimulation by foreign antigen. These memory cells are then sequestered in lymphoid 
tissue to exert their effects if stimulated by that specific antigen later. It is because of these 
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memory cells that secondary challenge by the same antigen produces a much more rapid 
immune response. 
Type 1 regulatory T (Tr1) cells are an inducible subset of regulatory T cells that play a role in 
promoting and maintaining tolerance103. The secretion of high levels of IL-10 is the main 
mechanism by which Tr1 cells exert their effects268. They also kill myeloid cells by the 
secretion of Granzyme B98. Prior to 2013, the main identifying method for Tr1 cells has 
been through their cytokine profile. Tr1 cells secrete a lot of IL-10 and minimal amounts of 
IL-4 and IL-17 which distinguishes them from Th2 and Th17 cells98. Tr1 cells also secrete IL-2 
and depending on the local cytokine environment can secrete IFN-y. In 2013, Roncarolo et 
al showed that the co-expression of cell surface markers CD49b and LAG-3 could be used to 
identify Tr1 cells and for the purposes of this study it was the co-expression of these cell 
surface markers that was used to identify the numbers of Tr1 cells present1.   
The generation of Tr1 cells from naïve T cells was first described by Groux et al105. They 
showed that naïve T cells from OVA TCR-transgenic mice repeatedly stimulated with OVA 
and IL-10 differentiated into T cells with a unique cytokine profile distinct from Th2 and Th1 
cells105. More recently these Tregs have been shown in humans268. These cells have been 
shown to have immunosuppressive properties that can prevent the development of T cell 
mediated autoimmunity269. Tr1 can control the activation of naive and memory T cells and 
suppress Th1 and Th2 mediated immune responses270, 271. The suppressive effects of Tr1 
cells are reversed by blocking antibodies against IL-10, showing that the inhibitory capacity 
of Tr1 cells is mainly mediated through production of IL-10272. 
Tr1 cells are induced when CD4+ T cells are activated by antigen in the presence of IL-10.106 
It had been difficult to distinguish these cells from other cell types, relying on 
characterisation using its unique cytokine profile. Tr1 cells are distinguished from Th1 cells 
by expression of minimal IL4 and down regulation of GATA3 expression1. Tr1 cells lack IL-17 
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and express low levels of RORC which distinguishes them from Th17 cells. Low levels of IL-2 
and IFN-γ which distinguishes them from CD25+Foxp3+ Treg cells. It has recently been 
shown that there are cell surface markers characteristic of Tr1 cells which allow for them to 
be differentiated from other regulatory T cells1. Tr1 cells are CD4+CD49b+LAG-3+1. This 
ability to differentiate Tr1 cells from other cells means further study of this cell type is 
possible. 
IL-10 is an immunomodulatory cytokine that plays an essential role in regulation of the 
immune system in a variety of ways. It is responsible controlling inflammatory responses by 
down regulating inflammatory cytokines, induces tolerance and is important in the down 
regulation of other immune responses107. IL-10 is indispensable for driving the 
differentiation of Tr1 cells but other cytokines are also involved. 
During infection IL-10 inhibits the activity of a variety of different cell types including Th1 
cells and macrophages. These cells are essential for the clearance of pathogens but can also 
be responsible for causing tissue damage which is why they must be regulated108. For this 
reason, IL-10 can be responsible for inhibiting clearance of pathogens and preventing 
inflammation associated immunopathology. 
The conclusion that Tr1 cells can be identified by the co expression of CD49b and LAG-3 has 
allowed for them to be studied in much more detail than previously1. LAG-3 is a protein 
antigen expressed on T cells and NK cells after cell activation. It is a CD antigen given the 
name CD223111. The expression of LAG-3 on the surface of activated T cells is upregulated 
by IL-2, IL-7 and IL-12 and its expression leads to the production of IFN-γ.  LAG-3 has also 
been shown to be expressed on activated B cells but not when the B cell is activated solely 
by a TLR agonist112.  LAG-3 expression on B cells could therefor serve as a marker for B cells 
that have been activated by T cells.  
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LAG-3 is a multifunctional protein and can affect a variety of different cell types. LAG-3 is a 
ligand for MHC class 2. The interaction between LAG-3 and MHC class 2 controls CD4+ T cell 
responses and leads to the down regulation of antigen specific CD4+ T cell proliferation and 
cytokine secretion113.  
LAG-3 has been shown to be important for maximal function of regulatory T cells. 
Antibodies against LAG-3 have been shown to inhibit suppression by induced Treg cells 
both in vitro and in vivo115. LAG-3 knockout mice have been shown to have regulatory T 
cells with reduced regulatory function115.  
CD49b (cluster of differentiation 49b) is a protein encoded by the CD49b gene. CD49b is the 
α2 integrin subunit of very late activation antigen 2 (VLA-2)1. Integrins are integral 
membrane glycoproteins composed of an alpha and a beta subunit and are found on a 
variety of cell types including T cells and NK cells116. 
Current vaccines against pneumococcus are centred on targeting the polysaccharide 
capsule. This is one of the main virulence factors of pneumococcus, with strains that lack a 
polysaccharide capsule being unable to cause invasive disease as they become trapped in 
cell surface mucous and are unable to get free41.   The original vaccines against 
pneumococcus were not very effective, being unable to produce an immune response in 
children as they act in a T cell independent fashion4. This led to the creation of 
pneumococcal polysaccharide conjugate vaccines which include polysaccharide conjugated 
to protein and are effective in young children. However, these vaccines are still limited by 
their narrow serotype coverage and expense. Vaccines contain polysaccharide against the 
most common invasive serotypes but not against all as this would be far too expensive. This 
means that pneumococcal infection caused by serotypes not contained within the vaccine 
became more dominant28. Recently, vaccine research has moved on from looking at 
polysaccharide vaccines towards looking at the potential use of pneumococcal proteins 
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that are well conserved amongst different serotypes in a vaccine. There are several 
pneumococcal proteins which are well conserved among pneumococcal serotypes such as 
pneumolysin and these are considered promising vaccine candidates273. 
One of the key virulence factors of pneumococcus is the cholesterol dependent cytolytic 
pore forming toxin pneumolysin274.  Pneumolysin acts by forming pores in the cell 
membrane causing the cell to lyse. It does this by binding to cells which then undergoes a 
conformational change leading to its insertion in the membrane and the formation of 
pores. Pneumolysin is expressed almost universally in all known clinical isolates of 
pneumococcus with isolates that do not express pneumolysin being shown to be effectively 
cleared from lungs which suggests it has an important role to play in pneumococcal 
virulence and pathogenesis47.  
Nasopharyngeal colonisation is very common in young children before natural immunity 
can develop. In the UK colonisation in children less than 3 years of age is between 40-
50%117 but in African children this can reach 90-100%118, 119. By the age of 3 most children 
have developed natural immunity against specific pneumococcal antigens. This natural 
immunity is responsible for the clearance of the pneumococcus from the nasopharynx 
before carriage status can be achieved. However, despite this natural immunity carriage 
can still occur throughout life and it is thought that Treg cells could have a role in this. 
Due to the success of vaccines targeted to the polysaccharide capsule of the 
pneumococcus, it has classically been thought that protection against it was due to an 
antibody-based response120. However, more and more publications are now suggesting an 
important role for CD4+ T cell immunity in protection against the pneumococcus. MHC-II 
knockout mice which lack the ability to induce cell-mediated immunity through the 
presentation of antigen show prolonged carriage 120 suggesting CD4+ T cells have an 
important role to play in pneumococcal carriage rather than antibody-based responses. 
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The role of Foxp3+ Treg cells in the carriage of pneumococcus has been studied and a role 
for these regulatory cells has been sugeested90, 129, 273. However, the role of Tr1 cells during 
pneumococcal colonisation and their potential role I carriage of the bacteria has not been 
studied.  
This study looked at the induction and activation of Tr1 cells in human tonsillar tissue by 
pneumococcus to see if Tr1 cells could have a role to play in the carriage of bacteria. 
5.2 Aims of the study 
In this chapter we have investigated: 
1) Whether stimulation of freshly isolated tonsillar MNC with pneumococcal CCS, 
both wild type and deficient in pneumolysin or capsule, causes the activation of 
pre-existing Tr1 cells.  
2) If pneumococcal CCS can induce Tr1 cells from naïve CD4+ T cells in CD45RO+cell-
depleted tonsillar MNC. 
3) If the toxoid of Pneumolysin, W433F and purified capsular polysaccharide T3P and 
6B can activate Tr1 cells in tonsillar MNC. 
4) If the toxoid of Pneumolysin, W433F and purified capsular polysaccharide T3P and 
6B can induce Tr1 cells from naïve T cells in CD45RO+ depleted tonsillar MNC. 
5.3 Experimental Design 
Tonsillar MNC were stimulated using pneumococcal concentrated culture supernatant 
(CCS) derived from wild type (WT) D39 pneumococcus or its pneumolysin (Ply-/-) deficient 
strains. For activation experiments, tonsillar MNC were directly stimulated whereas for 
induction experiments tonsillar MNC were first depleted of memory CD45RO+ T cells using 
MACS cell separation.  Freshly isolated tonsillar MNC s were cultured for 3 days before the 
activation of Tr1 cells was measured using intracellular cytokine staining followed by flow 
cytometric analysis. To assess the induction of Tr1 cells from naïve CD4+ T cells, CD45RO+ 
119 
 
cells were first depleted before the cells were again cultured for 3 days followed by FACS 
analysis. Tr1 cell responses were analysed by the measurement of the intracellular cytokine 
IL-10 and the co expression of the extracellular markers CD49b and LAG-3. 
5.3.1 Human subjects and samples 
Samples of tonsillar tissue were obtained from children undergoing routine 
adenotonsillectomy between the ages of 2-16 years of age. Any individual who had been 
exposed to antibiotics for three weeks prior to surgery or were suffering from severe 
infection or immunodeficiency were excluded from the study. All children involved in the 
study gave their permission to be involved through informed consent of their parent or 
guardian.  
5.3.2 Pneumococcal concentrated culture supernatant (CCS) 
Pneumococcal CCS was used for the stimulation of tonsillar MNC in this experiment. 
Pneumococcal CCS was prepared from the encapsulated type 2 strain D39 of S. pneumonia 
and its isogenic mutants, one of which was deficient in capsule (Cap-/-) and one of which 
was deficient in Pneumolysin (Ply -/-).  
To prepare Pneumococcal CCS, bacterial frozen stocks were cultured overnight on blood 
agar plates (Fisher Scientific, UK) (37°C, 5% CO2). After about 18 hours, typical α-
haemolytic colonies of S. pneumoniae were observed. Several colonies were then used to 
inoculate Todd Hewitt Broth (THB) (Oxoid, UK) containing 5% yeast extract which was then 
cultured overnight (37°C, 5% CO2). The following day, the optical density of the culture was 
measured at 620nm and then this was checked every 30 minutes until exponential phase of 
growth was reached (OD of 0.4-0.5 at 620nm). The broth culture was centrifuged at 3000 x 
g for 30 minutes and the supernatant removed. The supernatant was then passed through 
a 0.45 µm filter followed by a 0.2 µm filter. Concentration of the pneumococcal culture 
supernatant was then achieved by centrifuging the sample at 3000 x g for 30 minutes in a 
Vivaspin15 concentrator (Sartorius Stedim Biotech, Germany). This process was repeated 
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several times to ensure that the sample was concentrated tenfold. Samples were then 
aliquoted into 1.5 µl microcentrifuge tubes and stored at -80°C until use.  
5.3.3 Depletion of CD45RO+ cells from Tonsillar MNC 
For Tr1 cell induction experiment, to remove any pre-existing activated Treg cells, CD45RO+ 
cells were first depleted from the cell culture. CD45RO is expressed on a number of 
different cell types. It is found on both memory CD4+ and CD8+ T cells as well as being 
present on CD4+ effector T cells, macrophages and monocytes. Previously activated and 
induced Treg cells are CD45RO+, whereas naïve Treg cells are CD45RA+. Depletion of 
CD45RO+ cells will remove any previously activated Treg cells leaving a naïve population 
that have never encountered antigen and become activated.    
To deplete cells, approximately 50 x 106 cells were taken from tonsillar MNC mix and re-
suspended in 400 µl (80µl/107 cells) of depletion buffer (0.5% PBS BSA). To this, 100µl 
(20µl/107 cells) of CD45RO magnetic beads (Miltenyi Biotech) were added. The cell 
suspension was thoroughly vortexed followed by incubation at 4°C for 15 minutes. 
Following incubation, cells were washed with 10 ml (2 ml/107 cells) of depletion buffer at 
400 x g for 10 minutes. The cell pellet formed was re-suspended in 250µl (50µl/10 cells) 
before magnetic separation was carried out. The MACS LD column (Miltenyi Biotech) was 
placed inside the magnetic groove of the magnet and primed by the addition of 2 ml of 
depletion buffer, with care being taken to avoid bubbles. The cell suspension was then 
added to the column carefully and allowed to pass through. This process could take some 
time depending on the number of CD45RO cells present in the sample. After all the cell 
suspension had passed through the column, 2 ml of depletion buffer was passed through 
the column. The collected CD45RO-T cells collected by this process were then re suspended 
in RPMI medium to a concentration of 4 x 106 cells/ml. Analysis of these cells after 
stimulation and intracellular cytokine staining was performed by FACS analysis.  
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5.3.4 Stimulation of Tr1 cells from freshly isolated tonsillar MNC and CD45RO+ depleted 
tonsillar MNC. 
CD45RO-tonsillar MNC or freshly isolate tonsillar MNC were cultured for 3 days at 37°C 
with stimulation using a variety of different pneumococcal stimulants. After 3 days of 
culture, the frequency of Tr1 cells was measured using a combination of surface and 
intracellular staining. The co-staining of CD49b, LAG-3 and CD4 allowed for the 
identification of Tr1 cells and the intracellular staining of IL10 confirmed the cells were Tr1 
cells. 
5.3.4.1 Intracellular staining 
Tr1 cells are a suppressive subset of regulatory T cell which exert their effect mainly though 
the production of IL10. Tr1 cells can be identified by the co expression of surface markers 
CD49b and Lag 3 and the high expression of IL101.  This is the combination of markers I was 
staining for in order to identify a cell population as being Tr1 cells.  
To detect Tr1 cells, after incubation with BFA, adenotonsillar MNC were harvested from the 
plates into 1.5 ml Eppendorf tubes and washed with FACS staining buffer (0.02% PBS-BSA) 
by centrifugation at 600 x g for 8 minutes. After washing, 20 µl of Alexafluor 647 (BD 
Bioscience) conjugated CD49b, and 5 µl of PeCy7 (BD Bioscience) conjugated CD4 was 
added to each sample and tubes were incubated at 4 degrees for 30 minutes. 
Adenotonsillar MNC or PBMC were then washed using 1 ml of FACS staining buffer at 600 x 
g for 8 minutes. 350 µl of fixation/permeabilisation buffer was added to each sample and 
tubes incubated for 30 minutes at room temperature. Cells were then washed in 
permeabilisation buffer followed by centrifugation at 600 x g for 8 minutes, before the 
addition of 5 µl of APC (BD Bioscience) Conjugated IL10 and 20 µl of PE (R&D Systems) 
conjugated LAG3 to each sample. This was incubated at room temperature for a further 30 
minutes followed by a final wash step using 1 ml of permeabilisation buffer per sample, 
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followed by centrifugation for 8 minutes at 600 x g. The final step was the addition of 500 
µl of FACS staining buffer to each tube ready for FACS analysis. 
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5.4 Results 
5.4.1 Gating strategy for the identification of Tr1 cells 
For this study, Tr1 cells were defined as IL10-producing cells that were positive for both 
CD49b and LAG-3 when stained using intracellular cytokine staining. (Figure 5.4.1) The 
lymphocyte population was highlighted using the typical FSC and SSC configuration. Within 
the lymphocyte population the CD4+ cells were then defined in R2. R3 then highlights the 
cells within R2 which are both CD49b+ and LAG-3+ and are therefore defined as Tr1 cells. 
To confirm that these cells are Tr1 cells. The CD4+ population was also gated to show IL-10 
positive cells and using this gate, the cells within the R3 region were confirmed to be IL-10 
producing Tr1 cells  
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R1 
R2 R3 
(a) (b) (c) 
(d) (e) 
Figure 5.4.1 One representative figure that shows the gating strategy used for the identification of 
Tr1 cell frequency in freshly isolated tonsillar MNC  
(a) The lymphocyte population is highlighted in R1, using the typical FSC and SSC configuration. (b) 
Within the lymphocyte population the CD4+ cells are defined in R2. (c) R3 then highlights the cells 
within R2 which are both CD49b+ and LAG-3+ and are therefore defined as Tr1 cells. (d) IL-10 
positive cells within the CD4+ lymphocyte population. (e) In order to confirm the cells in R3 are Tr1 
cells they are then gated against IL-10. 
 
5.4.2 Optimal doses of pneumococcal CCS, pneumolysin toxoid W433F and purified 
capsular polysaccharide T3P and 6B to be used for the stimulation of Tr1 cells in human 
tonsillar MNC 
The optimal doses of D39 WT pneumococcal CCS to use for the stimulation of Tr1 cells 
were determined prior to activation experiments (Figure 5.4.2a). For determining the 
optimal dosage for activation experiments the whole cell population (WCP) was used. 
Freshly isolated tonsillar MNCs were stimulated using a variety of doses of each D39 WT 
pneumococcal CCS to determine which caused the optimum level of activation. A total of 4 
125 
 
N
eg
at
iv
e 
C
on
tr
ol
g/
m
l)

W
T 
C
C
S
 (1
 
g/
m
l)

W
T 
C
C
S
 (2
 
g/
m
l)

W
T 
C
C
S
 (4
 
0
1
2
3
4
5
%
C
D
4
9
b
/L
A
G
-3
+
samples were stimulated (n=4) with a dose of 1, 2 and 4 µg/ml. The optimum dose for the 
activation of Tr1 cells was shown to be 1 µg/ml (Figure 5.4.2a). This concentration of 1 
µg/ml was used in all experiments to stimulate tonsillar MNCs. 
 
 
 
 
 
 
 
 
 
Figure 5.4.2a. Dose response curve of WT pneumococcal CCS for Tr1 cells activation. 
Stimulation of tonsillar MNC with WT pneumococcal CCS shows the optimal concentration to be 1 
µg/ml (n=4)   
 
Concentration curves for W433F, T3P and 6B were done to determine the optimum dose 
for stimulation of freshly isolated tonsillar MNC for the activation of Tr1 cells. Figure 5.4.2b 
shows the dose curves for W433F (a), T3P (b) and 6B (c).  The dose curve for pneumolysin 
toxoid W433F shows the optimal dose for stimulation is 10 ng/ml (n=2). For both T3P and 
6B the optimal dose for stimulation is 1 µg/ml (n=2). These concentrations were used for 
the stimulation of human tonsillar MNC to see what effect they had on the activation of Tr1 
cells. 
 
 
 
 
 
126 
 
N
eg
at
iv
e 
C
on
tr
ol
W
43
3 
2.
5
W
43
3 
5
W
43
3 
10
W
43
3 
20
W
43
3 
40
W
43
3 
80
W
43
3 
12
0
0
2
4
6
%
C
D
4
9
b
/L
A
G
-3
+
N
eg
at
iv
e 
C
on
tr
ol
T3
P 
1
T3
P 
2
T3
P 
4
T3
P 
8
0
1
2
3
4
%
C
D
4
9
b
/L
A
G
-3
+
N
eg
at
iv
e 
C
on
tr
ol
6B
 1
6B
 2
6B
 4
6B
 8
0
1
2
3
4
5
%
C
D
4
9
b
/L
A
G
-3
+
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.2b. Dose response curves for W433F, T3P and 6B for Tr1 cell stimulation 
(a)The percentage of Tr1 cell activation by W433F is shown to be optimal at 10 ng/ml with higher 
concentrations seeming to have a toxic effect on the cells. (b) The frequency of Tr1 cell activation by 
T3P is shown to be optimal at 1µg/ml with higher concentrations seeming to have a toxic effect on 
the cells. (c) The frequency of Tr1 cell activation by 6B is shown to be optimal at 1µg/ml with higher 
concentrations seeming to have a toxic effect on the cells.  
 
 
5.4.3 Stimulation of human tonsillar MNC with pneumococcal CCS deficient in Ply and 
capsular polysaccharide show lower frequencies of Tr1 cell activation compared to 
stimulation with WT pneumococcal CCS 
Pneumococcal CCS was used to stimulate the WCP to determine if the absence of key 
pneumococcal virulence factors (pneumolysin and capsule) influence the activation of Tr1 
cells. Pneumococcal CCS was used to stimulate freshly isolated tonsillar MNC at a 
concentration of 1 µg/ml as outlined in Figure 5.4.2. Figure 5.4.3 shows that D39 WT 
pneumococcal CCS stimulation of tonsillar MNC leads to the activation of 4.06% of Tr1 cells. 
(a) (b) 
(c) 
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The use of Ply-/- CCS and Capsule -/- CCS for stimulation sees the percentage of Tr1 cell 
activation reduce significantly (2.37% and 2.46% respectively) 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.3. The frequency of Tr1 cell activation after stimulation with pneumococcal CCS 
The frequency of Tr1 cells is shown to be significantly higher in tonsillar MNC upon stimulation with 
WT CCS compared to a negative control (2.07% for the negative control and 4.06% when stimulated 
with WT CCS). (p = 0.0150, n = 4). Ply -/- CCS shows significantly less activation compared to the WT 
CCS (2.37% compared to 4.06%) (p = 0.0098, n = 4). Cap -/- CCS shows significantly less activation 
compared to WT CCS (2.46% compared to 4.06%) (p = 0.0242 n = 4) Mean + SEM are shown *p<0.05, 
**p<0.01, ***p<0.001. 
 
5.4.4 Stimulation of human tonsillar MNC with pneumolysin toxoid W433F and purified 
capsular polysaccharide (T3P and 6B) supports the importance of pneumolysin and 
polysaccharide in Tr1 cell activation 
Data already shown (Figure 5.4.3) suggests that pneumococcal virulence factors 
pneumolysin and polysaccharide capsule may be important for the activation of Tr1 cells in 
human tonsillar MNC. To confirm this, human tonsillar MNC were stimulated using a toxoid 
of pneumolysin (W433F) and two types of purified capsular polysaccharide (T3P and 6B).  
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Data shown in Figure 5.4.4 shows that compared to a medium control with no stimulation 
in which the percentage of activated Tr1 cells is 5.43%, the addition of W433F elicited an 
increase in Tr1 cells to 8.16%. The stimulation of tonsillar MNC with both T3P and 6B also 
shows significantly more activated Tr1 cells (7.73% and 8.00% respectively) compared to 
the unstimulated medium control (5.43%). The stimulation of tonsillar MNC with a 
combination of the two virulence factors, W433F with T3P and W433F with 6B also shows 
significantly more Tr1 cell activation (8.65% and 7.16% respectively) compared to an 
unstimulated control (5.43%) but there is no significance when compared to just W433F, 
T3P or 6B alone. 
 
 
 
 
 
 
Figure 5.4.4 The frequency of Tr1 cell activation after stimulation with pneumococcal capsular 
polysaccharide (T3P and 6B) and toxoid of pneumolysin W433F 
(a)The frequency of Tr1 cells after stimulation with purified pneumococcal capsular polysaccharide 
T3P is significantly higher when compared to an unstimulated negative control (7.73% compared to 
5.43%, p = 0.0210, n = 7). The frequency of Tr1 cells after stimulation with W433F is significantly 
higher when compared to an unstimulated negative control (8.16% compared to 5.43%, p = 0.0089, 
n = 7). Stimulation using a combination of T3P and W433F shows a significant increase in Tr1 cell 
frequency compared to a negative control (8.65% compare to 5.43%, p = 0.0111, n = 7) but no 
significant difference compared to T3P and W433F alone. (B) The frequency of Tr1 cells after 
stimulation with purified pneumococcal capsular polysaccharide 6B is significantly higher when 
compared to an unstimulated negative control (8.00% compared to 5.43%, p = 0.0010, n = 7). The 
frequency of Tr1 cells after stimulation with W433F is significantly higher when compared to an 
unstimulated negative control (8.16% compared to 5.43%, p = 0.0089, n = 7). Stimulation using a 
combination of 6B and W433F shows a significant increase in Tr1cell frequency compared to a 
negative control (7.16% compare to 5.43%, p =0.0132, n = 7) but no significant difference compared 
to 6B and W433F alone. Mean + SEM are shown *p<0.05, **p<0.01, ***p<0.001. 
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5.4.5 Stimulation of CD45RO+ cell-depleted tonsillar MNC with pneumococcal CCS 
deficient in Ply and capsular polysaccharide show lower frequencies of Tr1 cell induction 
compared to stimulation with WT pneumococcal CCS 
Freshly isolated human tonsillar MNC were depleted of CD45RO+ cells before being 
stimulated using pneumococcal CCS at concentrations previously described (Figure 5.4.2). 
WT pneumococcal CCS was used as well as pneumococcal CCS deficient in key 
pneumococcal virulence factors, pneumolysin and capsular polysaccharide to determine 
their importance in the induction of Tr1 cells. Figure 5.4.5 shows that when WT CCS is used 
to stimulate cells, the frequency of induced Tr1 cells is 4.11%. When pneumolysin deficient 
CCS is used, the percentage of induced Tr1 cells significantly reduces to 2.41%. The same 
thing is seen when Cap-/- CCS is used as the percentage if induced Tr1 cells is shown to be 
2.48%.   
 
 
 
 
 
 
 
 
 
Figure 5.4.5. The frequency of Tr1 cell induction after stimulation with pneumococcal CCS 
The frequency of Tr1 cells is shown to be significantly higher in tonsillar MNC upon stimulation with 
WT CCS compared to a negative control (0.57% for the negative control and 4.11% when stimulated 
with WT CCS). (p = 0.0004, n = 4). Ply -/- CCS shows significantly less activation compared to the WT 
CCS (2.41% compared to 4.11%) (p = 0.0100, n = 4). Cap -/- CCS shows significantly less activation 
compared to WT CCS (2.48% compared to 4.11%) (p = 0.0050 n = 4) Mean + SEM are shown *p<0.05, 
**p<0.01, ***p<0.001. 
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5.4.6 Stimulation of CD45RO+ cells-depleted human tonsillar MNC with pneumolysin 
toxoid W433F and purified capsular polysaccharide (T3P and 6B) supports the importance 
of pneumolysin and polysaccharide in Tr1 cell induction 
Data already shown (Figure 5.4.5) suggests that pneumococcal virulence factors 
pneumolysin and capsular polysaccharide may be important for the induction of Tr1 cells 
from naïve CD4+ T cells in human tonsillar MNC. Freshly isolated human tonsillar MNC 
were depleted of CD45RO+ cells before they were stimulated using a toxoid of 
pneumolysin (W433F) and purified capsular polysaccharide (T3P and 6B) to confirm their 
important in Tr1 cell induction.  
Data shown in Figure 5.4.6 shows that compared to a medium control with no stimulation 
(0.49%), the addition of W433F causes significantly more induction of Tr1 cells (3. 85%). 
The stimulation of tonsillar MNC with both T3P and 6B also shows significantly more 
activated Tr1 cells (4.24% and 4.23% respectively) compared to the unstimulated medium 
control (0.49%). The stimulation of tonsillar MNC with a combination of the two virulence 
factors, W433F with T3P and W433F with 6B also shows significantly more Tr1 cell 
activation (4.29% and 3.97% respectively) compared to an unstimulated control (2.36%) 
but there is no significance when compared to just W433F, T3P or 6B alone. 
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Figure 5.4.6. Figure 5.4.6. The frequency of Tr1 cell induction after stimulation with pneumococcal 
capsular polysaccharide (T3P and 6B) and toxoid of pneumolysin W433F 
(a)The frequency of Tr1 cells after stimulation with purified pneumococcal capsular polysaccharide 
T3P is significantly higher when compared to an unstimulated negative control (4.24% compared to 
0.49%, p = 0.0001, n = 7). The frequency of Tr1 cells after stimulation with W433F is significantly 
higher when compared to an unstimulated negative control (3.85% compared to 0.49%, p = 0.0004, 
n = 7). Stimulation using a combination of T3P and W433F shows a significant increase in Tr1 cell 
frequency compared to a negative control (4.29% compare to 0.49%, p = 0.0009, n = 7) but no 
significant difference compared to T3P and W433F alone. (b) The frequency of Tr1 cells after 
stimulation with purified pneumococcal capsular polysaccharide 6B is significantly higher when 
compared to an unstimulated negative control (4.23% compared to 0.49%, p = 0.0004, n = 7). The 
frequency of Tr1 cells after stimulation with W433F is significantly higher when compared to an 
unstimulated negative control (3.85% compared to 0.49%, p = 0.0004, n = 7). Stimulation using a 
combination of 6B and W433F shows a significant increase in Tr1 cell frequency compared to a 
negative control (3.97% compare to 0.49%, p = 0.0005, n = 7) but no significant difference compared 
to 6B and W433F alone. Mean + SEM are shown *p<0.05, **p<0.01, ***p<0.001. 
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5.5 Discussion 
Colonisation of the nasopharynx by pneumococcus is known to be a pre-requisite for both 
invasive disease and for carriage and spread of the bacteria through the community. 
Understanding Interactions between pneumococcus and cells of the immune system is key 
to develop effective strategies to combat both infection and carriage. The role of regulatory 
T cells and their relationship with pneumococcus has been studied but little information is 
available about interactions in human nasopharynx which as the site of colonisation. In 
terms of regulatory T cells and pneumococcus, the best studied would be Foxp3+ Treg cells 
90, 121, 275. Previous studies have shown that pneumococcal whole cell antigen (WCA) is able 
to induce Foxp3+ Treg cells in the nasopharynx which suggests there are some components 
of pneumococcus that could be specifically involved in inducing this cell type90.  Very little 
research has been done on other regulatory T cells such as type 1 regulatory T cells (Tr1). 
This chapter has looked at the relationship between Tr1 cells and pneumococcus and how 
specific pneumococcal components can both activate and induce Tr1 cells in tonsillar 
tissue.  
Any potential vaccine candidate would interact with many different immune cells and it is 
therefore important to understand how any interactions affect the overall outcome of 
patient health.  
Current pneumococcal vaccines have been successful in offering protection for those 
serotypes included but they do not confer protection for all serotypes and new serotypes 
have emerged to replace those that are now protected against181 182.   The original capsular 
polysaccharide vaccines were effective in adults but had limited efficacy in young children 
as they were T cell independent. Moving on to polysaccharide conjugate vaccines in which 
the polysaccharide capsule was conjugated to protein, the vaccines became more 
immunogenic in young children and their effectiveness against serotypes included in the 
vaccine was very apparent. However, these vaccines are expensive to produce and limited 
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in serotype coverage. Pneumococcal vaccine research has therefore moved into looking at 
potential vaccines that target all pneumococcal serotypes regardless of their capsular 
polysaccharide. One way of doing this is through targeting a pneumococcal protein which is 
found in all serotypes. There have been several candidates suggested including 
pneumolysin198.  
The data presented in this chapter shows that in human tonsillar tissue, both 
pneumococcal capsular polysaccharide and pneumolysin can both activate and induce Tr1 
cells. Section 5.4.3 shows a reduced response of Tr1 cells in tonsillar MNC following 
stimulation with pneumococcal CCS deficient in pneumolysin or capsule PS as compared to 
the wild type (WT) which has both. This suggest both pneumolysin and capsule could have 
a role to play in the activation of Tr1 cells.  
The next step was to look at the effected of purified capsular polysaccharide (T3P and 6B) 
and a toxoid of pneumolysin (W433F) on the activation of Tr1 cells. Figure 5.4.4 shows that 
the pneumolysin toxoid W43F and both capsular polysaccharides used (T3P and 6B) were 
able to elicit a significant increase in Tr1 cell numbers compared to an unstimulated 
negative control. The combination of W433F and T3P or W433F and 6B didn’t show any 
more significant activation than each component alone which is interesting as it seems to 
suggest they do the same thing without having an exacerbated effect on each other. It had 
previously been shown in a mouse model that the combination of T3P and Ply did confer an 
increased protective effect when compared to either the T3P or Ply alone127. 
This research looking at Tr1 cells responses to pneumococcal components is novel. There is 
already lots of research looking at Foxp3+ Treg cells responses but it is interesting to see 
that another category of regulatory T cells are reacting in much the same way. The 
stimulation using pneumolysin and capsular polysaccharide increased the numbers of Tr1 
cells seen significantly which certainly seems to indicate their importance for Tr1 cell 
activation. The presence of pre-existing Tr1 cells could be due to previous colonisation 
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events by the pneumococcus in the nasopharynx. This would explain why stimulation saw 
the numbers of these cells increasing as fresh stimulation would activate cells that had 
previously encountered the stimuli. 
We decided to deplete samples to see if Tr1 cells could be induced. In this instance we 
depleted samples of CD45RO+ cells. As with the activation experiments, initially cells were 
stimulated using pneumococcal CCS (Figure 5.4.5) to see whether any differences were 
observed in induction with and without pneumolysin and capsular polysaccharide. We did 
in fact once again see that when Ply-/- and Cap-/- CCS were used, the induction of Tr1 cells 
was significantly less than that when cells were stimulated using D39 WT pneumococcal 
CCS. This once again suggested pneumolysin and capsular polysaccharide are important 
players in Tr1 cell responses, so I then moved on to stimulation with purified pneumolysin 
toxoid (W433F) and purified capsular polysaccharide (T3P and 6B). (Figure 5.4.6) W433F 
stimulation alone showed significantly more Tr1 cells induction compared to the negative 
control. T3P and 6B stimulation alone also showed significantly more Tr2 cells induction 
compared to the negative control. And again, the combination of W433F with either of the 
two polysaccharides did not have an increased induction and was no different from to 
either components alone.  
These results mirror those seen using pneumolysin and capsular polysaccharide for the 
activation of Foxp3+ Treg cells suggesting that several categories of regulatory cells are 
affected by pneumococcus. Capsular polysaccharide is currently used in pneumococcal 
vaccines with great success, although there is the issue with the expense and the limited 
coverage of serotypes. In this study, 2 different types of purified capsular polysaccharide 
were used to stimulate cells, T3P and 6B, and both were able to activate pre-existing Tr1 
cells and induce Tr1 cells from naïve T cells. Pneumolysin was also able to both activate and 
induce Tr1 cells to much the same level as the capsular polysaccharide used. These results 
suggest Tr1 cells could have a role to play in the carriage of pneumococcus. 
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Regulatory T cells and their association with the mucosal immune system presents 
challenges to any therapies that would target bacteria that live at these sites. Any therapies 
would have to be non-toxic and not cause any worst effects through their modes of action. 
Regulatory T cells within the mucosal immune system are able to be induced upon 
stimulation by antigen, for example nasal antigen is able to induce Tr1 cells276. Tr1 cells 
have emerged as being very important in limiting excessive inflammatory responses277, 278. 
Their role during autoimmune diseases has been studied and they are regularly present 
during autoimmune inflammation105, 279. Regulatory T cells within mucosal tissue, whether 
its gut associated, nasopharynx associated or any other can be beneficial in preventing the 
excessive inflammation associated with unregulated effector cell responses60The results 
outlined here show that Tr1 cells are present in human tonsillar tissue and that 
pneumococcal antigen is able to activate pre exiting Tr1 cells and also induce Tr1 cells. The 
presence of Tr1 cells and their association with pneumococcal stimulation could suggest 
they have a role to play in the carriage of the bacteria. Their presence may allow the 
bacteria to persist within the nasopharynx without being cleared by effector CD4+ T cells 
which are being inhibited by their presence. Targeting any specific cell type such as Tr1 cells 
as a way of combatting carriage and therefore as a way of preventing spread of the 
bacteria through the population, is a challenging concept. To target these cells specifically 
would be very difficult and their reaction and responses to pneumococcal stimulation only 
give a small part of a much bigger picture of what interactions are occurring within the 
nasopharynx. But these cells do have some role to play in the carriage and persistence of 
infection and as such they could be worth exploring in more detail. 
It is interesting to note that in both activation and induction experiments, the combined 
use of capsular polysaccharide and pneumolysin confers no additional protection 
compared to when either is used individually. It was thought that the stimulation with both 
components which are so effective at eliciting a response individually would perhaps cause 
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an additive effect on the response. However, in this instance no further benefits seem to 
be present when using both capsular polysaccharide and pneumolysin in combination. It 
could be argued that the effect of pneumolysin is not very relevant when current vaccines 
already use pneumococcal polysaccharide which has been shown to be just as effective as 
the pneumolysin in these experiments. However, the difference is that pneumococcal 
polysaccharide is so limited in the number of serotypes and pneumolysin is universally 
expressed, so perhaps a new vaccine that, moves away from, capsular polysaccharide and 
targets a protein is the way to move forward with pneumococcal vaccine research.  
5.6 Summary 
The results presented in this study suggest that specific capsular and protein components 
of pneumococcus may play a role in the induction and activation of Tr1 cells in human 
NALT. Data presented here suggests that both capsular polysaccharide and pneumolysin 
can both activate and induce Tr1 cells, and as such their role during pneumococcal carriage 
must be understood if a mucosal vaccine is to be used to protect against pneumococcal 
disease. Capsular polysaccharide is already used in pneumococcal vaccines but a vaccine 
that targets a universally conserved protein such as pneumolysin could offer protection 
against all serotypes of pneumococcus rather than just a few specific serotypes. More 
information is required to understand the exact role Tr1 cells and other regulatory and 
effector T cells play before a mucosal vaccine could be suggested but this data shows how 
Tr1 cells are affected by these specific pneumococcal components and provides some 
information which could feed into further vaccine research. What is clear is that Tr1 cells 
are present in the nasopharynx and are affected by stimulation with pneumococcal antigen 
and as such they could have a role to play in the carriage of pneumococcus. 
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Chapter 6 
Role of TGF-β in the induction of Foxp3+ 
Treg cells in Human Nasal Associated 
Lymphoid Tissues  
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6.1 Introduction 
Streptococcus pneumonia (pneumococcus) is an important human pathogen that is 
responsible for several invasive and non-invasive diseases which range in severity from 
mild otitis media to severe meningitis and pneumonia2.   Pneumococcal disease is 
particularly prevalent in high risk groups including the elderly and young children and is a 
leading cause of childhood morbidity and mortality worldwide. 
Foxp3+ Treg cells have an important role in the prevention of autoimmune disease and in 
the maintenance of immune tolerance.  Foxp3+ Treg cells can be broadly classified into two 
subsets, naive Tregs (nTregs) and inducible Tregs (iTregs). iTregs are thought to acquire 
their suppressor activity through activation of CD4+CD25-FoxP3- T cells in the periphery 
upon stimulation by an antigen. Activation of iTregs occurs in the presence of TGF-β199. It is 
thought that iTregs could have a particularly important role to play at mucosal surfaces 
where there is an abundance of TGF-β1. TGF-β1 is not required for the differentiation of 
nTregs but does seem important in promoting their survival in the periphery99. 
Foxp3+ Treg cells use the αβTCR for antigen recognition and are restricted by MHC-II 
molecules as with other CD4+ T cells101. It is thought that there are two mechanisms by 
which Treg cells exert their suppressive effects. The contact dependent method involves 
CTLA-4 on the Treg cell and CD80/86 on APCs102. CTLA-4 is expressed at high levels on 
CD4+CD25+ Treg cells and it is thought that the CTLA-4 interacts with the CD80/86 on APCs 
which leads to the activation of an enzyme called IDO (indoleamine 2,3 dioxygenase) in 
dendritic cells280. This ultimately leads to decreased activation of effector T cells280, 281. The 
second mechanism is mediated through immunosuppressive cytokines. 
Immunosuppressive cytokines are also important in Treg associated suppression. IL-10 and 
TGF-β released by Treg cells are responsible for down regulating MHC II and co-stimulatory 
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molecules on dendritic cells which affects their ability to present antigens and so stops the 
activation of CD4+ T cells102. 
Nasopharyngeal colonisation is very common in young children before natural immunity 
can develop. In the UK colonisation in children less than 3 years of age is between 40-
50%117 but in African children this can reach 90-100%118, 119. By the age of 3 most children 
have developed natural immunity against specific pneumococcal antigens. This natural 
immunity is responsible for the clearance of the pneumococcus from the nasopharynx 
before carriage status can be achieved. However, despite this natural immunity carriage 
can still occur throughout life and it is thought that Treg cells could have a role in this.  
Due to the success of vaccines targeted to the polysaccharide capsule of the 
pneumococcus, it has classically been thought that protection against it was due to an 
antibody-based response120. However, more and more publications are now suggesting an 
important role for CD4+ T cell immunity in protection against the pneumococcus. MHC-II 
knockout mice which lack the ability to induce cell-mediated immunity through the 
presentation of antigen show prolonged carriage 120 suggesting CD4+ T cells have an 
important role to play in pneumococcal carriage rather than antibody-based responses. 
In a recent study by Zhang et al, adenoidal cells from children who tested positive for 
pneumococcal carriage were found to contain higher numbers of Foxp3+ Treg cells when 
stimulated with pneumococcal whole cell antigen than those taken from children that 
tested negative90. The Treg cells present are of a memory phenotype suggesting they have 
been induced by a previous colonisation event. This association between carriage state and 
the increased number of Treg cells in the nasopharynx suggests that colonisation with the 
pneumococcus leads to the promotion of pneumococcus specific Treg cells. As well as this, 
the depletion of these cells before stimulation with whole cell antigen led to an increase in 
CD4+ T cell proliferation and the re-introduction of the Treg cells suppressed this effect121. 
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This suggests that these memory Treg cells present in the nasopharynx have a potent 
inhibitory effect on CD4 T cell proliferation and may contribute to the persistence of 
carriage seen in young children. 
The importance of regulatory T cell function in the nasopharynx and their role in the 
carriage of pneumococcus have made these cells an attractive study for looking at potential 
therapies against the bacteria. Understanding how Foxp3+ Treg cells are activated in the 
nasopharynx would inform new therapies for targeting the carriage of the bacteria.  
6.1.1 Transforming growth factor beta (TGF-β) 
Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is expressed in 3 
different isoforms TGF-β1-3206. TGF-β is secreted by many different cell types has many 
roles including a role in regulating proliferation, differentiation, adhesion and migration207. 
After synthesis the TGFβ molecules are secreted as part of an inactive complex comprising 
of an N-terminal latency-associated peptide (LAP) and a mature TGF-β monomer at the C 
terminal. Homodimers of TGF-β and LAP interact in a non-covalent manner forming a 
complex known as small latent complex (SLC)208. LAP is then covalently linked to one of 
three latent TGFβ binding proteins (LGBTs) to form a larger complex called a large latent 
complex (LLC) which is then secreted out of the cell into the extracellular matrix209. 
The LLC will then remain in the extracellular matrix in an inactive state and requires further 
processing to release the active TGF-β product. For TGF-β to become active the LAP must 
be cleaved or modified in some way to expose the binding site of the TGF-β receptor205. 
6.1.2 Role of TGF-β in Foxp3+ Treg cell activation 
TGF-β and Treg cells are both important in the control of immune responses and in the 
maintenance of immune homeostasis. TGF-β appears to play a role as an effector cytokine 
involved in the immunosuppressive function on Treg cells.  
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TGF-β 1 has a role in the induction of both inducible Tregs which have an inhibitory role on 
Th17 cells which are responsible for the production of numerous pro-inflammatory 
cytokines including IL17A228. 
There are several mouse models that have been established which allow the investigation 
of the role of TGF-β in immune regulation. TGF-β -/- mice allowed the realisation of how 
important TGF-β 1is in immune system regulation. The mice in this model develop a rapid 
wasting syndrome which leads rapidly to death229.  Transgenic mice that have an impaired 
TGF-β signalling pathway show an increased susceptibility to the induction of disease, 
although it is not as severe as disease seen in TGF-β -/- mice230. Mice can survive for several 
months without developing severe disease. This can be explained by TGF-β acting on 
multiple cell types. So TGF-β can still influence some cells but not on others. So, mice show 
a susceptibility to the induction of allergic and autoimmune responses without developing 
spontaneous autoimmune disease. 
6.1.3 αvβ8 
αvβ8 is an integrin that has been shown to have a role to play in the activation of TGF-β235. 
Integrins are transmembrane receptors that act as a bridge for interactions between two 
cells or between cells and the extracellular matrix. Integrins are responsible for triggering 
chemical pathways which pass information about the exterior of the cell into the interior of 
the cell. In this way the chemical composition or the mechanical nature of the cell can be 
monitored, and events triggered at the cell surface can be rapidly responded to. 
6.1.4 Role of αvβ8 and Foxp3+ Treg cells in TGF-β activation 
TGF-β has been shown to play a role in Treg cell suppression of T cells but the mechanism 
by which this occurs isn’t well understood. TGF-β is always produced in an inactive state 
and must first be activated before it can bind to its receptor and exert and effect237. Foxp3+ 
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Treg cells have been shown to be able to activate TGF-β via the expression of the integrin 
αvβ8 and on activated Treg cells, this integrin is upregulated235. If Treg cells lack the 
expression of αvβ8 they become completely unable to suppress T cell mediated 
inflammatory responses235. 
6.2 Aims of study 
In this chapter we have investigated: 
1) The role of TGF-β in the activation of Foxp3+ Treg cells. 
2) The role of the integrin avb8 in the activation of TGF-β from its latent state to its 
active state. 
6.3 Experimental Design 
To determine the role of TGFβ in the activation of Foxp3+ Treg cells, adenotonsillar MNC 
were stimulated using pneumococcal CCS for 72 hours. The supernatant was then collected 
and analysed by TGF-β ELISA to measure the concentration of TGF-β in culture for both 
cells that were unstimulated and cells that were stimulated with pneumococcal CCS. Cells 
were then pre-incubated with anti-TGFβ and anti- αvβ8 followed by stimulation for 72 
hours with pneumococcal CCS to see if Foxp3+ Treg cell numbers were affected.  
6.3.1 Patients and samples 
Adenotonsillar tissue was obtained from both children and adults undergoing 
adenotonsillectomy. Full consent was obtained from each participating patient and full 
ethical approval for the study was given by the local ethics committee. 
6.3.2 Pneumococcal CCS 
Pneumococcal CCS was produced from a wild type strain of S. pneumoniae (D39) 
(NCTC7466)238. Bacterial frozen stocks were cultured overnight on blood agar plates (Fisher 
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Scientific, UK) (37°C, 5% CO2). After about 18 hours, typical α-haemolytic colonies of S. 
pneumoniae were observed. Several colonies were then used to inoculate Todd Hewitt 
Broth (THB) (Oxoid, UK) containing 5% yeast extract which was then cultured overnight 
(37°C, 5% CO2). The following day, the optical density of the culture was measured at 
620nm and then this was checked every 30 minutes until exponential phase of growth was 
reached (OD of 0.4-0.5 at 620nm). The broth culture was centrifuged at 3000 x g for 30 
minutes and the supernatant removed. The supernatant was then passed through a 0.45 
µm filter followed by a 0.2 µm filter. Concentration of the pneumococcal culture 
supernatant was then achieved by centrifuging the sample at 3000 x g for 30 minutes in a 
Vivaspin15 concentrator (Sartorius Stedim Biotech, Germany). This process was repeated 
several times to ensure that the sample was concentrated tenfold. Samples were then 
aliquoted into 1.5 µl microcentrifuge tubes and stored at -80°C until use. The protein 
concentration of pneumococcal CCS was measured using the Bradford protein. 
6.3.3 Cell culture and pre-incubation 
Adenotonsillar MNC cultures were set up to measure in vitro TGF-β levels. Cells were 
stimulated using WT pneumococcal CCS, WT pneumococcal CCS pre-incubated with anti-
TGF-β and WT pneumococcal CCS pre-incubated with anti-αvβ8. The process for the 
isolation of mononuclear cells from adenotonsillar tissue is outlined in the methods 
section. Briefly, adenotonsillar tissue was washed before being transferred to a sterile petri 
dish containing HBSS for mashing of the sample to allow the release of cells. The media 
containing the cells was passed through a filter before being layered carefully on to ficoll 
and centrifuged to allow the separation of the lymphocytes. The lymphocytes were then 
washed, and the pellet re-suspended before being counted using an automatic cell counter. 
The cells were then re-suspended to a working concentration of 4 x 106. To see the effect of 
TGF-β on Foxp3+ Treg cell activation some cells were added to an eppendorf with anti-TGFβ 
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and incubated at 37°C for 30 minutes before being cultured. To see if αvβ8 had any effect 
of Foxp3+ Treg cell activation some cells were added to an eppendorf and pre-incubated at 
37°C for 30 minutes with anti-αvβ8. A sample of cells was added to a plate with no 
additional stimulation as a negative control. Cells were added to the plate with no pre-
incubation and cells pre-incubated with anti-TGFβ and anti-αvβ8 were added. These cells 
were then stimulated with WT pneumococcal CCS before the plate was incubated at 37°C 
for 72 hours and supernatant was collected and stored in the freezer until use. 
6.3.4 Intracellular cytokine staining of Foxp3  
To determine the effects of αvβ8 and TGF-β on the activation of Foxp3+ Treg cells on 
tonsillar MNC, cells were stimulated with WT pneumococcal CCS both before and after pre-
incubation with anti- αvβ8 or anti-TGF-β. This meant that the levels of Foxp3+ Treg cell 
activation could be measured by intracellular cytokine staining to see if any differences 
were observed. The detailed method for the staining of Foxp3+ Treg cells can be found in 
chapter 2. Briefly, tonsillar MNC were isolated from tonsillar samples by ficoll gradient 
centrifugation. Cells were cultured in 96 well flat bottom plates (corning) at a concentration 
of 4 x 106 in RPMI (sigma) supplemented with glutamine, streptomycin, penicillin and 10% 
FBS. Cells were stimulated with WT pneumococcal CCS, both before or after pre-incubation 
with anti-αvβ8 or anti-TGF-β. Cells were then harvested into Eppendorf tubes before being 
stained with CD4 and Foxp3 following the method outlined in chapter 2. 
6.3.5 TGF-β ELISA 
Adenotonsillar MNC were stimulated using WT pneumococcal CCS, WT pneumococcal CCS 
pre-incubated with anti-TGF-β and WT pneumococcal CCS pre-incubated with anti-αvβ8. 
Supernatant was collected after 72 hours before analysis using TGF-β ELISA. The method is 
outlined in methods section. Briefly, capture antibody was used to coat 96 well plate and 
left overnight at 4°C. The plate was washed before being blocked and incubated for 1 hour 
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at room temperature. Standards and samples were prepared and added to the plate after 
washing before the plate was incubated for 2 hours at room temperature. The plate was 
washed, and detection antibody was added before the plate was incubated at room 
temperature for 1 hour. Avidin-HRP was added to each well for 30 minutes at room 
temperature before the plate was washed and substrate solution was added. The plate was 
left for 15 minutes in the dark before the addition of stop solution. Finally, the pate was 
read at 450 nm and the concentration of TGF-β measured against the standard curve. 
6.4 Results 
6.4.1 TGF-β present in medium control but level increases when stimulated with WT 
pneumococcal CCS 
Freshly isolated tonsillar MNC were stimulated for a period of 72 hours using WT 
pneumococcal CCS before the supernatant was collected for analysis. The in vitro 
production of TGF-β in tonsillar MNC after stimulation was then measured using the TGF-β 
ELISA assay. After stimulation using D39 WT pneumococcal CCS, the level of TGF-β in the 
culture supernatant was found to be significantly higher than in a medium control which 
received no stimulation (Figure 6.4.1) 
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Figure 6.4.1. TGF-β production in tonsillar MNC following stimulation by pneumococcal CCS 
The level of the cytokine TGF-β was measured by ELISA assay after 72 hours both with and without 
stimulation using WT pneumococcal CCS. The TGF-β concentration was significantly higher in the 
samples stimulated with WT pneumococcal CCS (1453.4 pg/ml) compared to the negative control 
samples (513.4 pg/ml) Mean+SEM are shown**p<0.01, 
 
6.4.2 Foxp3+ Treg cell percentage increases upon stimulation of tonsillar MNC with WT 
pneumococcal CCS 
Freshly isolated tonsillar MNC were cultured for 3 days both with and without stimulation 
using WT pneumococcal CCS. The stimulation of these cells with the pneumococcal CCS 
caused the percentage of Foxp3+ Treg cells to increase significantly. Figure 6.4.2 shows the 
gating strategy used to identify Foxp3+ Treg cells both with and without stimulation using 
pneumococcal CCS and the percentage of  Foxp3+ Treg cells identified under both 
conditions. 
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Figure 6.4.2. Foxp3+ Treg cell percentage in tonsillar MNC following stimulation by WT 
pneumococcal CCS 
The percentage of Foxp3+ Treg cells were by intracellular cytokine staining after 72 hours of 
stimulation both with and without stimulation using WT pneumococcal CCS. (a i) Tonsillar MNC 
sample with no stimulation (a ii) Tonsillar MNC sample after stimulation using WT pneumococcal 
CCS. R1 highlights the lymphocyte population, defined using typical FSC and SSC. Within the 
lymphocyte population the CD4+ cells are then defined in R2. Finally, the Foxp3+ Treg cells are 
identified by the gating of the CD4+ population (R2) and the positive staining of Foxp3 (b) The 
percentage of Foxp3+ Treg cells was significantly higher in the samples stimulated with WT 
pneumococcal CCS (11.82%) compared to the negative control samples (6.47%) (p=0.0076, n=6) 
Mean+SEM are shown**p<0.01. 
 
6.4.3 TGF-β level decreases upon pre-incubation using anti-TGF-β or anti-αvβ8 
Freshly isolated tonsillar MNC were pre-incubated with anti TGF-β or anti αvβ8. Cells were 
then stimulated using WT pneumococcal CCS and incubated for 3 days. The in vitro 
production of TGF-β in tonsillar MNC after stimulation was then measured using the TGF-β 
ELISA assay. Cells pre-incubated with anti TGF-β showed significantly decreased TGF-β 
production compared to a negative control. Cells pre-incubated with anti-αvβ8 showed 
significantly decreased TGF-β production compared to a negative control (Figure 6.4.3). 
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Figure 6.4.3. TGF-β production in tonsillar MNC following stimulation by pneumococcal CCS after 
pre-incubation with anti-TGF-β or anti-αvβ8 
The concentration of TGF-β is shown to be significantly lower in cells stimulated with WT 
pneumococcal CCS that were pre-incubated with anti TGF-β (308.548 pg/ml) when compared to cells 
stimulated with WT pneumococcal CCS alone. (1453.41 pg/ml) (p = 0.0056, n = 4) The concentration 
of TGF-β is shown to be significantly lower in cells stimulated with WT pneumococcal CCS that were 
pre-incubated with anti αvβ8 (348.627 pg/ml) when compared to cells stimulated with WT 
pneumococcal CCS alone. (1453.41 pg/ml) (p = 0.0123, n = 4) Mean + SEM are shown *p<0.05, 
**p<0.01, 
6.4.4 Foxp3+ Treg cell percentage is reduced when cells are pre-incubated with anti- αvβ8 
or anti-TGF-β 
Freshly isolated tonsillar MNC were pre-incubated with anti-TGF-β or anti-αvβ8. Cells were 
then stimulated using WT pneumococcal CCS and incubated for 3 days. To confirm that the 
TGF-β levels observed from the ELISA results changed as a result of Foxp3+ Treg cell 
activation, the percentage of Foxp3+ Treg cells were measured by intracellular cytokine 
staining followed by FACS analysis. Figure 6.4.4 shows the percentage of Foxp3+ Treg cells 
identified and a representative example of the gating strategy used to isolate Foxp3+ Treg 
cells from other cells. 
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Figure 6.4.4. Foxp3+ Treg cell percentage in tonsillar MNC following stimulation by pneumococcal CCS after pre-incubation 
with anti-TGF-β or anti-αvβ8 
(a i)Tonsillar MNC sample with no stimulation (a ii) Tonsillar MNC sample after stimulation using WT pneumococcal CCS. (a iii) 
Tonsillar MNC sample after stimulation with WT pneumococcal CCS when cells were pre incubated with anti-TGF β, (a iiii) 
Tonsillar MNC sample after stimulation with WT pneumococcal CCS when cells were pre incubate with αvβ8. R1 highlights the 
lymphocyte population, defined using typical FSC and SSC. Within the lymphocyte population the CD4+ cells are then defined 
in R2. Finally, the Foxp3+ Treg cells are identified by the gating of the CD4+ population (R2) and the positive staining of Foxp3 
(b i)The percentage of Foxp3+ Treg cells is shown to be significantly lower in cells stimulated with WT pneumococcal CCS that 
were pre-incubated with anti TGF-β (5.65%) when compared to cells stimulated with WT pneumococcal CCS alone. (11.82%) 
(p = 0.0003, n = 6) (b ii) The percentage of Foxp3+ Treg cells is shown to be significantly lower in cells stimulated with WT 
pneumococcal CCS that were pre-incubated with anti αvβ8 (5.82%) when compared to cells stimulated with WT 
pneumococcal CCS alone. (11.82%) (p = 0.0005, n = 6) Mean + SEM are shown, ***p<0.001. 
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6.5 Discussion 
CD4+ T cells have now been established as being an important part of protective immunity 
against pneumococcus, with MHC class-II deficient mice which have a significantly reduced 
number of CD4+ T cells being incredibly susceptible to infection by pneumococcus262. The 
role of pro-inflammatory CD4+ T cells during pneumococcal infection has been studied in 
detail282, 283 but the role of regulatory cells hasn’t been studied in as much detail and as 
such is an important gap in our knowledge about the immunology associated with 
pneumococcal carriage and disease. TGF-β is thought to be important in the differentiation 
of naïve CD4+ T cells into Foxp3+ Treg cells which can then proliferate and lead to 
suppression of the immune system284, 285. A study by Liao et al, showed that SPY1, a live 
attenuated vaccine against pneumococcus, is able to induce protective Treg cells286 which 
are vital for the maintenance of homeostasis of the immune system and prevent infection 
associated inflammation287. In addition to this they showed that the addition of a peptide, 
P17286, 288,  which inhibits TGF-β and therefore reduces the numbers of Foxp3+ Treg cells, 
impairs the effectiveness of SPY1 which suggests the ability of SPY1 to activate TGF-β and 
activate Treg cells is important for producing protective Treg immune responses in the 
nasopharynx287. This suggests TGF-β has an important role to play in the activation of 
Foxp3+ Treg cells and the carriage of pneumococcus in the nasopharynx. This protective 
role of regulatory T cells has also been shown in a mouse study by Neill et al275. This study 
showed that regulatory T cells have an important role to play in the prevention of immune 
mediated damage in the lungs of infected mice and that TGF-β has an important role to 
play in this275. They used 2 mice models which react very differently to pneumococcal 
infection289 and infected the lungs with pneumococcus. CBA/Ca mice which have fewer T 
regulatory cells and therefore less TGF-β showed insufficient immunosuppression and the 
bacteria was able to disseminate into the bloodstream before they could be cleared. In 
contrast, in BALB/c mice, a controlled and regulated pro-inflammatory environment was 
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created quickly after infection and bacteria were cleared. The presence of Treg cells in this 
environment acted to limit pro inflammatory responses to prevent tissue damage and 
maintain the integrity of the lungs and prevent bacteria getting into the bloodstream275. 
Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is expressed in 3 
different isoforms TGF-β 1-3206. TGF-β is secreted by many different cell types has many 
roles including a role in regulating proliferation, differentiation, adhesion and migration207. 
TGF-β molecules are proposed to act as cellular switches that regulate processes such as 
immune function. Many cell types have TGF-β receptors and as such can be either 
positively or negatively regulated by TGF-β207. TGF-β exists in an inactive or latent form and 
must be activated to be able to exert its suppressive effect205. The TGF-β molecules are 
secreted as part of an inactive complex in its latent form. Latent TGF-β is complexed with 
an N-terminal latency-associated peptide (LAP) and a mature TGF-β monomer at the C 
terminal205. This complex is known as the large latent complex (LLC) which is then secreted 
out of the cell into the extracellular matrix209. 
The LLC will then remain in the extracellular matrix in an inactive state and requires further 
processing to release the active TGF-β product210. The presence of TGF-β in an inactive 
complex allow for the closer regulation of TGF-β signalling, as many cells express TGF-β 
receptors, but it is not always beneficial for TGF-β to be exerting an effect. TGF-β present in 
its latent state allows it to quickly be cleaved to its active state under the right conditions. 
The ubiquitous expression of TGF-β and its receptor suggest that its regulation must be 
complex and multifactorial but one of the most important mechanisms of preventing the 
effect of TGF-β is by stopping the cleavage of the LLC to release active TGF-β. 
TGF-β synthesis is widespread as is expression of its receptors, but its activity is limited to 
areas where it is released from its latent state into its active state. 
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Foxp3+ Treg cells are important for the regulation of effector T cell responses which, if 
allowed to go unchecked, could cause severe host inflammation with damage to cells and 
tissues228. TGF-β is secreted by many different cell types including T cells macrophages and 
dendritic cells228. Its key functions include regulation of inflammatory cell responses and T 
cell regulation and differentiation. TGF-β has been shown to play a role in differentiation of 
both regulatory T cells and effector Th17 cells so is able to influence both regulatory 
responses as well as effector pro-inflammatory responses228.  
My results show that when freshly isolated tonsillar MNC are stimulated using WT 
pneumococcal CCS the concentration of TGF-β is increased compared to a negative control 
with no stimulation (Figure 6.4.1). To determine whether it was Foxp3+ Treg cells that were 
changing the levels of TGF-β, tonsillar MNC both with and without stimulation using WT 
pneumococcal CCS were analysed by intracellular cytokine staining and FACS analysis to see 
how the percentage of Foxp3+ Treg cells changed (Figure 6.4.2).  
My results suggest that TGF-β has a role to play in the activation of Foxp3+ Treg cells and 
that the integrin αvβ8 may be important for the activation of TGF-β from its latent to active 
state. Stimulation of freshly isolated tonsillar MNCs using WT pneumococcal CCS shows a 
significantly higher concentration of TGF-β compared to a negative control. When the cells 
are first pre-incubated with anti-TGF-β the concentration of TGF-β reduces significantly. 
Anti-TGF-β neutralises the effect of TGF-β and this suggests the TGF-β in the cell 
supernatant has a critical role in Foxp3+ Treg cell induction. 
The next stage in the story was looking at possible mechanisms for TGF-β activation as 
when it is secreted from cells it is in its inactive latent state. Before the latent TGF-β can 
exert an effect, it must first be cleaved into its active state. It has been suggested that the 
integrin αvβ8 could have a role to play in the activation of TGF-β. Freshly isolated tonsillar 
MNC were stimulated using pneumococcal WT CCS, both alone and that had been pre-
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incubated with anti- TGF-β and anti-αvβ8. The supernatant was harvested and analysed by 
ELISA to see how the concentration of TGF-β was affected (Figure 6.4.3). Cells that were 
stimulated with WT Pneumococcal CCS alone showed a concentration of (11.82%). When 
cells were pre-incubated with anti- TGF-β or ant avb8 the concentration of TGF-β was 
significantly reduced to 5.65% and 5.82% respectively. Once again, In order to determine 
whether it was Foxp3+ Treg cells that were changing the levels of TGF-β, tonsillar MNC 
both with and without stimulation using WT pneumococcal CCS were analysed by 
intracellular cytokine staining and FACS analysis to see how the percentage of Foxp3+ Treg 
cells changed (Figure 6.4.4). 
Knowing the mechanism through which Foxp3+ Treg cells exert their suppressive effects 
would allow for a more informed therapeutic strategy against pneumococcal infection. The 
nasopharynx has long been established as the site of colonisation of pneumococcus with 
more colonisation events occurring in the early years of life90 when infection can be more 
severe.  
A protective role of regulatory cells in pneumococcal disease and infection has been shown 
in several studies275, 287 as has already been mentioned. The fact that regulatory T cells are 
clearly playing such an important role in pneumococcal disease and carriage just highlights 
how important it is for us to understand the immunology of pneumococcal infection, both 
of effector and regulatory T cells. A clear and complete picture is needed to be able to 
create an effective therapeutic strategy against infection. Vaccination has proven to be an 
effective strategy against pneumococcus and the evolution of pneumococcal vaccines from 
polysaccharide vaccines to conjugate vaccines has shown effective at reducing the 
instances of colonisation an invasive disease29, 178, 187 188, 189. Current pneumococcal vaccines 
can be administered by injection or mucosally but are mainly delivered via injection287. A 
mucosal vaccine which is administered directly into the nose could prove to be an effective 
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way of stimulating both a systemic immune response and a mucosal immune responses 
whereas an injected vaccine stimulates predominantly the systemic immune system and 
therefore less efficient in affect the carriage and clearance if the bacteria from the 
nasopharynx 287.  
The results here all underlines the importance of knowing what regulatory immune 
responses are elicited by pneumococcus and how they are activated. It is clear that Treg 
play an important role during pneumococcal colonisation and disease and understanding 
these cell responses could be important for the future therapeutic strategy against 
pneumococcal colonisation and disease.  
6.6 Summary 
The results presented in this study suggest that the TGF-β has a role to play in the 
activation of Foxp3+ Treg cells. Given that TGF-β is present in its latent, inactive state and 
must be activated to be able to exert its inhibitory effects, we investigated the possible role 
of the integrin αvβ8 in the activation of TGF-β. Results presented here suggest that αvβ8 
could have a role to play in TGF-β activation. Understanding the activation of these cells 
and how they are activated is important for understanding why they are present during 
pneumococcal carriage and what role they have to play during persistence of infection.  
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Chapter 7 
Discussion and conclusion 
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7.1 Discussion 
 Streptococcus pneumoniae (pneumococcus) infection remains a global problem and is a 
major cause of morbidity and mortality worldwide, being responsible for many both 
invasive and non-invasive diseases such as pneumoniae, meningitis and bacteraemia40. 
Pneumococcus is particularly prevalent in developing countries and mainly affects those in 
at risk groups such as the very young, the elderly and those with underlying health 
issues290. Each year pneumococcal diseases cause the deaths of approximately 1 million 
children under 5 years of age25. 
Although pneumococcus can cause serious illness and complications in at risk individuals, 
many people are harmless carriers of the bacteria. The nasopharynx is the natural site of 
pneumococcal colonisation and many individuals can be colonised asymptomatically 
without becoming seriously ill3. These people then become carriers for the spread of the 
bacterium through the community. Young children are very common carriers of the 
bacteria and in some populations as many as 90% of children under 2 are colonised4. The 
diseases caused by pneumococcus occur when the bacteria is able to spread from the 
nasopharynx into other areas of the body, areas which at other times would remain sterile 
such as the lungs, brain or blood4. 
CD4+ T cells have now been established as being an important part of protective immunity 
against pneumococcus, with MHC class-II deficient mice which have a significantly reduced 
number of CD4+ T cells being incredibly susceptible to infection by pneumococcus262. The 
role of pro-inflammatory CD4+ T cells during pneumococcal infection has been studied in 
detail282, 283 but the role of regulatory T cells has not been studied in as much detail and as 
such is an important gap in our knowledge about the immunology associated with 
pneumococcal carriage and disease. 
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It has been hypothesised that mucosal regulatory T cells in NALT may have a role to play in 
mediating pneumococcal carriage in the nasopharynx. In this study, we investigated the 
association of human mucosal regulatory T cells Foxp3+ Treg and Tr1 cells with 
pneumococcal antigens by analysing the numbers of Foxp3+ Treg and Tr1 cells in children 
and adult tonsillar tissue. 
The nasopharynx is the site of colonisation of pneumococcus and colonisation is a common 
event in young children. Colonisation of the nasopharynx by pneumococcus is a pre-
requisite for disease and can occur asymptomatically with no disease being present at all. 
Colonisation is also responsible for the spread of the bacteria through the community. This 
suggest that the reduction of carriage through vaccination could be an effective means of 
preventing pneumococcal disease.  
Both adult and children tonsillar tissue was shown to have significantly more Tr1 and 
Foxp3+ regulatory T cells compared to PBMC samples. (Figure 3.4.1b, Figure 3.4.1c, Figure 
3.4.2b, Figure 3.4.2c) This suggests that the mucosal compartment in the nasopharynx is 
exposed to increased numbers of microbes compared to the peripheral blood which 
experiences very little microbial exposure. The systemic compartment is a usually sterile 
site, whereas the nasopharynx is a site of microbial colonisation, so it is consistent with the 
hypothesis that an increased exposure to microbes in the nasopharynx leads to an increase 
in T regulatory cells.  
We have also shown that the frequency of both Foxp3+ Treg cells in tonsillar MNC and 
PBMC changes with age. Children tonsillar samples were shown to have significantly more 
Tr1 and Foxp3+ regulatory T cell than adult samples. (Figure 3.4.3, Figure 3.4.4). 
Presumably this is due to the tonsils being the site of colonisation and children 
experiencing high numbers of colonisation event compared to adults. It is thought that 
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almost all children are colonised by at least one pneumococcal serotype in their first couple 
of years of life.5    
One of the main age groups targeted by vaccines, including pneumococcal vaccines in those 
under the age of two. The reasons for this are quite clear, babies are born and move from a  
sterile environment and are instantly bombarded by a whole host of new and potentially 
dangerous pathogens, all the while with an immune system that isn’t as developed as it will 
become291. An infant has no antigen experience and as such have to rely on their innate 
immune system to protect them from harmful antien292, 293. Pneumococcal polysaccharide 
vaccines produced a poor immunogenic response in this age group due to the limitations of 
the infant’s immune system, an issue which has been overcome by the development of 
pneumococcal polysaccharide conjugate vaccines172.  As we age and become exposed to 
more pathogens, our immune system develops and strengthens, and we are more able to 
defend ourselves from infection. A memory response is formed which is triggered upon 
encounter with the same antigen, mounting a much quicker and more effective response 
to get rid of the pathogen compared to an antigen that is encountered for the first time51. 
A strong memory T cell presence is seen in young children, which declines with age. Babies 
do not have the ability to launch a successful immune response against pathogens and the 
presence of memory T cells could be a mechanism with which they prevent and regulate 
excessive inflammatory responses294. This could be one of the reasons why vaccine induced 
responses are so poor from infants, the presence of Treg cells dampens down the pro 
inflammatory responses. Treg cells are induced by pathogens to regulate inflammatory 
responses so it makes a lot of sense that a vaccine would also influence these cells as they 
play a large part on immune responses against pathogens. It would be logical to assume 
that the Treg cell responses would be beneficial, preventing an excessive pro inflammatory 
immune response that could cause damage to the host such as tissue damage291. However, 
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studies have shown that the presence of Treg cells can interfere with vaccine induced 
immunity to the extent that the effects of the vaccine hampered which has led to studies in 
which Treg cells are depleted prior to vaccination which leads to a more successful vaccine 
induced immune response295-297.  
There is already research looking at Foxp3+ Treg cell numbers in the nasopharynx and 
peripheral blood but to the best of my knowledge this is the first research to look at Tr1 
cells numbers in tonsillar samples of healthy adults and children and to compare Tr1 cell 
frequencies in 2 separate compartments, the NALT and PBMCs. The pattern of results 
observed is the same as that seen with Foxp3+ Treg cells, with much higher frequencies 
observed in the nasopharynx, where colonisation occurs, compared to the peripheral blood 
which is a sterile site that doesn’t encounter pathogenic stimulation. This could suggest 
that Tr1 cells are also activated or primed by colonisation events by pneumococcus. Tr1 
cells could play a similar role in inhibiting the clearance of the bacteria from the 
nasopharynx and could play a role in the spread of the bacteria through persistence of 
carriage. 
The nasopharynx is the site of colonisation for pneumococcus, where it can be a harmless 
commensal bacterium. However, the colonisation without clearance of the bacteria allow it 
to spread through communities and if it is able to migrate from the nasopharynx into other 
site such as the lungs or blood it can cause severe disease4. Due to the protective effects of 
pneumococcal polysaccharide-based vaccines, antibodies against the capsule have 
traditionally been thought to be the main component of natural immunity against 
pneumococcus298. More recently, CD4+ T cell responses against pneumococcus have 
increasingly become recognised as being an important player in immune responses against 
the bacteria, both in promoting clearance of bacteria by inducing Th17 mediated pro-
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inflammatory responses, but also in carriage of the bacteria through the activation of 
regulatory T cells responses120.  
It has been shown that pneumococcal antigen specific Th17 cells present in mucosal tissue 
increase with age. As we age we are exposed to increasing numbers of colonisation events 
and this could be why the numbers of effector CD4+ T cells increase with age299. The 
colonisation and carriage of pneumococcus is assumed to be regulated by natural immunity 
to pneumococcus which begins to be acquired from very early infancy300. With increased 
exposure events, the build-up of immunity against pneumococcus is thought to be the 
cause of the gradual decrease in pneumococcal carriage and infection which is seen with 
age301, 302.  Despite this, some children experience persistence of carriage and 
understanding how this works is essential to being able to develop better ways of fighting 
pneumococcal disease90. Regulatory cells have come to the forefront in the explanation as 
to why some children still see persistence of carriage despite colonisation events which 
would have provided them with a robust effector T cell response and in theory should 
allow for the clearance of the bacteria. Regulatory T cells are very important for preventing 
an excessive pro inflammatory response. They prevent self-tissue damage, but their 
presence also contributes to the persistence of carriage90. It has been suggested that 
specific pneumococcal components could be responsible for the induction of regulatory T 
cells in the nasopharynx and studies have shown that stimulation of adenoidal cells with 
pneumococcal whole cell antigen does show a significant increase in the numbers of 
regulatory T cells observed and in those samples which are culture positive for 
pneumococcus the increase is significantly higher90. This suggests the local colonisation of 
the nasopharynx with the bacteria causes antigen specific induction of Treg cells.   
Understanding the regulation of naturally-acquired mucosal immunity should help inform 
the design of novel vaccination strategies against pneumococcal colonization and/or 
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infection. Currently available vaccines target specific capsular polysaccharide and their 
efficacy is limited as only a certain number of serotypes are included in the vaccine47. 
Polysaccharide vaccines are also limited by the fact they induce a T cell independent 
antibody response which is ineffective in children under 2 years of age4, 12. This issue was 
overcome by the formation of polysaccharide conjugate vaccines in which the 
polysaccharide is conjugated to a protein, however these vaccines are also limited by the 
serotypes included and are too expensive for routine use in developing countries. These 
reasons clearly explain why there is need to develop a suitable protein vaccine which would 
be effective against all serotypes and this is a key priority in pneumococcal vaccine 
research. There are several pneumococcal proteins that have been identified as potential 
targets for inclusion in a pneumococcal protein vaccine and numerous studies have shown 
their protective efficacy in animal models303-305.  
Pneumolysin is a protein which is highly conserved amongst S. pneumoniae isolates and is 
able to destroy cells by forming pores in cell membranes that contain cholesterol47. Studies 
in experimental mice models have shown that pneumolysin can induce protective 
immunity against pneumococcus200, 202, 203. This PhD project has investigated the role of 
pneumolysin and capsular polysaccharide in the induction of regulatory T cells in human 
tonsillar tissue and blood samples.  
During the last decade, research into Foxp3+ Treg cells has grown, showing that these cells 
play an important role in regulation during infections. However, if a cell response is skewed 
towards regulatory cells, persistence of infection can be seen306. Foxp3+ Treg cells have a 
close and finely balanced relationship with Th17 cells, which are of an effector phenotype 
and act to clear infection. This relationship is tightly controlled, with an imbalance playing a 
role in several diseases88, 307, 308. It is also interesting to note that the differentiation of both 
cells types involves a key role for TGF-β309. 
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Recent studies have reported that the numbers of Foxp3+ Treg cells in adenotonsillar tissue 
varies depending on the presence or absence of pneumococci, which indicates that 
carriage has an effect on this cell type90, 121. In people who have asthma, a reduced number 
of Treg cells are observed, with those that are present having a reduced functional 
capacity310, 311. Treg cells act to regulate inflammation and as such their presence could be 
an effective therapy for fighting diseases such as asthma. With this in mind studies have 
been undertaken which have attempted to harness the regulatory capacity of Treg cells in 
order to control asthma312. Mouse models using live or killed pneumococcus or 
pneumococcal vaccines have been used and have been shown to reduce the hallmarks of 
allergic airways disease suggesting certain pneumococcal components may be important 
for inducing regulatory T cells313-315. A combination of Type 3 polysaccharide and a 
pneumolysin toxoid which were co administered in a mouse model at various intervals 
showed a significant decrease in the hallmark AAD characteristics and were able to induce 
Treg cells in significantly higher levels compared to controls and compared to when each 
was administered separately316. Using this information, I designed my own investigation 
looking at the effects of pneumococcal polysaccharide and a toxoid of pneumolysin (in this 
case, W433F). I used the polysaccharide and pneumolysin toxoid together or separately. 
Interestingly, in my studies I did not see an increased activation of Foxp3+ Treg cells when 
polysaccharide plus pneumolysin toxoid were used to stimulate cells together. However, 
each individual component used showed a significant increase in Foxp3+ Treg cell numbers 
compared to an unstimulated control.  
Chapter 4 investigated the relationship between Foxp3+ Treg cells and pneumococcus by 
stimulated tonsillar MNC with pneumococcal CCS, purified capsular polysaccharide and 
pneumolysin toxoid, W433F. It was observed that pneumococcal capsular polysaccharide 
and pneumolysin are able to stimulate an increase in Foxp3+ Treg in adenotonsillar tissue 
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(Figure 4.4.5). There is limited data about the role of regulatory T cells and their 
relationship with pneumococcus during colonisation of the nasopharynx. Data relating to 
human samples is particularly limited. A previous study showed the pneumococcal whole 
cell antigen (WCA) was able to induce Foxp3+ Treg cell proliferation in tonsillar MNCs which 
suggests there are pneumococcal protein/s which could have a role to play in the induction 
of these cells.90 Currently, it remains unclear which pneumococcal proteins may have a role 
in the activation or induction of regulatory T cells in in human nasopharynx-associated 
tissue (NALT). The identification of such protein/s would be useful information to further 
our understanding on the role of Treg in pneumococcal carriage and on novel vaccination 
strategies against pneumococcal disease.  
Pneumococcal vaccine research has become more focussed on identifying pneumococcal 
proteins which could be included in a vaccine that would then be effective against all 
known serotypes240, 264, 265. Pneumococcal proteins including pneumolysin and choline 
binding protein A have been studied to see if they could be used in a vaccine198.  
In this study we investigated the importance of pneumolysin and capsular polysaccharide in 
the activation of Foxp3+ Treg cells. I initially stimulated tonsillar MNC with pneumococcal 
CCS with and without pneumolysin and capsule to determine their importance in Foxp3+ 
Treg cell activation. Stimulation using D39 WT strain of pneumococcal CCS showed 
significantly higher activation of Foxp3+ Treg cells (Figure 4.4.4) compared to both mutant 
strains used. The first mutant strain was pneumolysin (Ply) deficient (Ply -/-) and the second 
was capsule deficient (Cap -/-). These initial results suggested that both pneumolysin and 
capsular polysaccharide could be important for the activation of Foxp3+ Treg cells.  
After the initial findings using pneumococcal CCS I wanted to look at whether purified 
capsular polysaccharide and the toxoid of pneumolysin, W433F, could activate Foxp3+ Treg 
cells compared to a negative control. My results show that W433F and purified capsular 
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polysaccharide are able to activate pre-existing Foxp3+ Treg cells to significantly higher 
levels compared to an unstimulated control. Two different types of capsular polysaccharide 
were used, T3P and 6B and both were shown to activate Foxp3+ Treg cells compared to the 
negative control. Capsular polysaccharide is currently used in pneumococcal vaccines and 
we know it is effective at preventing pneumococcal disease. In my results, pneumolysin has 
been shown to be effective at activating Foxp3+ Treg cells.  As it is expressed by most if not 
all clinical isolates of pneumococcus, the inclusion of pneumolysin in a vaccine would 
potentially confer protection against most serotypes whilst remaining relatively cheap to 
produce.  
The pre-existing Foxp3+ Treg cells detected in tonsillar tissue are likely to be those which 
are primed due to previous pneumococcal colonisation events in the nasopharynx. The 
ability of both W433F and both capsular polysaccharides used to activate these cells 
suggests that both the polysaccharide capsule and pneumolysin can activate these cells and 
therefore play a role in the carriage of pneumococcus in the nasopharynx.  
Tr1 cells have been shown to have a role to play in the regulation of various mucosal sites 
including the gut317. These cells are distinct from Foxp3+ Treg cells, lacking expression of 
the key transcription factors, Foxp3,  and are suppressive through the production of IL10 
and TGF-β106. Tr1 cells are differentiated in the periphery and are activated in an antigen 
specific manner where they are able to regulate both naïve and memory T cell responses105, 
106. Tr1 cells require activation through their T cell receptor to exert their suppressive 
effects and this happens in an antigen specific manner105, 277. Once activated however, they 
exert their effects in a non-specific way277. 
Mouse models have suggested that cellular therapy with Tr1 cells is feasible318. Translating 
the success of mouse models into a successful human therapy has its challenges but 
evidence is increasing that Tr1 cells could be a feasible immunomodulatory therapy for a 
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variety of human diseases277, 318. Tr1 cells have been shown to be able to suppress antigen 
specific CD4+ T cell proliferation. It was also shown that Tr1 cell clones transferred into 
SCID mice could prevent experimentally induced colitis105, 155. IL10 is able to act to directly 
inhibit cytokines that would induce antigen specific CD4+ T cells as well as being able to 
inhibit antigen presenting cells, both of which reduce inflammation319. 
A recent a phase I/IIa clinical trial has been performed in which Tr1 cells have been 
assessed for their impact on Crohn’s Disease320. Ovalbumin specific Tr1 cells have been 
shown to reduce in vivo inflammatory responses in animal models to prevent and control 
colitis105, 321. The phase I/IIa clinical trial was performed to assess the efficacy and safety of 
ovalbumin Tr1 cell injections in Crohn’s disease patients and showed that the Crohn’s 
disease activity index of patents injected was significantly reduced320.  
Clearly Tr1 cell research has become much more intensive recently and understanding how 
this cell type is involved in numerous diseases and auto immune disorders is important to 
be able to successfully create effective therapies. The role of Tr1 cells in pneumococcal 
disease hasn’t been investigated but the fact Foxp3+ Treg cells have such an important role 
to play could mean other regulatory T cells are also involved. Tr1 cells could have a role to 
play in the carriage of pneumococcus and the persistence of infection. 
Chapter 5 investigated the relationship between pneumococcus and Tr1 cells in human 
tonsillar tissue. We investigated the importance of pneumolysin and capsular 
polysaccharide in the activation and induction of Tr1 cells. To determine whether capsular 
polysaccharide and pneumolysin had a role to play in Tr1 cell activation, I initially 
stimulated human tonsillar MNC with pneumococcal CCS. Stimulation using D39 WT strain 
of pneumococcal CCS showed significantly higher activation of Tr1 cells (Figure 5.4.3) 
compared to both mutant strains used. The first mutant strain was pneumolysin (Ply) 
deficient (Ply -/-) and the second was capsule deficient (Cap -/-). These initial results 
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suggested that both pneumolysin and capsular polysaccharide could be important for the 
activation of Tr1 cells.  
After the initial findings using pneumococcal CCS I wanted to look at whether purified 
capsular polysaccharide and the toxoid of pneumolysin, W433F, could activate Tr1 cells 
compared to a negative control. Figure 5.4.4 shows that the pneumolysin toxoid W433F 
and both capsular polysaccharides used (T3P and 6B) were able to elicit a significant 
increase in Tr1 cell numbers compared to an unstimulated negative control. The 
combination of W433F and T3P or W433F and 6B didn’t show any more significant 
activation than each component alone which is interesting as it seems to suggest they do 
the same thing without having an additive effect. It had previously been shown in a mouse 
model that the combination of T3P and Ply did confer an increased protective effect when 
compared to either the T3P or Ply alone127. 
This research looking at Tr1 cells responses to pneumococcal components is novel. There is 
already lots of research looking at Foxp3+ Treg cells responses but it is interesting to see 
that another category of regulatory T cells are reacting in much the same way. The 
stimulation using pneumolysin and capsular polysaccharide increased the numbers of Tr1 
cells significantly which indicate their importance for Tr1 cell activation. The presence of 
pre-existing Tr1 cells could be due to previous colonisation events by the pneumococcus in 
the nasopharynx. This would explain why stimulation saw the numbers of these cells 
increasing as fresh stimulation would activate cells that had previously encountered the 
stimuli. 
To determine if Tr1 cells could be induced, we depleted samples of CD45RO+ cells. As with 
the activation experiments, initially cells were stimulated using pneumococcal CCS (Figure 
5.4.5) to see whether any differences were observed in induction with and without 
pneumolysin and capsular polysaccharide. We did in fact once again see that when Ply-/- 
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and Cap-/- CCS were used, the induction of Tr1 cells was significantly less than that when 
cells were stimulated using D39 WT pneumococcal CCS. This once again suggested 
pneumolysin and capsular polysaccharide are important players in Tr1 cell responses. So, I 
then moved on to stimulation with purified pneumolysin toxoid (W433F) and purified 
capsular polysaccharide (T3P and 6B). (Figure 5.4.6) W433F stimulation alone showed 
significantly more Tr1 cells induction compared to the negative control. T3P and 6B 
stimulation alone also showed significantly more Tr1 cells induction compared to the 
negative control. And again, the combination of W433F with either of the two 
polysaccharides did not have an increased induction and was no different from to either 
components alone.  
These results mirror those seen using pneumolysin and capsular polysaccharide for the 
activation of Foxp3+ Treg cells suggesting that several categories of regulatory cells are 
affected by pneumococcus. In this study, 2 different types of purified capsular 
polysaccharide were used to stimulate cells, T3P and 6B, and both were able to activate 
pre-existing Tr1 cells and induce Tr1 cells from naïve T cells. Pneumolysin was also able to 
both activate and induce Tr1 cells to much the same level as the capsular polysaccharide 
used. These results suggest Tr1 cells could have a role to play in the carriage of 
pneumococcus. 
The pre-existing Foxp3+ Treg and Tr1 cells detected in tonsillar tissue are likely to be those 
which are primed due to previous pneumococcal colonisation events in the nasopharynx. 
The ability of both W433F and both capsular polysaccharides used to activate these cells 
suggests that both the polysaccharide capsule and pneumolysin are able to activate these 
cells and therefore play a role in the carriage of pneumococcus in the nasopharynx.  
The ability of pneumolysin to activating pre-existing Foxp3+ Treg and Tr1 cells suggests that 
this pneumococcal protein does specifically influence the immune response generated in 
response to pneumococcal exposure. Understanding the precise mechanism of these 
168 
 
interactions and its effects on other immune cells is key to further research, which aims to 
include this protein in any future vaccines.  
In addition to this, my research has focussed on the interactions between pneumococcus 
and regulatory cells in the nasopharynx. Given that the nasopharynx is the site of 
pneumococcal colonisation, that prolonged carriage of the bacteria leads to spread 
throughout the community and that disease cannot occur without colonisation, the 
nasopharynx could be a potential target for a future vaccine that directly works at the 
mucosal site rather than through the blood. Again, it is important to understand the 
balances and intricacies of how any potential vaccine would work and how it would affect 
the hosts’ natural response, but this is certainly an interesting and potentially rewarding 
area of research which could have very fruitful results in the future. 
The overall findings in this study support the hypothesis that both pneumococcal 
polysaccharide and pneumolysin have an important role in the activation of Foxp3+ Treg 
and Tr1 cells in the nasopharynx. They suggest that in the mucosal tissue of the 
nasopharynx pneumolysin and capsular polysaccharide can promote regulatory T cells 
which contribute to the persistence of carriage and the delay in pneumococcal clearance.  
TGF-β is thought to be important in the conversion of naïve CD4+ T cells into Foxp3+ Treg 
cells which can then proliferate and lead to suppression of the immune system284, 285. A 
study by Liao et al, showed that SPY1, a live attenuated vaccine against pneumococcus, is 
able to induce protective Treg cells286 which are vital for the maintenance of homeostasis 
of the immune system and prevent infection associated inflammation287. In addition to this 
they showed that the addition of a peptide, P17286, 288,  which inhibits TGF-β and therefore 
reduces the numbers of Foxp3+ Treg cells, impairs the effectiveness of SPY1 which suggests 
the ability of SPY1 to activate TGF-β and activate Treg cells is important for producing 
protective Treg immune responses in the nasopharynx287. This suggests TGF-β has an 
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important role to play in the activation of Foxp3+ Treg cells and the carriage of 
pneumococcus in the nasopharynx. This protective role of regulatory T cells has also been 
shown in a mouse study by Neill et al275. This study showed that regulatory T cells have an 
important role to play in the prevention of immune mediated damage in the lungs of 
infected mice and that TGF-β has an important role to play in this275. They used 2 mice 
models which react very differently to pneumococcal infection289 and infected the lungs 
with pneumococcus. CBA/Ca mice which have fewer T regulatory cells and therefore less 
TGF-β showed insufficient immunosuppression and the bacteria was able to disseminate 
into the bloodstream before they could be cleared. In contrast, in BALB/c mice, a controlled 
and regulated pro-inflammatory environment was created quickly after infection and 
bacteria were cleared. The presence of Treg cells in this environment acted to limit pro 
inflammatory responses to prevent tissue damage and maintain the integrity of the lungs 
and prevent bacteria getting into the bloodstream275. 
 It has been suggested that TGF-β has a role to play in the activation of Foxp3+ Treg cells 
and in this study, we investigated the possible role of integrin, avb8 on the activation of 
TGF-β and the effect of this on the activation of Foxp3+ Treg cells.  
Initially, tonsillar MNC were stimulated with WT pneumococcal CCS before the supernatant 
was analysed for the presence of TGF-β and cells were stained by intracellular cytokine 
staining to detect the presence of Foxp3+ Treg cells. My results show that when freshly 
isolated tonsillar MNC are stimulated using WT pneumococcal CCS the concentration of 
TGF-β is increased compared to a negative control with no stimulation (Figure 6.4.1). FACS 
analysis of the cells showed that the percentage of Foxp3+ Treg cells increased when cells 
were stimulated with WT pneumococcal CCS compared to an unstimulated sample, which 
correlates with the increase in TGF-β concentration seen.  
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Tonsillar MNC stimulated with WT pneumococcal CCS after pre-incubation with anti-avb8 
and anti-TGF beta both showed decreased levels of TGF-β when compared to cells 
stimulated with WT pneumococcal CCS alone. FACS analysis also revealed that the cells 
stimulated after pre-incubation with anti-TGF-β and anti-αvβ8 showed a reduction in the 
percentage of Foxp3+ Treg cells present compared to cells stimulated using WT 
pneumococcal CCS alone. These combined results seem to suggest a cascade of activation 
for Foxp3+ Treg cells, with αvβ8 being important for the activation of TGF-β which in turn is 
needed for the activation of Foxp3+ Treg cells. 
Knowing the mechanism through which Foxp3+ Treg cells exert their suppressive effects 
would allow for a more informed therapeutic strategy against pneumococcal infection. The 
nasopharynx has long been established as the site of colonisation of pneumococcus with 
more colonisation events occurring in the early years of life90 when infection can be more 
severe.  
A protective role of regulatory cells in pneumococcal disease and infection has been shown 
in several studies275, 287 as has already been mentioned. The fact that regulatory T cells are 
clearly playing such an important role in pneumococcal disease and carriage just highlights 
how important it is for us to understand the immunology of pneumococcal infection, both 
of effector and regulatory T cells. A clear and complete picture is needed to be able to 
create an effective therapeutic strategy against infection. Vaccination has proven to be an 
effective strategy against pneumococcus and the evolution of pneumococcal vaccines from 
polysaccharide vaccines to conjugate vaccines has shown effective at reducing the 
instances of colonisation an invasive disease29, 178, 187 188, 189. Current pneumococcal vaccines 
can be administered by injection or mucosally but are mainly delivered via injection287. A 
mucosal vaccine which is administered directly into the nose could prove to be an effective 
way of stimulating both a systemic immune response and a mucosal immune responses 
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whereas an injected vaccine only stimulates the systemic immune system and therefore 
doesn’t offer an effective way affecting the carriage and clearance of the bacteria from the 
nasopharynx 287.  
The results here all underlines the importance of knowing what regulatory immune 
responses are elicited by pneumococcus and how they are activated. It is clear they are 
playing a role during pneumococcal colonisation and disease and understanding these cell 
responses could be important for the future therapeutic strategy against pneumococcal 
colonisation and disease.  
7.2 Conclusion 
Results presented in this study show that there are significant numbers of both Foxp3 
regulatory and Tr1 cells in human tonsillar tissue which could have an important role in 
mediating the carriage of pneumococcus and as such be an important target for vaccines to 
prevent carriage. It was also shown that the numbers of Foxp3+ Treg and Tr1cells are 
significantly higher in children tonsil samples compared to adult tonsil samples.  Children 
are known to have multiple colonisation event throughout their early years, a phenomenon 
that decreases with age. This study suggests a relationship between the age of the patients 
and the number of regulatory T cells in the nasopharynx where one influences the other. 
The decrease in colonisation seen with age could be either due to the reduced number of 
regulatory cells in the nasopharynx the numbers of regulatory cells in the nasopharynx are 
reduced due to a reduce number of colonisation events.  
The stimulation of human tonsillar MNC with pneumococcus showed a significant increase 
in both Foxp3 regulatory and Tr1 cells, which suggests antigen specific Treg cells may be 
present in the nasopharynx, presumably because of previous colonisation events. Results 
presented in this study show that pneumolysin and capsular polysaccharide may contribute 
to the activation of Foxp3+ Treg cells and to the activation and induction of Tr1 cells in 
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human NALT and have a role to play in the modulation of carriage of the bacteria It has also 
been shown that TGF-β has a role to play in the activation of Foxp3+ Treg cells and that the 
activation of the TGF-β is affected  by the presence of the integrin, αvβ8. Adenotonsillar 
MNC stimulated by WT pneumococcal CCS in the presence of anti- TGF-β and anti- αvβ8 
show a significantly lower concentration of TGF-β and a significantly lower percentage of 
Foxp3+ Treg cells.   
In conclusion, these findings add information to our understanding of how pneumolysin 
and capsular polysaccharide mediate the activation of regulatory T cells, information that 
could be used in the development of future vaccines against pneumococcal disease. 
Understanding the complete immune response against pneumococcus and how the 
immune response reacts to stimulation using pneumococcal antigens could have 
implications in future vaccination strategies against pneumococcus. A vaccine that is 
directly applied to the nasopharynx could be effective at regulating carriage of the bacteria 
and thus preventing its spread through the community.  
 
 
 
 
 
 
 
 
 
 
 
173 
 
References 
1. Gagliani N, Magnani CF, Huber S, Gianolini ME, et al. Coexpression of CD49b and 
LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 
2013;19(6):739-46. 
2. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, et al. Burden of disease caused by 
Streptococcus pneumoniae in children younger than 5 years: global estimates. 
Lancet 2009;374(9693):893-902. 
3. Brooks GFC, K.C. 'The Streptococci'. 24th ed. Blacklick, OH, USA: McGraw-Hill 
Medical Publishing Division, 2007:233-248.  
4. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the 
key to pneumococcal disease. Lancet Infect Dis 2004;4(3):144-54. 
5. Kayhty H, Auranen K, Nohynek H, Dagan R, et al. Nasopharyngeal colonization: a 
target for pneumococcal vaccination. Expert Rev Vaccines 2006;5(5):651-67. 
6. Esposito S, Terranova L, Patria MF, Marseglia GL, et al. Streptococcus pneumoniae 
colonisation in children and adolescents with asthma: impact of the heptavalent 
pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-
valent pneumococcal conjugate vaccine. BMC Infectious Diseases 2016;16:12. 
7. Rodrigues F, Danon L, Morales-Aza B, Sikora P, et al. Pneumococcal Serotypes 
Colonise the Nasopharynx in Children at Different Densities. PLoS ONE 
2016;11(9):e0163435. 
8. Wilson R, Cohen JM, Reglinski M, Jose RJ, et al. Naturally Acquired Human 
Immunity to Pneumococcus Is Dependent on Antibody to Protein Antigens. PLoS 
Pathog 2017;13(1):e1006137. 
9. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus 
pneumoniae virulence factors in host respiratory colonization and disease. Nature 
Reviews Microbiology 2008;6(4):288-301. 
10. Mac LC, Hodges RG. Prevention of pneumococcal pneumonia by immunization with 
specific capsular polysaccharides. J Exp Med 1945;82:445-65. 
11. Lee CJ, Banks SD, Li JP. Virulence, immunity, and vaccine related to Streptococcus 
pneumoniae. Crit Rev Microbiol 1991;18(2):89-114. 
12. Bogaert D, Hermans PW, Adrian PV, Rumke HC, et al. Pneumococcal vaccines: an 
update on current strategies. Vaccine 2004;22(17-18):2209-20. 
13. Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: 
does serotype replacement matter? Lancet 2000;356(9237):1210-1. 
14. Pichichero ME, Khan MN, Xu Q. Next generation protein based Streptococcus 
pneumoniae vaccines. Human Vaccines & Immunotherapeutics 2016;12(1):194-
205. 
15. Principi N, Esposito S. Development of pneumococcal vaccines over the last 10 
years. Expert Opinion on Biological Therapy 2018;18(1):7-17. 
16. Brooks GFaC, K.C. 'The Streptococci'. 24th ed. Blacklick, OH, USA: McGraw-Hill 
Medical Publishing Division, 2007:233-248. (Jawetz, Melnickand Adelberg's medical 
microbiology).  
17. Vasanthakumari R. Textbook of Microbiology. New Delhi: BI Publications Pvt 
Limited, 2007.  
18. Martín-Galiano AJ, Balsalobre L, Fenoll A, de la Campa AG. Genetic Characterization 
of Optochin-Susceptible Viridans Group Streptococci. Antimicrobial Agents and 
Chemotherapy 2003;47(10):3187-94. 
174 
 
19. Mitchell AM, Mitchell TJ. Streptococcus pneumoniae: virulence factors and 
variation. Clin Microbiol Infect 2010;16(5):411-8. 
20. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin 
Microbiol 1995;33(10):2759-62. 
21. Calix JJ, Nahm MH. A new pneumococcal serotype, 11E, has a variably inactivated 
wcjE gene. J Infect Dis 2010;202(1):29-38. 
22. Silhavy TJ, Kahne D, Walker S. The Bacterial Cell Envelope. Cold Spring Harbor 
Perspectives in Biology 2010;2(5):a000414. 
23. Brown S, Santa Maria JP, Walker S. Wall Teichoic Acids of Gram-Positive Bacteria. 
Annual review of microbiology 2013;67:10.1146/annurev-micro-092412-155620. 
24. Gray BM, Converse GM, 3rd, Dillon HC, Jr. Epidemiologic studies of Streptococcus 
pneumoniae in infants: acquisition, carriage, and infection during the first 24 
months of life. J Infect Dis 1980;142(6):923-33. 
25. Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. 
J Med Microbiol 2002;51(2):98-104. 
26. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, et al. Study of community 
acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications 
for management guidelines. Thorax 2001;56(4):296-301. 
27. Kalin M. Pneumococcal serotypes and their clinical relevance. Thorax 
1998;53(3):159-62. 
28. Richter SS, Heilmann KP, Dohrn CL, Riahi F, et al. Pneumococcal serotypes before 
and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg 
Infect Dis 2013;19(7):1074-83. 
29. Whitney CG, Farley MM, Hadler J, Harrison LH, et al. Decline in invasive 
pneumococcal disease after the introduction of protein-polysaccharide conjugate 
vaccine. N Engl J Med 2003;348(18):1737-46. 
30. Moore MR, Gertz RE, Jr., Woodbury RL, Barkocy-Gallagher GA, et al. Population 
snapshot of emergent Streptococcus pneumoniae serotype 19A in the United 
States, 2005. J Infect Dis 2008;197(7):1016-27. 
31. Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, 
serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin 
Microbiol Infect 2010;16(5):402-10. 
32. Kyaw MH, Lynfield R, Schaffner W, Craig AS, et al. Effect of introduction of the 
pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N 
Engl J Med 2006;354(14):1455-63. 
33. Pilishvili T, Lexau C, Farley MM, Hadler J, et al. Sustained reductions in invasive 
pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-
41. 
34. Ardanuy C, Rolo D, Fenoll A, Tarrago D, et al. Emergence of a multidrug-resistant 
clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob 
Chemother 2009;64(3):507-10. 
35. Baik I, Curhan GC, Rimm EB, Bendich A, et al. A prospective study of age and 
lifestyle factors in relation to community-acquired pneumonia in US men and 
women. Arch Intern Med 2000;160(20):3082-8. 
36. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of 
pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, 
and/or chronic heart disease on community-acquired pneumonia and invasive 
pneumococcal disease. Thorax 2015;70(10):984-9. 
37. Goss CH, Rubenfeld GD, Park DR, Sherbin VL, et al. Cost and incidence of social 
comorbidities in low-risk patients with community-acquired pneumonia admitted 
to a public hospital. Chest 2003;124(6):2148-55. 
175 
 
38. Read R, Hart CA, Cant AJ, Gordon S, et al. Respiratory infections: Proceedings of the 
Eighth Liverpool Tropical School Bayer Symposium of Microbial Disease held on 3 
February 2001, 2002.  
39. Hyams C, Camberlein E, Cohen JM, Bax K, et al. The Streptococcus pneumoniae 
capsule inhibits complement activity and neutrophil phagocytosis by multiple 
mechanisms. Infect Immun 2010;78(2):704-15. 
40. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, 
microbiology, and pathogenesis. Cold Spring Harb Perspect Med 2013;3(7). 
41. Nelson AL, Roche AM, Gould JM, Chim K, et al. Capsule enhances pneumococcal 
colonization by limiting mucus-mediated clearance. Infect Immun 2007;75(1):83-
90. 
42. Perez-Dorado I, Galan-Bartual S, Hermoso JA. Pneumococcal surface proteins: 
when the whole is greater than the sum of its parts. Mol Oral Microbiol 
2012;27(4):221-45. 
43. Gosink KK, Mann ER, Guglielmo C, Tuomanen EI, et al. Role of novel choline binding 
proteins in virulence of Streptococcus pneumoniae. Infect Immun 
2000;68(10):5690-5. 
44. Frolet C, Beniazza M, Roux L, Gallet B, et al. New adhesin functions of surface-
exposed pneumococcal proteins. BMC Microbiol 2010;10:190. 
45. Bergmann S, Hammerschmidt S. Versatility of pneumococcal surface proteins. 
Microbiology 2006;152(Pt 2):295-303. 
46. Lofling J, Vimberg V, Battig P, Henriques-Normark B. Cellular interactions by LPxTG-
anchored pneumococcal adhesins and their streptococcal homologues. Cell 
Microbiol 2011;13(2):186-97. 
47. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus 
pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev 
Microbiol 2008;6(4):288-301. 
48. Wolf AI, Strauman MC, Mozdzanowska K, Williams KL, et al. Pneumolysin 
Expression by Streptococcus pneumoniae Protects Colonized Mice from Influenza 
Virus-induced Disease. Virology 2014;0:254-65. 
49. Paterson GK, Mitchell TJ. Innate immunity and the pneumococcus. Microbiology 
2006;152(Pt 2):285-93. 
50. Schmalstieg F, Goldman A. Jules Bordet (1870-1961): a bridge between early and 
modern immunology, 2009.  
51. Janeway CA Jr TP, Walport M, et al. Immunobiology: The Immune System in Health 
and Disease. 5th edition ed. New York: Garland Science, 2001.  
52. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive 
immune responses. Cell Res 2010;20(1):34-50. 
53. Paterson GK, Orihuela CJ. Pneumococci: immunology of the innate host response. 
Respirology 2010;15(7):1057-63. 
54. Noris M, Remuzzi G. Overview of Complement Activation and Regulation. Seminars 
in Nephrology 2013;33(6):479-92. 
55. Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol 
2002;20:197-216. 
56. Knapp S, Wieland CW, van 't Veer C, Takeuchi O, et al. Toll-like receptor 2 plays a 
role in the early inflammatory response to murine pneumococcal pneumonia but 
does not contribute to antibacterial defense. J Immunol 2004;172(5):3132-8. 
57. Koppe U, Suttorp N, Opitz B. Recognition of Streptococcus pneumoniae by the 
innate immune system. Cell Microbiol 2012;14(4):460-6. 
58. Zhu J, Yamane H, Paul WE. Differentiation of Effector CD4 T Cell Populations. 
Annual review of immunology 2010;28:445-89. 
176 
 
59. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4(+)T cells: differentiation and 
functions. Clin Dev Immunol 2012;2012:925135. 
60. Jäger A, Kuchroo VK. Effector and regulatory T cell subsets in autoimmunity and 
tissue inflammation. Scandinavian journal of immunology 2010;72(3):173-84. 
61. Jonuleit H, Schmitt E. The Regulatory T Cell Family: Distinct Subsets and their 
Interrelations. The Journal of Immunology 2003;171(12):6323-7. 
62. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine 
secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73. 
63. Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens. 
Virulence 2010;1(5):423-7. 
64. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce 
the production of IL-17 in Th cells. J Immunol 2000;165(11):6107-15. 
65. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008;112(5):1557-69. 
66. Navegantes KC, de Souza Gomes R, Pereira PAT, Czaikoski PG, et al. Immune 
modulation of some autoimmune diseases: the critical role of macrophages and 
neutrophils in the innate and adaptive immunity. Journal of Translational Medicine 
2017;15:36. 
67. Deo SS, Mistry KJ, Kakade AM, Niphadkar PV. Role played by Th2 type cytokines in 
IgE mediated allergy and asthma. Lung India : Official Organ of Indian Chest Society 
2010;27(2):66-71. 
68. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunological 
Reviews 2008;223:87-113. 
69. Mantegazza AR, Magalhaes JG, Amigorena S, Marks MS. Presentation of 
phagocytosed antigens by MHC class I and II. Traffic (Copenhagen, Denmark) 
2013;14(2):135-52. 
70. Chaplin DD. Overview of the Immune Response. The Journal of allergy and clinical 
immunology 2010;125(2 Suppl 2):S3-23. 
71. Pennock ND, White JT, Cross EW, Cheney EE, et al. T cell responses: naïve to 
memory and everything in between. Advances in Physiology Education 
2013;37(4):273-83. 
72. Smith-Garvin JE, Koretzky GA, Jordan MS. T Cell Activation. Annual review of 
immunology 2009;27:591-619. 
73. Bretscher PA. A two-step, two-signal model for the primary activation of precursor 
helper T cells. Proceedings of the National Academy of Sciences of the United States 
of America 1999;96(1):185-90. 
74. Budd RC, Fortner KA. Chapter 12 - T Lymphocytes. In: Firestein GS, Budd RC, Gabriel 
SE, McInnes IB, O'Dell JR, eds. Kelley and Firestein's Textbook of Rheumatology 
(Tenth Edition). Elsevier, 2017:189-206. 
http://www.sciencedirect.com/science/article/pii/B9780323316965000127. 
75. Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to 
immunoregulation and back again. EMBO Reports 2007;8(12):1142-8. 
76. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: 
how does the immune system decide to mount a helper T-cell response? 
Immunology 2008;123(3):326-38. 
77. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and 
Implications of Their Inhibition. American Journal of Clinical Oncology 
2016;39(1):98-106. 
78. Vandenborre K, Van Gool SW, Kasran A, Ceuppens JL, et al. Interaction of CTLA-4 
(CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 
1999;98(3):413-21. 
177 
 
79. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: Adversaries and 
collaborators. Annals of the New York Academy of Sciences 2010;1183:211-21. 
80. Gagliani N, Huber S. Basic Aspects of T Helper Cell Differentiation. Methods Mol 
Biol 2017;1514:19-30. 
81. Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive 
CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl 
Acad Sci U S A 2003;100(25):15047-52. 
82. Walker JA, McKenzie ANJ. TH2 cell development and function. Nat Rev Immunol 
2018;18(2):121-33. 
83. Chang SH, Dong C. IL-17F: regulation, signaling and function in inflammation. 
Cytokine 2009;46(1):7-11. 
84. Kabir S. The role of interleukin-17 in the Helicobacter pylori induced infection and 
immunity. Helicobacter 2011;16(1):1-8. 
85. Zhang Q, Bagrade L, Bernatoniene J. Low CD4 T cell immunity to pneumolysin is 
associated with nasopharyngeal carriage of pneumococci in children (vol 195, pg 
1194, 2007). Journal of Infectious Diseases 2008;197(9). 
86. Lu YJ, Gross J, Bogaert D, Finn A, et al. Interleukin-17A mediates acquired immunity 
to pneumococcal colonization. PLoS Pathog 2008;4(9):e1000159. 
87. Guglani L, Khader SA. Th17 cytokines in mucosal immunity and inflammation. 
Current opinion in HIV and AIDS 2010;5(2):120-7. 
88. Sehrawat S, Rouse BT. Interplay of Regulatory T Cell and Th17 Cells during 
Infectious Diseases in Humans and Animals. Frontiers in Immunology 2017;8(341). 
89. Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent 
clearance of pneumococcal colonization in mice. Journal of Clinical Investigation 
2009;119(7):1899-909. 
90. Zhang Q, Leong SC, McNamara PS, Mubarak A, et al. Characterisation of regulatory 
T cells in nasal associated lymphoid tissue in children: relationships with 
pneumococcal colonization. PLoS Pathog 2011;7(8):e1002175. 
91. Mureithi MW, Finn A, Ota MO, Zhang Q, et al. T cell memory response to 
pneumococcal protein antigens in an area of high pneumococcal carriage and 
disease. J Infect Dis 2009;200(5):783-93. 
92. Lim H, Hillsamer P, H. Kim C. Regulatory T cells can migrate to follicles upon T cell 
activation and suppress GC-Th cells and GC-Th cell-driven B cell responses, 2004.  
93. Gol-Ara M, Jadidi-Niaragh F, Sadria R, Azizi G, et al. The Role of Different Subsets of 
Regulatory T Cells in Immunopathogenesis of Rheumatoid Arthritis. Arthritis 
2012;2012:805875. 
94. Vadas MA, Miller JF, McKenzie IF, Chism SE, et al. Ly and Ia antigen phenotypes of T 
cells involved in delayed-type hypersensitivity and in suppression. J Exp Med 
1976;144(1):10-9. 
95. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, et al. Immunologic self-tolerance 
maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). 
Breakdown of a single mechanism of self-tolerance causes various autoimmune 
diseases. J Immunol 1995;155(3):1151-64. 
96. Rudensky AY. Regulatory T Cells and Foxp3. Immunological reviews 
2011;241(1):260-8. 
97. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 
2000;101(5):455-8. 
98. Bacchetta R, Gambineri E, Roncarolo MG. Role of regulatory T cells and FOXP3 in 
human diseases. J Allergy Clin Immunol 2007;120(2):227-35; quiz 36-7. 
99. Eisenstein EM, Williams CB. The T(reg)/Th17 cell balance: a new paradigm for 
autoimmunity. Pediatr Res 2009;65(5 Pt 2):26R-31R. 
178 
 
100. Liu W, Putnam AL, Xu-Yu Z, Szot GL, et al. CD127 expression inversely correlates 
with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 
2006;203(7):1701-11. 
101. Benoist C, Mathis D. Treg cells, life history, and diversity. Cold Spring Harb Perspect 
Biol 2012;4(9):a007021. 
102. Velavan TP, Ojurongbe O. Regulatory T cells and parasites. J Biomed Biotechnol 
2011;2011:520940. 
103. Gregori S, Bacchetta R, Battaglia M, Roncarolo MG. Type 1 regulatory T (Tr1) cells: 
from the bench to the bedside. Journal of Translational Medicine 2012;10(3):I7. 
104. Bacchetta R, Bigler M, Touraine JL, Parkman R, et al. High levels of interleukin 10 
production in vivo are associated with tolerance in SCID patients transplanted with 
HLA mismatched hematopoietic stem cells. J Exp Med 1994;179(2):493-502. 
105. Groux H, O'Garra A, Bigler M, Rouleau M, et al. A CD4+ T-cell subset inhibits 
antigen-specific T-cell responses and prevents colitis. Nature 1997;389(6652):737-
42. 
106. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, et al. Interleukin-10-secreting 
type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50. 
107. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. 
Immunological reviews 2008;226:205-18. 
108. Couper KN, Blount DG, Riley EM. IL-10: The Master Regulator of Immunity to 
Infection. The Journal of Immunology 2008;180(9):5771. 
109. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 
clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 
1989;170(6):2081-95. 
110. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the 
interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765. 
111. Huard B, Gaulard P, Faure F, Hercend T, et al. Cellular expression and tissue 
distribution of the human LAG-3-encoded protein, an MHC class II ligand. 
Immunogenetics 1994;39(3):213-7. 
112. Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K. Expression of lymphocyte 
activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol 
2005;35(7):2081-8. 
113. Hemon P, Jean-Louis F, Ramgolam K, Brignone C, et al. MHC class II engagement by 
its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J 
Immunol 2011;186(9):5173-83. 
114. Li N, Workman CJ, Martin SM, Vignali DA. Biochemical analysis of the regulatory T 
cell protein lymphocyte activation gene-3 (LAG-3; CD223). J Immunol 
2004;173(11):6806-12. 
115. Huang C-T, Workman CJ, Flies D, Pan X, et al. Role of LAG-3 in Regulatory T Cells. 
Immunity 2004;21(4):503-13. 
116. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285(5430):1028-32. 
117. Hussain M, Melegaro A, Pebody RG, George R, et al. A longitudinal household study 
of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol 
Infect 2005;133(5):891-8. 
118. Abdullahi O, Nyiro J, Lewa P, Slack M, et al. The descriptive epidemiology of 
Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage 
in children and adults in Kilifi district, Kenya. Pediatr Infect Dis J 2008;27(1):59-64. 
119. Obaro SK, Monteil MA, Henderson DC. The pneumococcal problem. Bmj 
1996;312(7045):1521-5. 
179 
 
120. Malley R, Trzcinski K, Srivastava A, Thompson CM, et al. CD4+ T cells mediate 
antibody-independent acquired immunity to pneumococcal colonization. Proc Natl 
Acad Sci U S A 2005;102(13):4848-53. 
121. Jiang XL, Zhang GL, Yang T, Yang BH, et al. Association of Pneumococcal Carriage 
and Expression of Foxp3+ Regulatory T Cells and Th17 Cells in the Adenoids of 
Children. Respiration 2015;90(1):25-32. 
122. Pimenta FC, Miyaji EN, Areas AP, Oliveira ML, et al. Intranasal immunization with 
the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces 
protection against colonization with Streptococcus pneumoniae and has negligible 
impact on the nasopharyngeal and oral microbiota of mice. Infect Immun 
2006;74(8):4939-44. 
123. Lu YJ, Forte S, Thompson CM, Anderson PW, et al. Protection against Pneumococcal 
colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with 
the cell wall polysaccharide. Infect Immun 2009;77(5):2076-83. 
124. Ogunniyi AD, LeMessurier KS, Graham RM, Watt JM, et al. Contributions of 
pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of 
Streptococcus pneumoniae D39 in a mouse model. Infect Immun 2007;75(4):1843-
51. 
125. Hirst RA, Kadioglu A, O'Callaghan C, Andrew PW. The role of pneumolysin in 
pneumococcal pneumonia and meningitis. Clin Exp Immunol 2004;138(2):195-201. 
126. Richards L, Ferreira DM, Miyaji EN, Andrew PW, et al. The immunising effect of 
pneumococcal nasopharyngeal colonisation; protection against future colonisation 
and fatal invasive disease. Immunobiology 2010;215(4):251-63. 
127. Thorburn AN, Foster PS, Gibson PG, Hansbro PM. Components of Streptococcus 
pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory 
T cells. J Immunol 2012;188(9):4611-20. 
128. Khan MN, Pichichero ME. The host immune dynamics of pneumococcal 
colonization: Implications for novel vaccine development. Human Vaccines & 
Immunotherapeutics 2014;10(12):3688-99. 
129. Mubarak A, Ahmed MS, Upile N, Vaughan C, et al. A dynamic relationship between 
mucosal T helper type 17 and regulatory T-cell populations in nasopharynx evolves 
with age and associates with the clearance of pneumococcal carriage in humans. 
Clin Microbiol Infect 2016;22(8):736.e1-7. 
130. Stephen-Victor E, Bosschem I, Haesebrouck F, Bayry J. The Yin and Yang of 
regulatory T cells in infectious diseases and avenues to target them. Cell Microbiol 
2017;19(6). 
131. Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol Rev 
2008;226:160-71. 
132. Khader SA, Bell GK, Pearl JE, Fountain JJ, et al. IL-23 and IL-17 in the establishment 
of protective pulmonary CD4+ T cell responses after vaccination and during 
Mycobacterium tuberculosis challenge. Nat Immunol 2007;8(4):369-77. 
133. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, et al. Pathogen-specific 
regulatory T cells delay the arrival of effector T cells in the lung during early 
tuberculosis. J Exp Med 2010;207(7):1409-20. 
134. Richert-Spuhler LE, Lund JM. The Immune Fulcrum: Regulatory T Cells Tip the 
Balance Between Pro- and Anti-inflammatory Outcomes upon Infection. Progress in 
molecular biology and translational science 2015;136:217-43. 
135. Muller A, Solnick JV. Inflammation, immunity, and vaccine development for 
Helicobacter pylori. Helicobacter 2011;16 Suppl 1:26-32. 
136. Flach CF, Ostberg AK, Nilsson AT, Malefyt Rde W, et al. Proinflammatory cytokine 
gene expression in the stomach correlates with vaccine-induced protection against 
180 
 
Helicobacter pylori infection in mice: an important role for interleukin-17 during 
the effector phase. Infect Immun 2011;79(2):879-86. 
137. Kao JY, Zhang M, Miller MJ, Mills JC, et al. Helicobacter pylori immune escape is 
mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. 
Gastroenterology 2010;138(3):1046-54. 
138. Raghavan S, Quiding-Jarbrink M. Immune modulation by regulatory T cells in 
Helicobacter pylori-associated diseases. Endocr Metab Immune Disord Drug Targets 
2012;12(1):71-85. 
139. Andreasen C, Powell DA, Carbonetti NH. Pertussis toxin stimulates IL-17 production 
in response to Bordetella pertussis infection in mice. PLoS One 2009;4(9):e7079. 
140. Pandiyan P, Conti HR, Zheng L, Peterson AC, et al. CD4(+)CD25(+)Foxp3(+) 
regulatory T cells promote Th17 cells in vitro and enhance host resistance in mouse 
Candida albicans Th17 cell infection model. Immunity 2011;34(3):422-34. 
141. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective 
immunity to viral infection by regulatory T cells. Science 2008;320(5880):1220-4. 
142. Walther M, Jeffries D, Finney OC, Njie M, et al. Distinct roles for FOXP3 and FOXP3 
CD4 T cells in regulating cellular immunity to uncomplicated and severe 
Plasmodium falciparum malaria. PLoS Pathog 2009;5(4):e1000364. 
143. Oldenhove G, Bouladoux N, Wohlfert EA, Hall JA, et al. Decrease of Foxp3+ Treg cell 
number and acquisition of effector cell phenotype during lethal infection. Immunity 
2009;31(5):772-86. 
144. Jung D, Alt FW. Unraveling V(D)J Recombination: Insights into Gene Regulation. Cell 
2004;116(2):299-311. 
145. Ollila J, Vihinen M. B cells. Int J Biochem Cell Biol 2005;37(3):518-23. 
146. Agrawal S, Smith SA, Tangye SG, Sewell WA. Transitional B cell subsets in human 
bone marrow. Clin Exp Immunol 2013;174(1):53-9. 
147. Gonzalez SF, Lukacs-Kornek V, Kuligowski MP, Pitcher LA, et al. COMPLEMENT-
DEPENDENT TRANSPORT OF ANTIGEN INTO B CELL FOLLICLES. Journal of 
immunology (Baltimore, Md. : 1950) 2010;185(5):2659-64. 
148. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 1993;11:331-60. 
149. Blum JS, Wearsch PA, Cresswell P. Pathways of Antigen Processing. Annual review 
of immunology 2013;31:443-73. 
150. O'Connor BP, Gleeson MW, Noelle RJ, Erickson LD. The rise and fall of long-lived 
humoral immunity: terminal differentiation of plasma cells in health and disease. 
Immunological reviews 2003;194:61-76. 
151. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide 
antigens. J Infect Dis 1992;165 Suppl 1:S49-52. 
152. Vos Q, Lees A, Wu ZQ, Snapper CM, et al. B-cell activation by T-cell-independent 
type 2 antigens as an integral part of the humoral immune response to pathogenic 
microorganisms. Immunol Rev 2000;176:154-70. 
153. Zhang L, Li Z, Wan Z, Kilby A, et al. Humoral Immune Responses to Streptococcus 
pneumoniae in the Setting of HIV-1 Infection. Vaccine 2015;33(36):4430-6. 
154. Fukuyama Y, King JD, Kataoka K, Kobayashi R, et al. Secretory-IgA antibodies play an 
important role in the immunity to Streptococcus pneumoniae. J Immunol 
2010;185(3):1755-62. 
155. !!! INVALID CITATION !!! {}. 
156. Leiva LE, Monjure H, Sorensen RU. Recurrent respiratory infections, specific 
antibody deficiencies, and memory B cells. J Clin Immunol 2013;33 Suppl 1:S57-61. 
157. Warnatz K, Salzer U, Rizzi M, Fischer B, et al. B-cell activating factor receptor 
deficiency is associated with an adult-onset antibody deficiency syndrome in 
humans. Proc Natl Acad Sci U S A 2009;106(33):13945-50. 
181 
 
158. Hellings P, Jorissen M, Ceuppens JL. The Waldeyer's ring. Acta Otorhinolaryngol 
Belg 2000;54(3):237-41. 
159. Brandtzaeg P. Potential of nasopharynx-associated lymphoid tissue for vaccine 
responses in the airways. Am J Respir Crit Care Med 2011;183(12):1595-604. 
160. Brandtzaeg P. Immunology of tonsils and adenoids: everything the ENT surgeon 
needs to know. Int J Pediatr Otorhinolaryngol 2003;67 Suppl 1:S69-76. 
161. Passali D, Damiani V, Passàli G, Maria Passàli F, et al. Recurrent and chronic 
inflammations of Waldeyer's ring in childhood: infectious, structural and 
immunological features, 2003.  
162. Mattila PS, Hammaren-Malmi S, Saxen H, Kaijalainen T, et al. Adenoidectomy and 
nasopharyngeal carriage of Streptococcus pneumoniae in young children. Arch Dis 
Child 2010;95(9):696-702. 
163. van Staaij BK, van den Akker EH, van der Heijden GJ, Schilder AG, et al. 
Adenotonsillectomy for upper respiratory infections: evidence based? Arch Dis 
Child 2005;90(1):19-25. 
164. Butler JC, Shapiro ED, Carlone GM. Pneumococcal vaccines: history, current status, 
and future directions. Am J Med 1999;107(1a):69s-76s. 
165. Tillett WS, Francis T. SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-
PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS. The Journal of Experimental 
Medicine 1930;52(4):561-71. 
166. Austrian R, Gold J. PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO 
BACTEREMIC PNEUMOCOCCAL PNEUMONIA. Ann Intern Med 1964;60:759-76. 
167. Hilleman MR, McLean AA, Vella PP, Weibel RE, et al. Polyvalent pneumococcal 
polysaccharide vaccines. Journal of Infection 1979;1:73-88. 
168. Prevention of pneumococcal disease: recommendations of the Advisory Committee 
on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(Rr-8):1-24. 
169. Shapiro ED, Berg AT, Austrian R, Schroeder D, et al. The protective efficacy of 
polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325(21):1453-
60. 
170. Noah ND. Vaccination against pneumococcal infection. Bmj 1988;297(6660):1351-
2. 
171. Rohani MY, Raudzah A, Ng AJ, Ng PP, et al. Epidemiology of Streptococcus 
pneumoniae Infection in Malaysia. Epidemiology and Infection 1999;122(1):77-82. 
172. Borgono JM, McLean AA, Vella PP, Woodhour AF, et al. Vaccination and 
revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and 
infants. Proc Soc Exp Biol Med 1978;157(1):148-54. 
173. Zarei A, Almehdar H, Redwan E. Hib Vaccines: Past, Present, and Future 
Perspectives, 2016.  
174. Kayhty H, Ahman H, Ronnberg PR, Tillikainen R, et al. Pneumococcal 
polysaccharide-meningococcal outer membrane protein complex conjugate vaccine 
is immunogenic in infants and children. J Infect Dis 1995;172(5):1273-8. 
175. Ahman H, Kayhty H, Lehtonen H, Leroy O, et al. Streptococcus pneumoniae 
capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in 
early infancy and able to induce immunologic memory. Pediatr Infect Dis J 
1998;17(3):211-6. 
176. Ahman H, Kayhty H, Tamminen P, Vuorela A, et al. Pentavalent pneumococcal 
oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an 
antibody response in infants. Pediatr Infect Dis J 1996;15(2):134-9. 
177. Shinefield HR, Black S, Ray P, Chang I, et al. Safety and immunogenicity of 
heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. 
Pediatr Infect Dis J 1999;18(9):757-63. 
182 
 
178. Black S, Shinefield H, Fireman B, Lewis E, et al. Efficacy, safety and immunogenicity 
of heptavalent pneumococcal conjugate vaccine in children. Northern California 
Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 
2000;19(3):187-95. 
179. CDC. 'Preventing Pneumococcal Disease Among Infants and Young Children: 
Recommendations of the Advisory Committee on Immunization Practices (ACIP)', 
Morbidity and Mortality Weekly Report (MMWR). (2000);49(RR09):1-38. 
180. Pneumococcal conjugate vaccine for childhood immunization--WHO position 
paper. Wkly Epidemiol Rec 2007;82(12):93-104. 
181. O'Brien KL, Millar EV, Zell ER, Bronsdon M, et al. Effect of pneumococcal conjugate 
vaccine on nasopharyngeal colonization among immunized and unimmunized 
children in a community-randomized trial. J Infect Dis 2007;196(8):1211-20. 
182. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, et al. Invasive pneumococcal 
disease caused by nonvaccine serotypes among alaska native children with high 
levels of 7-valent pneumococcal conjugate vaccine coverage. Jama 
2007;297(16):1784-92. 
183. Aguiar SI, Brito MJ, Goncalo-Marques J, Melo-Cristino J, et al. Serotypes 1, 7F and 
19A became the leading causes of pediatric invasive pneumococcal infections in 
Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine 
2010;28(32):5167-73. 
184. Kellner JD. Update on the success of the pneumococcal conjugate vaccine. 
Paediatrics & Child Health 2011;16(4):233-6. 
185. Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and 
children - use of 13-valent pneumococcal conjugate vaccine and 23-valent 
pneumococcal polysaccharide vaccine - recommendations of the Advisory 
Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(Rr-
11):1-18. 
186. Tan TQ. Pediatric Invasive Pneumococcal Disease in the United States in the Era of 
Pneumococcal Conjugate Vaccines. Clinical Microbiology Reviews 2012;25(3):409-
19. 
187. McIntosh ED, Conway P, Willingham J, Hollingsworth R, et al. Pneumococcal 
pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent 
pneumococcal conjugate vaccine (PCV). Vaccine 2005;23(14):1739-45. 
188. Direct and indirect effects of routine vaccination of children with 7-valent 
pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--
United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54(36):893-7. 
189. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, et al. Effect of use of 13-valent 
pneumococcal conjugate vaccine in children on invasive pneumococcal disease in 
children and adults in the USA: analysis of multisite, population-based surveillance. 
Lancet Infect Dis 2015;15(3):301-9. 
190. Kayhty H, Karanko V, Peltola H, Makela PH. Serum antibodies after vaccination with 
Haemophilus influenzae type b capsular polysaccharide and responses to 
reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 
1984;74(5):857-65. 
191. Mazmanian SK, Kasper DL. The love-hate relationship between bacterial 
polysaccharides and the host immune system. Nat Rev Immunol 2006;6(11):849-58. 
192. Barrett DJ, Lee CG, Ammann AJ, Ayoub EM. IgG and IgM pneumococcal 
polysaccharide antibody responses in infants. Pediatr Res 1984;18(11):1067-71. 
193. Dintzis RZ. Rational design of conjugate vaccines. Pediatr Res 1992;32(4):376-85. 
183 
 
194. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal 
conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet 
Infect Dis 2007;7(9):597-606. 
195. Nieminen T, Kayhty H, Leroy O, Eskola J. Pneumococcal conjugate vaccination in 
toddlers: mucosal antibody response measured as circulating antibody-secreting 
cells and as salivary antibodies. Pediatr Infect Dis J 1999;18(9):764-72. 
196. Millar EV, Watt JP, Bronsdon MA, Dallas J, et al. Indirect effect of 7-valent 
pneumococcal conjugate vaccine on pneumococcal colonization among 
unvaccinated household members. Clin Infect Dis 2008;47(8):989-96. 
197. Hammitt LL, Bruden DL, Butler JC, Baggett HC, et al. Indirect effect of conjugate 
vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in 
invasive pneumococcal disease. J Infect Dis 2006;193(11):1487-94. 
198. Zhang Q, Bernatoniene J, Bagrade L, Pollard AJ, et al. Serum and mucosal antibody 
responses to pneumococcal protein antigens in children: relationships with carriage 
status. Eur J Immunol 2006;36(1):46-57. 
199. Marriott HM, Mitchell TJ, Dockrell DH. Pneumolysin: a double-edged sword during 
the host-pathogen interaction. Curr Mol Med 2008;8(6):497-509. 
200. Musher DM, Phan HM, Baughn RE. Protection against bacteremic pneumococcal 
infection by antibody to pneumolysin. J Infect Dis 2001;183(5):827-30. 
201. Hermand P, Vandercammen A, Mertens E, Di Paolo E, et al. Preclinical evaluation of 
a chemically detoxified pneumolysin as pneumococcal vaccine antigen. Human 
Vaccines & Immunotherapeutics 2017;13(1):220-8. 
202. Verhoeven D, Perry S, Pichichero ME. Contributions to protection from 
Streptococcus pneumoniae infection using the monovalent recombinant protein 
vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during 
challenge. Clin Vaccine Immunol 2014;21(8):1037-45. 
203. Malley R, Henneke P, Morse SC, Cieslewicz MJ, et al. Recognition of pneumolysin by 
Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad 
Sci U S A 2003;100(4):1966-71. 
204. Whatmore AM, Dowson CG. The autolysin-encoding gene (lytA) of Streptococcus 
pneumoniae displays restricted allelic variation despite localized recombination 
events with genes of pneumococcal bacteriophage encoding cell wall lytic enzymes. 
Infect Immun 1999;67(9):4551-6. 
205. Hyytiainen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: 
extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab 
Sci 2004;41(3):233-64. 
206. Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine 
Netw 1996;7(3):363-74. 
207. Bonewald LF. Regulation and regulatory activities of transforming growth factor 
beta. Crit Rev Eukaryot Gene Expr 1999;9(1):33-44. 
208. Miyazono K, Ichijo H, Heldin CH. Transforming growth factor-beta: latent forms, 
binding proteins and receptors. Growth Factors 1993;8(1):11-22. 
209. Rifkin DB. Latent transforming growth factor-beta (TGF-beta) binding proteins: 
orchestrators of TGF-beta availability. J Biol Chem 2005;280(9):7409-12. 
210. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 
2003;116(Pt 2):217-24. 
211. Lawrence DA, Pircher R, Kryceve-Martinerie C, Jullien P. Normal embryo fibroblasts 
release transforming growth factors in a latent form. J Cell Physiol 1984;121(1):184-
8. 
212. Taylor AW. Review of the activation of TGF-β in immunity. Journal of Leukocyte 
Biology 2009;85(1):29-33. 
184 
 
213. Taipale J, Miyazono K, Heldin CH, Keski-Oja J. Latent transforming growth factor-
beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding 
protein. J Cell Biol 1994;124(1-2):171-81. 
214. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming 
growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular 
mechanism for release of TGF-beta from bone matrix. J Biol Chem 
2002;277(24):21352-60. 
215. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: 
mechanisms and physiology. Cytokine Growth Factor Rev 2000;11(1-2):59-69. 
216. Khalil N. TGF-beta: from latent to active. Microbes Infect 1999;1(15):1255-63. 
217. Chong H, Vodovotz Y, Cox GW, Barcellos-Hoff MH. Immunocytochemical 
localization of latent transforming growth factor-beta1 activation by stimulated 
macrophages. J Cell Physiol 1999;178(3):275-83. 
218. Glinka Y, Prud'homme GJ. Neuropilin-1 is a receptor for transforming growth factor 
beta-1, activates its latent form, and promotes regulatory T cell activity. J Leukoc 
Biol 2008;84(1):302-10. 
219. Nakamura K, Kitani A, Fuss I, Pedersen A, et al. TGF-beta 1 plays an important role 
in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and 
mice. J Immunol 2004;172(2):834-42. 
220. Chen ML, Yan BS, Bando Y, Kuchroo VK, et al. Latency-associated peptide identifies 
a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and 
enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol 
2008;180(11):7327-37. 
221. Annes JP, Chen Y, Munger JS, Rifkin DB. Integrin α(V)β(6)-mediated activation of 
latent TGF-β requires the latent TGF-β binding protein-1. The Journal of Cell Biology 
2004;165(5):723-34. 
222. Travis MA, Reizis B, Melton AC, Masteller E, et al. Loss of integrin alpha(v)beta8 on 
dendritic cells causes autoimmunity and colitis in mice. Nature 
2007;449(7160):361-5. 
223. Yang Z, Mu Z, Dabovic B, Jurukovski V, et al. Absence of integrin-mediated 
TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J 
Cell Biol 2007;176(6):787-93. 
224. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91. 
225. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the 
nucleus. Cell 2003;113(6):685-700. 
226. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 
2005;19(23):2783-810. 
227. Clarke DC, Brown ML, Erickson RA, Shi Y, et al. Transforming growth factor beta 
depletion is the primary determinant of Smad signaling kinetics. Mol Cell Biol 
2009;29(9):2443-55. 
228. Konkel JE, Chen W. Balancing acts: the role of TGF-beta in the mucosal immune 
system. Trends Mol Med 2011;17(11):668-76. 
229. Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, et al. Immune dysregulation 
in TGF-beta 1-deficient mice. J Immunol 1994;153(5):1936-46. 
230. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta 
controls T helper type 1 cell development through regulation of natural killer cell 
interferon-gamma. Nat Immunol 2005;6(6):600-7. 
231. Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007;8(5):215. 
232. Huveneers S, Danen EH. Adhesion signaling - crosstalk between integrins, Src and 
Rho. J Cell Sci 2009;122(Pt 8):1059-69. 
233. EHJ D. Integrins: An Overview of Structural and Functional Aspects  (accessed. 
185 
 
234. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nature 
Reviews Cancer 2002;2:91. 
235. Worthington JJ, Kelly A, Smedley C, Bauche D, et al. Integrin alphavbeta8-Mediated 
TGF-beta Activation by Effector Regulatory T Cells Is Essential for Suppression of T-
Cell-Mediated Inflammation. Immunity 2015;42(5):903-15. 
236. Chen W, Jin W, Hardegen N, Lei KJ, et al. Conversion of peripheral CD4+CD25- naive 
T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription 
factor Foxp3. J Exp Med 2003;198(12):1875-86. 
237. Worthington JJ, Klementowicz JE, Travis MA. TGFbeta: a sleeping giant awoken by 
integrins. Trends Biochem Sci 2011;36(1):47-54. 
238. Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK, et al. Immunization of mice 
with combinations of pneumococcal virulence proteins elicits enhanced protection 
against challenge with Streptococcus pneumoniae. Infect Immun 2000;68(5):3028-
33. 
239. Berry AM, Ogunniyi AD, Miller DC, Paton JC. Comparative virulence of 
Streptococcus pneumoniae strains with insertion-duplication, point, and deletion 
mutations in the pneumolysin gene. Infect Immun 1999;67(2):981-5. 
240. Zhang Q, Choo S, Finn A. Immune responses to novel pneumococcal proteins 
pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Infect 
Immun 2002;70(10):5363-9. 
241. Mahmood T, Yang P-C. Western Blot: Technique, Theory, and Trouble Shooting. 
North American Journal of Medical Sciences 2012;4(9):429-34. 
242. Gallagher SR. One-dimensional SDS gel electrophoresis of proteins. Curr Protoc 
Immunol 2006;Chapter 8:Unit 8.4. 
243. Adan A, Alizada G, Kiraz Y, Baran Y, et al. Flow cytometry: basic principles and 
applications. Crit Rev Biotechnol 2017;37(2):163-76. 
244. Muirhead KA, Horan PK, Poste G. Flow Cytometry: Present and Future. 
Bio/Technology 1985;3:337. 
245. Ibrahim SF, van den Engh G. Flow cytometry and cell sorting. Adv Biochem Eng 
Biotechnol 2007;106:19-39. 
246. Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature 
cytokines in autoimmune and inflammatory diseases. Cytokine 2015;74(1):5-17. 
247. The enzyme-linked immunosorbent assay (ELISA). Bulletin of the World Health 
Organization 1976;54(2):129-39. 
248. Gaastra W. Enzyme-linked immunosorbant assay (ELISA). Methods Mol Biol 
1984;1:349-55. 
249. Lim HW, Hillsamer P, Kim CH. Regulatory T cells can migrate to follicles upon T cell 
activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin 
Invest 2004;114(11):1640-9. 
250. Belkaid Y. Role of Foxp3-positive regulatory T cells during infection. European 
journal of immunology 2008;38(4):918-21. 
251. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M. Tr1 cells and the counter-
regulation of immunity: natural mechanisms and therapeutic applications. Curr Top 
Microbiol Immunol 2014;380:39-68. 
252. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the 
human immune system. Nat Rev Immunol 2010;10(7):490-500. 
253. Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune 
homeostasis and suppression. Toxicol Pathol 2012;40(2):186-204. 
254. Palomares O, Martin-Fontecha M, Lauener R, Traidl-Hoffmann C, et al. Regulatory T 
cells and immune regulation of allergic diseases: roles of IL-10 and TGF-beta. Genes 
Immun 2014;15(8):511-20. 
186 
 
255. Wolf AM, Wolf D, Steurer M, Gastl G, et al. Increase of regulatory T cells in the 
peripheral blood of cancer patients. Clin Cancer Res 2003;9(2):606-12. 
256. Piccirillo CA. Regulatory T cells in health and disease. Cytokine 2008;43(3):395-401. 
257. Brandtzaeg P, Pabst R. Let's go mucosal: communication on slippery ground. Trends 
in Immunology 2004;25(11):570-7. 
258. McGhee JR, Fujihashi K. Inside the mucosal immune system. PLoS Biol 
2012;10(9):e1001397. 
259. Rose MA, Schubert R, Strnad N, Zielen S. Priming of Immunological Memory by 
Pneumococcal Conjugate Vaccine in Children Unresponsive to 23-Valent 
Polysaccharide Pneumococcal Vaccine. Clinical and Diagnostic Laboratory 
Immunology 2005;12(10):1216-22. 
260. Morandi F, Pozzi S, Barco S, Cangemi G, et al. CD4+CD25hiCD127− Treg and 
CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood 
samples from children with neuroblastoma. OncoImmunology 
2016;5(12):e1249553. 
261. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. 
Science 1994;265(5177):1385-7. 
262. Kadioglu A, Coward W, Colston MJ, Hewitt CR, et al. CD4-T-lymphocyte interactions 
with pneumolysin and pneumococci suggest a crucial protective role in the host 
response to pneumococcal infection. Infect Immun 2004;72(5):2689-97. 
263. McCool TL, Weiser JN. Limited role of antibody in clearance of Streptococcus 
pneumoniae in a murine model of colonization. Infect Immun 2004;72(10):5807-13. 
264. Chen A, Mann B, Gao G, Heath R, et al. Multivalent Pneumococcal Protein Vaccines 
Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit 
Strong and Broad Protection. Clin Vaccine Immunol 2015;22(10):1079-89. 
265. Swiatlo E, Ware D. Novel vaccine strategies with protein antigens of Streptococcus 
pneumoniae. FEMS Immunol Med Microbiol 2003;38(1):1-7. 
266. Ginsburg AS, Nahm MH, Khambaty FM, Alderson MR. Issues and Challenges in the 
Development of Pneumococcal Protein Vaccines: A Two Day International 
Symposium. Expert review of vaccines 2012;11(3):279-85. 
267. Berical AC, Harris D, Dela Cruz CS, Possick JD. Pneumococcal Vaccination Strategies. 
An Update and Perspective. Annals of the American Thoracic Society 
2016;13(6):933-44. 
268. Zeng H, Zhang R, Jin B, Chen L. Type 1 regulatory T cells: a new mechanism of 
peripheral immune tolerance. Cell Mol Immunol 2015;12(5):566-71. 
269. Pot C, Apetoh L, K Kuchroo V. Type 1 Regulatory T cells (Tr1) in autoimmunity, 2011.  
270. Chapter 10 - Regulation of Immune Responses in the Periphery. In: Mak TW, 
Saunders ME, Jett BD, eds. Primer to the Immune Response (Second Edition). 
Boston: Academic Cell, 2014:227-46. 
http://www.sciencedirect.com/science/article/pii/B9780123852458000108. 
271. Hall BM. T Cells: Soldiers and Spies—The Surveillance and Control of Effector T Cells 
by Regulatory T Cells. Clinical Journal of the American Society of Nephrology : CJASN 
2015;10(11):2050-64. 
272. Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, et al. The 
Development and Function of Regulatory T Cells. Cellular and molecular life 
sciences : CMLS 2009;66(16):2603-22. 
273. Zhang Q, Bagrade L, Bernatoniene J, Clarke E, et al. Low CD4 T cell immunity to 
pneumolysin is associated with nasopharyngeal carriage of pneumococci in 
children. J Infect Dis 2007;195(8):1194-202. 
274. Paton JC. Novel pneumococcal surface proteins: role in virulence and vaccine 
potential. Trends Microbiol 1998;6(3):85-7; discussion 7-8. 
187 
 
275. Neill DR, Fernandes VE, Wisby L, Haynes AR, et al. T regulatory cells control 
susceptibility to invasive pneumococcal pneumonia in mice. PLoS Pathog 
2012;8(4):e1002660. 
276. Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev 
2011;241(1):241-59. 
277. Battaglia M, Gregori S, Bacchetta R, Roncarolo MG. Tr1 cells: from discovery to 
their clinical application. Semin Immunol 2006;18(2):120-7. 
278. Allan SE, Broady R, Gregori S, Himmel ME, et al. CD4+ T-regulatory cells: toward 
therapy for human diseases. Immunol Rev 2008;223:391-421. 
279. Barrat FJ, Cua DJ, Boonstra A, Richards DF, et al. In vitro generation of interleukin 
10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and 
inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 
2002;195(5):603-16. 
280. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan 
catabolism. Nat Rev Immunol 2004;4(10):762-74. 
281. Munn DH, Sharma MD, Lee JR, Jhaver KG, et al. Potential regulatory function of 
human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 
2002;297(5588):1867-70. 
282. Groneck L, Schrama D, Fabri M, Stephen TL, et al. Oligoclonal CD4+ T cells promote 
host memory immune responses to Zwitterionic polysaccharide of Streptococcus 
pneumoniae. Infect Immun 2009;77(9):3705-12. 
283. Wang B, Dileepan T, Briscoe S, Hyland KA, et al. Induction of TGF-beta1 and TGF-
beta1-dependent predominant Th17 differentiation by group A streptococcal 
infection. Proc Natl Acad Sci U S A 2010;107(13):5937-42. 
284. Chen W, Jin W, Hardegen N, Lei K-j, et al. Conversion of Peripheral CD4(+)CD25(−) 
Naive T Cells to CD4(+)CD25(+) Regulatory T Cells by TGF-β Induction of 
Transcription Factor Foxp3. The Journal of Experimental Medicine 
2003;198(12):1875-86. 
285. Huber S, Schramm C, Lehr HA, Mann A, et al. Cutting edge: TGF-beta signaling is 
required for the in vivo expansion and immunosuppressive capacity of regulatory 
CD4+CD25+ T cells. J Immunol 2004;173(11):6526-31. 
286. Xu X, Wang H, Liu Y, Wang Y, et al. Mucosal immunization with the live attenuated 
vaccine SPY1 induces humoral and Th2-Th17-regulatory T cell cellular immunity and 
protects against pneumococcal infection. Infect Immun 2015;83(1):90-100. 
287. Liao H, Peng X, Gan L, Feng J, et al. Protective Regulatory T Cell Immune Response 
Induced by Intranasal Immunization With the Live-Attenuated Pneumococcal 
Vaccine SPY1 via the Transforming Growth Factor-β1-Smad2/3 Pathway. Frontiers 
in Immunology 2018;9:1754. 
288. Dotor J, Lopez-Vazquez AB, Lasarte JJ, Sarobe P, et al. Identification of peptide 
inhibitors of transforming growth factor beta 1 using a phage-displayed peptide 
library. Cytokine 2007;39(2):106-15. 
289. Gingles NA, Alexander JE, Kadioglu A, Andrew PW, et al. Role of genetic resistance 
in invasive pneumococcal infection: identification and study of susceptibility and 
resistance in inbred mouse strains. Infect Immun 2001;69(1):426-34. 
290. Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine 
1999;17 Suppl 1:S79-84. 
291. Ndure J, Flanagan KL. Targeting regulatory T cells to improve vaccine 
immunogenicity in early life. Frontiers in Microbiology 2014;5:477. 
292. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. 
Nat Rev Immunol 2007;7(5):379-90. 
188 
 
293. Ghazal P, Dickinson P, Smith CL. Early life response to infection. Curr Opin Infect Dis 
2013;26(3):213-8. 
294. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans 
from infancy to old age. Proceedings of the Royal Society B: Biological Sciences 
2015;282(1821):20143085. 
295. Lahl K, Sparwasser T. In vivo depletion of FoxP3+ Tregs using the DEREG mouse 
model. Methods Mol Biol 2011;707:157-72. 
296. Klages K, Mayer CT, Lahl K, Loddenkemper C, et al. Selective depletion of Foxp3+ 
regulatory T cells improves effective therapeutic vaccination against established 
melanoma. Cancer Res 2010;70(20):7788-99. 
297. Mattarollo SR, Steegh K, Li M, Duret H, et al. Transient Foxp3(+) regulatory T-cell 
depletion enhances therapeutic anticancer vaccination targeting the immune-
stimulatory properties of NKT cells. Immunol Cell Biol 2013;91(1):105-14. 
298. Musher DM, Groover JE, Rowland JM, Watson DA, et al. Antibody to capsular 
polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and 
response to revaccination. Clin Infect Dis 1993;17(1):66-73. 
299. Pido-Lopez J, Kwok WW, Mitchell TJ, Heyderman RS, et al. Acquisition of 
pneumococci specific effector and regulatory Cd4+ T cells localising within human 
upper respiratory-tract mucosal lymphoid tissue. PLoS Pathog 
2011;7(12):e1002396. 
300. Lipsitch M, Whitney CG, Zell E, Kaijalainen T, et al. Are anticapsular antibodies the 
primary mechanism of protection against invasive pneumococcal disease? PLoS 
Med 2005;2(1):e15. 
301. Hill PC, Akisanya A, Sankareh K, Cheung YB, et al. Nasopharyngeal carriage of 
Streptococcus pneumoniae in Gambian villagers. Clin Infect Dis 2006;43(6):673-9. 
302. Robinson KA, Baughman W, Rothrock G, Barrett NL, et al. Epidemiology of invasive 
Streptococcus pneumoniae infections in the United States, 1995-1998: 
Opportunities for prevention in the conjugate vaccine era. Jama 
2001;285(13):1729-35. 
303. Gamez G, Hammerschmidt S. Combat pneumococcal infections: adhesins as 
candidates for protein-based vaccine development. Curr Drug Targets 
2012;13(3):323-37. 
304. Bologa M, Kamtchoua T, Hopfer R, Sheng X, et al. Safety and immunogenicity of 
pneumococcal protein vaccine candidates: Monovalent choline-binding protein A 
(PcpA) vaccine and bivalent PcpA–pneumococcal histidine triad protein D vaccine. 
Vaccine 2012;30(52):7461-8. 
305. Kamtchoua T, Bologa M, Hopfer R, Neveu D, et al. Safety and immunogenicity of 
the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine 
candidate in adults. Vaccine 2013;31(2):327-33. 
306. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining 
inflammation. Cell 2010;140(6):845-58. 
307. Lee GR. The Balance of Th17 versus Treg Cells in Autoimmunity. International 
Journal of Molecular Sciences 2018;19(3):730. 
308. Pandiyan P, Conti HR, Zheng L, Peterson AC, et al. CD4(+) CD25(+) Foxp3(+) 
regulatory T cells promote Th17 cells in vitro and enhance host resistance in mouse 
Candida albicans Th17 cell infection model. Immunity 2011;34(3):422-34. 
309. Ishigame H, Zenewicz LA, Sanjabi S, Licona-Limon P, et al. Excessive Th1 responses 
due to the absence of TGF-beta signaling cause autoimmune diabetes and 
dysregulated Treg cell homeostasis. Proc Natl Acad Sci U S A 2013;110(17):6961-6. 
189 
 
310. Lee JH, Yu HH, Wang LC, Yang YH, et al. The levels of CD4(+)CD25(+) regulatory T 
cells in paediatric patients with allergic rhinitis and bronchial asthma. Clinical and 
Experimental Immunology 2007;148(1):53-63. 
311. Grindebacke H, Wing K, Andersson AC, Suri-Payer E, et al. Defective suppression of 
Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen 
season. Clin Exp Allergy 2004;34(9):1364-72. 
312. Thorburn AN, Hansbro PM. Harnessing regulatory T cells to suppress asthma: from 
potential to therapy. Am J Respir Cell Mol Biol 2010;43(5):511-9. 
313. Preston JA, Thorburn AN, Starkey MR, Beckett EL, et al. Streptococcus pneumoniae 
infection suppresses allergic airways disease by inducing regulatory T-cells. Eur 
Respir J 2011;37(1):53-64. 
314. Preston JA, Essilfie AT, Horvat JC, Wade MA, et al. Inhibition of allergic airways 
disease by immunomodulatory therapy with whole killed Streptococcus 
pneumoniae. Vaccine 2007;25(48):8154-62. 
315. Thorburn AN, O'Sullivan BJ, Thomas R, Kumar RK, et al. Pneumococcal conjugate 
vaccine-induced regulatory T cells suppress the development of allergic airways 
disease. Thorax 2010;65(12):1053-60. 
316. Thorburn AN, Brown AC, Nair PM, Chevalier N, et al. Pneumococcal components 
induce regulatory T cells that attenuate the development of allergic airways disease 
by deviating and suppressing the immune response to allergen. J Immunol 
2013;191(8):4112-20. 
317. Sun M, He C, Cong Y, Liu Z. Regulatory immune cells in regulation of intestinal 
inflammatory response to microbiota. Mucosal immunology 2015;8(5):969-78. 
318. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol 
2005;5(4):343-9. 
319. Pestka S, Krause CD, Sarkar D, Walter MR, et al. Interleukin-10 and related 
cytokines and receptors. Annu Rev Immunol 2004;22:929-79. 
320. Desreumaux P, Foussat A, Allez M, Beaugerie L, et al. Safety and efficacy of antigen-
specific regulatory T-cell therapy for patients with refractory Crohn's disease. 
Gastroenterology 2012;143(5):1207-17.e2. 
321. Foussat A, Cottrez F, Brun V, Fournier N, et al. A comparative study between T 
regulatory type 1 and CD4+CD25+ T cells in the control of inflammation. J Immunol 
2003;171(10):5018-26. 
 
 
 
 
 
 
 
 
 
 
 
190 
 
Appendices 
Appendix-I 
Preparation of different media and buffers 
Skim milk, Tryptone, Glucose, Glycerol Transport Medium (STGG)  
STGG transport medium was prepared using the following method.   
1. 40 ml 10% milk was prepared by adding 4 grams of skimmed milk powder 
(Oxoid, UK) into 40 ml of distilled water in a sterile 100 ml glass bottle. 
2. The bottle was autoclaved at 121°C for 5 minutes with the cap loosened.  
3. Upon completion of autoclaving, the cap was tightened, and the bottle 
taken into a bio-safety cabinet.  
4. In another sterile 500 ml glass bottle, 6 ml of Tryptone soya broth (Oxoid, 
UK), 2.2 ml of 45% D-Glucose solution (Sigma Aldrich, UK) and 20 ml of 
Glycerol (Sigma Aldrich, UK) were added with 131.8 ml of distilled water to 
make the final volume 160 ml.   
5. The bottle was shaken gently to dissolve all ingredients and the bottle was 
then autoclaved at 121°C for 10 minutes with the cap loosened.  
6. After that, the cap was tightened, and the bottle was taken into a bio-safety 
cabinet.  
7. Then, the previously prepared sterile 10% skimmed milk (40 ml) was added 
into the 500 ml bottle to make 200 ml of 2% skimmed milk medium.  
8. The milk was mixed thoroughly with the other contents by gentle shaking of 
the bottle.  
9. Aliquots of 1.0 ml media were prepared into 1.5 ml screw-capped vials.  
10. The tubes were then kept in a refrigerator (2-8°C) until used for nasal swab 
inoculation.  
11. Quality control test for sterility of the STGG medium was performed 
periodically by plating a full loop of a homogenized vial from each lot onto a 
blood agar plate, then incubating the plate at 37°C overnight. If growth of 
any organisms was suspected, the entire batch was disposed of. 
Todd-Hewitt-Yeast Broth (THYB)   
Todd-Hewitt Broth with 0.5% yeast extract was prepared using the following procedure.  
1. 36.4 grams of Todd-Hewitt Broth (Oxoid, Basingstoke, UK) and 5 grams of 
yeast extract were added to a sterile 1 litre glass bottle.  
2. 1000 ml of distilled water was added to the bottle and mixed thoroughly, 
until all components were fully dissolved. 
3. The bottle was autoclaved at 115°C for 10 minutes with the cap loosened.  
4. After autoclaving, the bottle cap was closed tightly and then kept in the cold 
room until used for growing bacteria.  
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Laemmli Reducing Buffer   
10.0 ml Laemmli reducing Buffer for western Blot sample dilution was prepared 
using the following recipe ingredients: 
0.5 M Tris pH 6.8  1.25 ml  
10% (w/v) SDS   2.0 ml  
0.5% Bromphenol Blue  0.20 ml  
Glycerol      2.50 ml  
Deionized H2O   3.55 ml  
β-mercaptoethanol  0.50 ml (50 µl for each 0.95 ml)  
10x Tris Buffered Saline (TBS) pH 7.4   
1 Litre 10x TBS was prepared in a sterile 1 litre glass bottle, using the 
following ingredients:  
Tris       30 gm  
NaCl     80 gm  
KCl        2 gm  
Deionized H2O 900 ml  
The pH was adjusted to 7.4 by adding concentrated HCl drop by drop, with 
gentle shaking of the bottle and measurement with a pH meter. When the 
pH was adjusted to the correct level, the bottle was topped-up to 1 litre by 
adding deionized water.  
Western Blot Washing Buffer (TBS-T)   
1 litre of Western Blot washing buffer (1xTBS with 0.05% Tween20) was prepared 
in a sterile glass bottle, using the following method: 
10x TBS      100 ml  
Deionized H2O  900 ml  
Tween-20     0.5 ml  
Western Blot Blocking Buffer (5% skimmed milk in TBS-T)   
500 ml of Western Blot blocking buffer (5% skimmed milk in TBS-T) was 
prepared in a sterile glass bottle, with a magnetic stirrer bead inside, using 
following recipe-  
Skimmed milk     25 gram  
10x TBS       50 ml  
Deionized H2O    450 ml  
Tween-20     0.25 ml   
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The bottle was kept on a magnetic stirrer which allowed the milk to dissolve 
effectively. 
10x Phosphate Buffered Saline (PBS) pH 7.4   
1 litre of 10x PBS was prepared in a sterile 1 litre glass bottle, using the 
following ingredients:  
Na2HPO4      14.4 gm  
KH2PO4     2.4 gm  
NaCl       80 gm  
KCl          2 gm  
Deionized H2O    900 ml 
The pH was then adjusted to 7.4 by adding concentrated HCl drop by drop, 
with gentle shaking of the bottle and measurement with a pH meter. When 
the pH had been adjusted to the correct level, the bottle was topped up to 1 
litre with deionised water. 
ELISA/ELISpot Washing Buffer (PBS-T)   
1 litre of ELISA/ELISpot washing buffer (1xPBS with 0.05% Tween20) was 
prepared in a sterile glass bottle, using following recipe-  
10x PBS       100 ml  
Deionized H2O    900 ml  
Tween-20      0.5 ml  
P-Nitrophenyl Phosphate (PNPP) Substrate for ELISA  
1 litre of p-nitrophenyl phosphate (PNPP) substrate (1M diethanolamine) 
buffer (pH 9.8) was prepared in a sterile glass bottle, using following recipe-  
Diethanolamine 97 ml  
Deionized H2O  800 ml  
MgCl2   100mg   
The bottle was then placed on a magnetic stirrer with a magnetic flea inside 
to allow for the contents to thoroughly mix. Whilst stirring, the pH was 
measured and adjusted to 9.8 by adding 10M hydrochloric acid. Once the 
pH was adjusted to the correct level, the buffer was transferred to a 
measuring cylinder and topped up to 1 litre using distilled water. 
The buffer was then transferred back to the bottle and stored at 4˚C. Finally, 
the substrate was prepared by dissolving a p-nitrophenyl phosphate 
disodium salt (5mg) tablet into 5 ml of substrate buffer to give a PNPP 
concentration of 1 mg/ml. 
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Appendix II  
List of antibodies/chemicals and reagents/Consumables 
 
Chemicals/Reagents Manufacturer Catalogue Number 
Agar Sigma Aldrich, UK A1296 
Agarose Sigma Aldrich, UK A9539 
Amphotericin B Sigma Aldrich, UK A2942 
Blood Agar Base Oxoid Ltd, UK CM0055B 
Bovine Serum Albumin (BSA) Sigma Aldrich, UK A8327 
Bradford Protein Dye Reagent Sigma Aldrich, UK B6916 
Brefeldin A eBioscience, UK 00-4506-51 
Phosphate Buffered Saline 
(PBS) (tablet) 
Sigma Aldrich, UK P4417 
Ficoll-Plaque Premium GE Healthcare Life Sciences, 
UK 
17-5442-03 
Foetal Bovine Serum (FBS) Sigma Aldrich, UK F7524 
Foxp3/Transcription factor 
staining buffer set 
eBioscience, UK 00-5523-00 
Gentamycin Sigma Aldrich, UK G1272 
Glucose Sigma Aldrich, UK G8769 
Hanks Balanced Salt Solution 
(HBSS) 
Sigma Aldrich, UK H9269 
Horse Blood (Defibrinated) Oxoid Ltd, UK SR0050C 
Horseradish Peroxidase 
Avidin D 
Vector Lab. Inc., USA A-2004 
Antibodies/kits Manufacturer Catalogue no 
Anti-rabbit IgG-HRP                  
(produced in donkey)      
Santa Cruz Biotech, Germany SC2077 
CD45RO microbeads                      
(mouse anti-human IgG2a) 
Miltenyi Biotech, Germany 130-092-355 
Human CD-4 PE                           
(clone: RPAT4)  
BD Biosciences, UK 555347 
Human CD-4 PE-Cy7                          
(clone: SK3) 
BD Biosciences, UK 557852 
Human CD49b AlexaFluor647  
(clone: 12F1) 
BD Biosciences, UK 564118 
Human Foxp3 AlexaFluor647 
(clone: 259D/C7) 
BD Biosciences, UK 560045 
Human IL-10 APC  
(clone: JES3-19F1) 
BD Biosciences, UK 554707 
TGF-β-1,2,3 Monoclonal 
Antibody (1D11.16.8) 
functional grade  
eBioscience, UK 16-9243-85 
Human LAG-3 PE R&D Systems FAB2319P 
194 
 
Hydrogen Peroxide Sigma Aldrich, UK H1009 
Intracellular fixation buffer eBioscience, UK 00-8222-49 
Immun-Star WesternC 
Chemiluminescent Kit 
Bio-Rad, UK 170-5070 
L-glutamine Sigma Aldrich, UK G7513 
NN Dimethylformamide 
(DMF) 
Sigma Aldrich, UK D4551 
Optochin disk Oxoid Ltd, UK DD0001B 
Penicillin/Streptomycin Sigma Aldrich, UK P0781 
Permeabilisation buffer (10x) eBioscience, UK 00-8333 
Quick-load DNA Ladder (1KB) New England Biolabs, USA N3232L 
RPMI 1640 Sigma Aldrich, UK R5886 
Skimmed Milk Powder Oxoid Ltd, UK LP0031B 
Streptactin-HRP Bio-RAD, UK 61-0381 
Tryptone Soya Broth Oxoid Ltd, UK B00369E 
Yeast Extract Sigma Aldrich, UK Y1625 
 
Consumables Manufacturer Catalogue Number 
BD Falcon cell strainer 
(70µm, nylon) 
BD Biosciences, UK 352350 
Columbia blood agar plate Oxoid Ltd, UK   OXPB 0199A 
Dryswab™ in peel pouch                                                                  Medical Wire & Equipment, 
UK 
MW113 
ELISA plates (96 well, flat, 
high protein binding EIA/RIA 
plate) 
Corning, USA via Appleton 
Woods, UK  
 
CC679 
MACS cell separation LD 
columns                                                 
Miltenyi Biotech Ltd, 
Germany 
130-042-901  
 
Mini Protean precast TGX gel 
(12%) 
Bio-Rad, UK 456-1044 
Oracol saliva collection 
system                                                  
Malvern Medical Dev. Ltd, 
UK
510  
 
Transblot turbo mini transfer 
pack 
Bio-Rad, UK 170-4156 
Vivaspin 15R hydrosart                                                   
(MWCO: 5000) 
Sartorius Stedim, Germany VS15RH11    
 
 
 
